aspirin has been researched along with Ischemic Attack, Transient in 822 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Its efficacy may exceed aspirin in improving clinical outcomes in patients with acute ischemic stroke who are ineligible for rt-PA." | 9.69 | A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke. ( Aref, HM; El-Khawas, H; Elbassiouny, A; Roushdy, TM; Shokri, HM; Zeinhom, MG, 2023) |
| "The Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial showed that ticagrelor-aspirin combination therapy reduced the risk of stroke compared with a clopidogrel-aspirin combination among carriers of CYP2C19 loss-of-function (LOF) alleles after a transient ischemic attack (TIA) or minor ischemic stroke." | 9.69 | Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial. ( Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, Y; Xie, X; Xu, A; Xu, Q; Zhao, X, 2023) |
| "In this secondary analysis of a randomized controlled trial involving patients with minor ischemic stroke or TIA, compared with clopidogrel-ASA, patients with obesity received more clinical benefit from ticagrelor-ASA therapy than those without obesity." | 9.69 | Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack. ( Jiang, Y; Jing, J; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, Y; Xie, X; Zhang, J; Zhao, X, 2023) |
| "The aim of this study is to investigate the effect of gradual dipyridamole titration and the incidence of dipyridamole-induced headache in patients with ischemic stroke or transient ischemic attack (TIA)." | 9.51 | Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial. ( Cha, JK; Chang, DI; Chang, JY; Chung, JW; Hong, KS; Jung, KH; Kang, MK; Kim, BK; Kim, HY; Lee, KY; Lee, SJ; Park, JM; Park, MS; Rha, JH; Shin, DI; Yoon, BW, 2022) |
| "In the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial, acute treatment with clopidogrel-aspirin was associated with significantly reduced risk of recurrent stroke." | 9.51 | Infarct on Brain Imaging, Subsequent Ischemic Stroke, and Clopidogrel-Aspirin Efficacy: A Post Hoc Analysis of a Randomized Clinical Trial. ( de Havenon, A; Easton, JD; Henninger, N; Johnston, SC; Kim, AS; Kvernland, A; Liberman, AL; Mac Grory, B; Rostanski, SK; Yaghi, S, 2022) |
| " Aspirin increased major or CRNM bleeding, particularly in patients without prior stroke/TIA/TE." | 9.51 | Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. ( Alexander, JH; Aronson, R; Bahit, MC; Berwanger, O; Dombrowski, KE; Goodman, SG; Granger, CB; Halvorsen, S; Jordan, JD; Kolls, BJ; Li, Z; Lopes, RD; Mehran, R; Thomas, L; Vinereanu, D; Vora, AN; Windecker, S; Wojdyla, DM, 2022) |
| "Ticagrelor-aspirin was associated with reduced risk of new stroke in patients without hypertension (32 [4." | 9.51 | Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack. ( Bath, PM; Chen, G; Huang, P; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, F; Wang, Y; Xie, X; Zhao, X; Zuo, Y, 2022) |
| "Dual antiplatelet therapy (DAPT) with ticagrelor and aspirin has been found to be effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA) in individuals who carry CYP2C19 loss-of-function (LOF) alleles; however, uncertainties remain about the time course of benefit and risk with ticagrelor and aspirin in these patients." | 9.51 | Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial. ( Bath, PM; Cheng, J; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, Y; Wang, Z; Xie, X; Yang, H; Zhao, X, 2022) |
| "Whether aspirin platelet reactivity affects platelet function and clinical outcomes with different antiplatelet therapies in patients with mild stroke or transient ischemic attack (TIA) remains unclear." | 9.51 | Aspirin platelet reactivity on platelet function and clinical outcome in minor stroke or transient ischemic attack. ( Chen, W; Guo, L; Jiang, L; Liu, L; Pan, Y; Wang, Y; Xu, Y; Yao, D; Zhao, X, 2022) |
| "In patients with acute mild-moderate ischemic stroke or high-risk transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and Aspirin for Prevention of Stroke and Death) demonstrated that when added to aspirin, ticagrelor reduced stroke or death but increased risk of severe hemorrhage compared with placebo." | 9.41 | Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. ( Amarenco, P; Aunes, M; Denison, H; Evans, SR; Himmelmann, A; Jahreskog, M; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Molina, CA; Nylander, S; Röther, J; Wang, Y, 2021) |
| "Ticagrelor is slightly better than clopidogrel and aspirin in preventing stroke, especially ischemic stroke, with significant safety risks." | 9.41 | Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis. ( Chen, Y; Li, D; Liu, S; Ma, X; Zhong, P, 2023) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel was recommended as the secondary prevention of minor ischemic stroke or transient ischaemic attack (TIA)." | 9.41 | Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis. ( Ge, F; Li, M; Lin, H; Shi, J; Yang, Q; Zhang, X, 2023) |
| "The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain." | 9.41 | A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. ( Almeida, AP; Ardito, RV; Atik, FA; Barreto, DO; Berwanger, O; Campos, VB; Cavalcante, MA; Cavalcanti, AB; D'Oliveira Vieira, R; Damiani, L; de Barros E Silva, PGM; de Lima, CEB; de Souza Neto, JD; Dos Santos, JRY; Farias, FR; Ferreira, JFM; Figueira, FAMS; Fonseca, FH; Guimarães, HP; Hoffmann-Filho, CR; Junior, RA; Kalil, PSA; Kojima, F; Lamprea, D; Laranjeira, L; Leiria, TLL; Liporace, IL; Lopes, RD; Magalhães, CC; Maldonado, JGA; Mesas, CE; Moisés, VA; Nakagawa, RH; Paiva, MSMO; Paixão, M; Patriota, R; Pavanello, R; Pinto, IM; Precoma, DB; Sampaio, BS; Sampaio, RO; Saraiva, JFK; Silveira, FS; Tarasoutchi, F; Zilli, AC, 2021) |
| "Clopidogrel and aspirin are key intervention for acute ischemic stroke (AIS) and transient ischemic attack (TIA)." | 9.41 | Personalized antiplatelet therapy based on clopidogrel/aspirin resistance tests in acute ischemic stroke and transient ischemic attack: Study protocol of a multi-center, single-blinded and randomized controlled trial. ( Chen, J; Gao, P; Han, M; Jia, W; Kuang, J; Peng, C; Starcevich, K; Tu, J; Wang, J; Wu, Y; Yi, Y; Yin, S; Zhang, X, 2021) |
| " Approach and Results: The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) randomized patients with acute minor ischemic stroke or high-risk transient ischemic attack to clopidogrel plus aspirin or aspirin alone from October 1, 2009, to July 30, 2012, in China." | 9.34 | Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial. ( Li, H; Li, J; Lin, J; Liu, L; Wang, A; Wang, Y; Zhao, X; Zuo, Z, 2020) |
| "Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke or transient ischemic attack (TIA)." | 9.34 | Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Molina, CA; Wang, Y, 2020) |
| "Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone." | 9.30 | Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. ( Barsan, W; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY; Tillman, H, 2019) |
| "Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin has been suggested by American Heart Association/American Stroke Association guidelines for minor stroke (MS) and transient ischemic attack (TIA) patients." | 9.30 | Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile. ( Chen, W; Chen, Z; Dai, L; Li, H; Meng, X; Mo, J; Wang, A; Wang, Y; Wangqin, R; Xian, Y; Xu, J; Zhao, X, 2019) |
| "In patients with acute minor ischemic stroke or high-risk transient ischemic attack enrolled in the POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke [POINT] Trial), the combination of clopidogrel and aspirin for 90 days reduced major ischemic events but increased major hemorrhage in comparison to aspirin alone." | 9.30 | Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. ( Albers, GW; Barsan, WG; Cucchiara, BL; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Kleindorfer, DO; Lindblad, AS; Lutsep, HL; Palesch, YY; Pearson, C; Sethi, P; Vora, N; Zurita, KG, 2019) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 9.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis." | 9.24 | Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "In the SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), ticagrelor was not superior to aspirin." | 9.24 | Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS, 2017) |
| "Ticagrelor is an effective antiplatelet therapy for patients with coronary atherosclerotic disease and might be more effective than aspirin in preventing recurrent stroke and cardiovascular events in patients with acute cerebral ischaemia of atherosclerotic origin." | 9.24 | Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is effective in preventing recurrent strokes after minor ischemic stroke or transient ischemic attack (TIA)." | 9.22 | Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Zitikyte, G, 2022) |
| "This systematic review aimed to compare early use of P2Y12 inhibitors (clopidogrel/ticagrelor) plus aspirin to aspirin alone for acute treatment and secondary prevention in acute non-cardioembolic minor ischemic stroke or TIA." | 9.22 | P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: A systematic review and meta-analysis. ( Bellesini, M; Galli, E; Maroni, L; Pomero, F; Squizzato, A, 2022) |
| "P2Y12 receptor inhibitor plus aspirin vs aspirin given within 24 h after acute noncardioembolic ischemic stroke or TIA reduces the risk of subsequent stroke." | 9.22 | P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis. ( Huang, WY; Lee, M; Ovbiagele, B, 2022) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 9.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "Ticagrelor may be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and cardiovascular events in patients with acute cerebral ischemia." | 9.22 | Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS, 2016) |
| "Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone." | 9.22 | Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016) |
| "Dual clopidogrel-aspirin therapy was associated with a marked reduction in new strokes compared with the therapy of aspirin alone in patients with normal renal function (hazard ratio, 0." | 9.22 | Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Wu, Y; Zhao, X; Zhou, Y, 2016) |
| "The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreases the 90-day risk of stroke without increasing hemorrhage in comparison with aspirin alone, but provided insufficient data to establish whether the benefit persisted over a longer period of time beyond the trial termination." | 9.20 | Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| "We compared the effect of clopidogrel plus aspirin vs aspirin alone on functional outcome and quality of life in the Clopidogrel in High-risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial of aspirin-clopidogrel vs aspirin alone after acute minor stroke or TIA." | 9.20 | Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. ( Fang, J; Hu, B; Johnston, SC; Li, H; Liu, L; Meng, X; Wang, A; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Zhao, X, 2015) |
| "To study whether Clopidogrel-Aspirin combined treatment for high risk transient ischaemic attack (TIA) or minor stroke results in increased number of lesions associated with anti-thrombotic cerebral haemorrhage or cerebral micro-bleeds (CMB) than aspirin alone treatment." | 9.20 | Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds. ( Wang, P; Wang, Y; Wang, Z; Xin, H; Xu, C, 2015) |
| "We showed that slower than standard dose escalation of dipyridamole in combination therapy with acetylsalicylic acid does not reduce headaches as a side effect." | 9.19 | The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE). ( de Vogel, EM; de Vos-Koppelaar, NC; Dieleman, HG; Kerkhoff, H; Zock, E, 2014) |
| "Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage." | 9.17 | Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013) |
| "In AVERROES, 5599 patients (mean age 70 years) with atrial fibrillation who were at increased risk of stroke and unsuitable for vitamin K antagonist therapy were randomly assigned to receive apixaban (5 mg twice daily) or aspirin (81-324 mg per day)." | 9.16 | Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. ( Connolly, SJ; Diener, HC; Eikelboom, J; Hankey, GJ; Hart, RG; Hohnloser, SH; Joyner, CD; Lip, GY; O'Donnell, M; Shestakovska, O; Yusuf, S, 2012) |
| " Platelet surface marker expression, leucocyte-platelet complex formation and inhibition of platelet function at high shear stress as detected by the PFA-100® Collagen-Adenosine-diphosphate (C-ADP) and Collagen-Epinephrine cartridges was assessed in 52 patients within 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke on aspirin, and then 14 d (14 d) and >90 d (90 d) after adding dipyridamole." | 9.15 | Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study. ( Collins, DR; Coughlan, T; Egan, B; Feeley, TM; Kinsella, JA; McCabe, DJ; Murphy, RP; O'Neill, D; Tierney, S; Tobin, WO, 2011) |
| "The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study is an international double-blind, randomized controlled trial designed to investigate the superiority of the specific TP receptor antagonist terutroban (30 mg/day) over aspirin (100 mg/day), in reducing cerebrovascular and cardiovascular events in patients with a recent history of ischemic stroke or transient ischemic attack." | 9.14 | The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, M; Mattle, HP; Rothwell, PM, 2009) |
| "Secondary pharmacological prevention of ischemic stroke or transient ischemic attack (TIA) is often provided with acetylsalicylic acid (ASA), dipyridamole (DP) or a combination of the two." | 9.14 | Dipyridamole-associated headache in stroke patients--interindividual differences? ( Lökk, J, 2009) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 9.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Patients experiencing acute ischemic stroke or transient ischemic attack are commonly treated with clopidogrel and/or aspirin (mono- and dual-antiplatelet therapy) to minimize the risk for recurrent stroke." | 9.12 | Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis. ( Huang, Z; Yang, Y; Zhang, X, 2021) |
| "As compared to aspirin alone, short-term DAPT within 24 hours of high-risk transient ischemic attack or mild-moderate ischemic stroke reduces the risk of recurrent stroke at the expense of higher risk of major bleeding." | 9.12 | Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials. ( Aggarwal, D; Arora, S; Bhatia, K; Hussain, Z; Jain, V; Qamar, A; Ricciardi, M; Tafur, A; Uberoi, G; Vaduganathan, M; Zhang, C, 2021) |
| "In patients with noncardioembolic mild stroke or high-risk transient ischemic attack, DAPT with aspirin and clopidogrel/ticagrelor is more effective than aspirin alone for recurrent stroke prevention with a small absolute increase in the risk of severe or moderate bleeding." | 9.12 | P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack. ( Fisher, M; Gu, HQ; Johnston, SC; Li, ZX; Wang, YJ; Xian, Y; Xiong, Y, 2021) |
| "gov databases, main international conference proceedings were searched for randomized controlled trials comparing DAPT versus aspirin monotherapy in patients with acute ischemic stroke or TIA not eligible for thrombolysis or thrombectomy presenting in the first 24 hours after the acute event." | 9.12 | Clinical Effects of Dual Antiplatelet Therapy or Aspirin Monotherapy after Acute Minor Ischemic Stroke or Transient Ischemic Attack, a Meta-Analysis. ( Condello, F; Ferrante, G; Liccardo, G, 2021) |
| " Orbofiban, despite no significant excess risk of ICH, was not effective in preventing ischemic stroke or TIA." | 9.12 | Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. ( Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE, 2006) |
| "Combination of low-dose aspirin and modified-release dipyridamole (ASA+MR-DP) provides a significantly increased benefit in stroke prevention over aspirin alone." | 9.12 | Dose titration to reduce dipyridamole-related headache. ( Chang, YJ; Lee, TH; Ryu, SJ, 2006) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 9.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "There is still worldwide disagreement about the optimal lowest dose of aspirin to be used in patients after a transient ischemic attack (TIA) or nondisabling stroke." | 9.11 | What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? ( Dippel, DW; Koudstaal, PJ; Leebeek, FW; Li, SS; Mehicevic, A; Van Kooten, F; van Vliet, HH, 2004) |
| "This pilot trial has not found differences between triflusal and aspirin in the prevention of vascular complications after TIA or ischemic stroke, although given the wide CI, potentially important group differences could not be ruled out." | 9.11 | Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. ( Abiusi, G; Bauso-Tosselli, L; Culebras, A; Domínguez, R; Famulari, A; Ferrari, J; Gori, H; Reich, E; Rey, R; Rotta-Escalante, R; Vila, J, 2004) |
| "Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis." | 9.11 | Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005) |
| "To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan." | 9.10 | Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003) |
| "The Coumadin Aspirin Reinfarction Study demonstrated that combination treatment with fixed dose warfarin (1 or 3 mg) + aspirin 80 mg was not superior to aspirin 160 mg alone after myocardial infarction for reducing nonfatal reinfarction, nonfatal stroke, and cardiovascular death." | 9.09 | Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). ( Berkowitz, SD; Califf, RM; Daly, R; Fuster, V; Gattis, WA; Gheorghiade, M; Harrington, RA; Hellkamp, AS; Kopecky, SL; Langer, A; Larsen, RL; O'Connor, CM; O'Gara, PT, 2001) |
| "Mortality rates in this group were not significantly different for patients not taking aspirin as compared with the rates for those taking aspirin, although patients not taking aspirin had a higher incidence of myocardial infarction (27%) as compared with patients taking aspirin (8%), p < 0." | 9.07 | Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis. ( Hobson, RW; Krupski, WC; Weiss, DG, 1993) |
| "Background and Purpose- The role of aspirin plus clopidogrel (A+C) therapy compared with aspirin monotherapy in patients presenting with acute ischemic stroke (IS) or transient ischemic attack remains uncertain." | 9.01 | Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. ( Hammad, T; Kaluski, E; Khan, SU; Meyer, MA; Nasir, F; Rahman, H, 2019) |
| "To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)." | 8.98 | Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018) |
| "Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain." | 8.95 | Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014." | 8.93 | Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016) |
| "Aspirin is recommended for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% reduction in long-term risk of recurrent stroke." | 8.93 | Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. ( Algra, A; Chen, Z; Diener, HC; Mehta, Z; Norrving, B; Rothwell, PM, 2016) |
| "Low-dose aspirin, alone or in combination, is recommended for the secondary prevention of acute non-cardioembolic ischemic stroke and transient ischemic attack, starting soon after the acute event." | 8.93 | Aspirin, stroke and drug-drug interactions. ( Petrucci, G; Rocca, B; Russo, NW, 2016) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 8.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "The safety and efficacy of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in the setting of secondary stroke prevention are reviewed." | 8.91 | Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. ( Davis, KA; Dietrich, E; Miyares, MA, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 8.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| "Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke." | 8.89 | The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013) |
| "We performed meta-analyses to assess the effectiveness and safety of combination therapy with aspirin and dipyridamole (A+D) versus aspirin (A) alone in secondary prevention after transient ischemic attack (TIA) or stroke of presumed arterial origin within one week and six months." | 8.89 | The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. ( Li, X; Zhou, G; Zhou, S; Zhou, X, 2013) |
| "To study the effect of combination therapy with aspirin and dipyridamole (A+D) over aspirin alone (ASA) in secondary prevention after transient ischaemic attack (TIA) or minor stroke of presumed arterial origin and to perform subgroup analyses to identify patients that might benefit most from secondary prevention with A+D." | 8.84 | Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. ( Algra, A; Bath, PM; Diener, HC; Gray, LJ; Guiraud-Chaumeil, B; Halkes, PH; Yatsu, FM, 2008) |
| "This meta-analysis systematically reviewed randomized controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and TIA to determine the efficacy of these agents in preventing recurrent cerebral and systemic vascular events." | 8.84 | Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. ( Gorelick, PB; Nguyen, D; Verro, P, 2008) |
| "Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results." | 8.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "Among patients with TIA or mild ischemic stroke, the combination of cinnamon and aspirin could be superior to aspirin alone for reducing the risk of 90-day recurrent stroke." | 8.12 | Cinnamon and Aspirin for Mild Ischemic Stroke or Transient Ischemic Attack: A Pilot Trial. ( Fan, Y; He, P; He, Z; Li, Z; Liang, J; Wu, Y; Zhang, L, 2022) |
| "The goal of this work was to investigate the short-term time-course benefit and risk of ticagrelor with aspirin in acute mild-moderate ischemic stroke or high-risk TIA in The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial." | 8.12 | Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Li, H; Molina, CA; Pan, Y; Wang, Y, 2022) |
| "Among the 3456 patients included, a total of 10 patients in the Clopidogrel Discontinuation Group and 11 patients in the non-Clopidogrel Discontinuation Group presented ischemic stroke recurrence during the 90-180-day period." | 8.12 | No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke. ( Jing, J; Johnston, SC; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, D; Wang, Y; Zhang, X; Zhao, X, 2022) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 8.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 8.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "Fifty one acute stroke/transient ischemic attack (TIA) patients (ASG) with a history of regular aspirin intake for the previous 7 days or more were included to the study within 24 hours of symptoms onset." | 8.02 | Biochemical aspirin resistance in acute stroke patients and its association with clinical factors: a prospective pilot study. ( Fiszer, U; Kubiak-Balcerewicz, K; Morton, M; Sarnowska, A, 2021) |
| "Patients with ischemic stroke receiving aspirin (100 mg/day) for three months were recruited for a multicenter, prospective, cohort study." | 8.02 | Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions. ( Chen, Y; Deng, W; Huang, W; Jiang, H; Li, J; Liang, Z; Liu, Q; Ou, Z; Ouyang, F; Wu, Z; Xing, S; Zeng, J; Zhang, Y, 2021) |
| " Here we assessed the contribution of clopidogrel versus aspirin to the development of pneumonia during an acute ischemic stroke admission." | 8.02 | Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients. ( Feng, Q; Fu, J; Jin, X; Shan, B; Shen, R; Yu, Z; Zhou, H; Zhu, H, 2021) |
| " We conducted a network meta-analysis to compare ticagrelor with other receptor antagonists (P2Y12) inhibitors and aspirin in monotherapy or combination in the treatment of patients with high risk for cardiovascular or cerebrovascular disease, defined as coronary artery disease, acute coronary syndrome, stroke or transient ischemic attack, or peripheral artery disease." | 8.02 | Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. ( Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021) |
| " Clopidogrel plus aspirin treatment was associated with reduced risk of new stroke in patients with ABCB1 -154 TT and 3435 CC genotype (hazard ratio [HR], 0." | 7.91 | Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. ( Chen, W; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Simon, T; Wang, D; Wang, Y; Zhao, X, 2019) |
| "The relationship of CYP2C19 genotype and clinical efficacy in stroke or transient ischemic attack (TIA) patients treated with clopidogrel monotherapy or clopidogrel plus aspirin remains unknown." | 7.88 | Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis. ( Cui, M; Gu, ZC; Li, WY; Pan, MM; Yao, JC, 2018) |
| "WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG." | 7.88 | Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. ( Agoritsas, T; Booth, B; Fisch, L; Fobuzi, AC; Fraiz, A; Gorthi, SP; Guyatt, G; Hao, Q; Heen, AF; Horton, E; Jusufovic, M; Katragunta, N; Lytvyn, L; Muller, J; O'Donnell, M; Prasad, K; Rochwerg, B; Siemieniuk, J; Siemieniuk, R; Vandvik, PO, 2018) |
| "Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds." | 7.85 | Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome ( Albers, GW; Amarenco, P; Aunes, M; Bokelund-Singh, S; Denison, H; Easton, JD; Evans, SR; Held, P; Jahreskog, M; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| " MIAs were frequently preceded or followed by ocular ischemic events of blurred vision, scotomas, transient flashing of the eyes, and sudden transient partial blindness preceded or followed erythromelalgia in the toes or fingers." | 7.81 | Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ( Berneman, Z; De Raeve, H; Gadisseur, A; Lam, KH; Michiels, JJ; Schroyens, W, 2015) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Treatment with the combination of clopidogrel and aspirin taken soon after a transient ischemic attack (TIA) or minor stroke was shown to reduce the 90-day risk of stroke in a large trial in China, but the cost-effectiveness is unknown." | 7.80 | Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. ( Johnston, SC; Liu, G; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, Y; Zhao, K; Zhao, X, 2014) |
| "We examined 157 aspirin-treated patients with acute stroke or TIA, 128 aspirin-free and 15 aspirin-treated healthy subjects (HS)." | 7.79 | TXA2 synthesis and COX1-independent platelet reactivity in aspirin-treated patients soon after acute cerebral stroke or transient ischaemic attack. ( Lago, A; Moscardo, A; Parkhutik, V; Santos, MT; Tembl, J; Valles, J, 2013) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 7.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "To examine healthcare costs among patients hospitalized for transient ischemic attack or ischemic stroke (TIA/stroke) and prescribed aspirin plus extended-release dipyridamole (ASA-ERDP) or clopidogrel (CLOPID) within 30 days post-discharge using a retrospective claims database from a large US managed care organization." | 7.78 | One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel. ( Burton, TM; Lacey, M; Lang, K; Liu, F; Monsalvo, ML; Sander, S; Yu, Y, 2012) |
| " In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques." | 7.78 | Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012) |
| "Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain." | 7.76 | Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010) |
| "The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke." | 7.76 | Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010) |
| "The authors prospectively included acute ischemic stroke/TIA patients who were treated at Thammasat Hospital from August, 2006 to July, 2007 and had already been on aspirin." | 7.74 | Aspirin non-responders in Thai ischemic stroke/TIA patients. ( Dharmasaroja, P, 2008) |
| "Vascular events commonly recur in stroke patients on aspirin, and may reflect incomplete inhibition of platelet function with aspirin therapy." | 7.73 | Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. ( Brown, MM; Harrison, P; Lawrie, AS; Machin, SJ; Mackie, IJ; McCabe, DJ; Purdy, G; Sidhu, PS, 2005) |
| "There is substantial interpatient variability in response to aspirin after an ischemic stroke or transient ischemic attack (TIA), as assessed by ex vivo effects of aspirin on platelet aggregation." | 7.73 | Sex difference in the antiplatelet effect of aspirin in patients with stroke. ( Brace, LD; Cavallari, LH; Helgason, CM; Nutescu, EA; Viana, MA, 2006) |
| "A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented." | 7.69 | Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis: a case report. ( Ashkenazi, E; Israel, Z; Spektor, S, 1995) |
| "Terutroban is a specific TP receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which may be of interest for the secondary prevention of ischemic stroke." | 6.74 | Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, MG; Mattle, HP; Rothwell, PM, 2009) |
| " The number of patients with adverse events and bleeding complications, and their severity, were significantly greater in the triple therapy group (p<0." | 6.73 | A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. ( Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008) |
| "Patients with minor ischemic stroke or transient ischemic attack represent a high-risk population for recurrent stroke." | 6.72 | Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Shorr, R; Zitikyte, G, 2021) |
| "Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke." | 6.61 | Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019) |
| " Although administration of antiplatelet agents has been confirmed to be one of the major approaches for secondary prevention of noncardioembolic stroke, the short-term or long-term use of aspirin plus clopidogrel for secondary stroke prevention remains to be controversial." | 6.52 | Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention. ( Chen, W; Wang, Y, 2015) |
| "Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (it may possibly be beneficial to women also), myocardial infarction and death in patients with unstable angina, thromboembolic complications associated with artificial heart valves in patients receiving oral anticoagulants (although gastrointestinal bleeding is prohibitive with this combination), and thrombotic occlusion of silicone rubber arteriovenous cannulae in uremic patients undergoing hemodialysis." | 6.15 | Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. ( Harker, LA, 1986) |
| " Its efficacy may exceed aspirin in improving clinical outcomes in patients with acute ischemic stroke who are ineligible for rt-PA." | 5.69 | A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke. ( Aref, HM; El-Khawas, H; Elbassiouny, A; Roushdy, TM; Shokri, HM; Zeinhom, MG, 2023) |
| "This study was performed to investigate whether ticagrelor/aspirin versus clopidogrel/aspirin can further reduce the residual risk of stroke recurrence in patients with positive diffusion-weighted imaging (DWI) in the High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial." | 5.69 | Genotype-Guided Dual Antiplatelet Use for Transient Ischemic Attack and Minor Stroke by Imaging Status: Subgroup Analysis of the CHANCE-2 Trial. ( Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Wang, A; Wang, Y; Xie, X; Xu, Q; Zhao, X, 2023) |
| "The aim of this study was to determine the effect of smoking status on subsequent stroke risk in patients with minor ischemic stroke or TIA and to determine whether smoking modifies the effect of clopidogrel-based DAPT on subsequent stroke risk." | 5.69 | Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial. ( de Havenon, A; Easton, JD; Furie, KL; Henninger, N; Johnston, SC; Kim, A; Lang, AE; Mac Grory, B; Shu, L; Yaghi, S, 2023) |
| "The Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial showed that ticagrelor-aspirin combination therapy reduced the risk of stroke compared with a clopidogrel-aspirin combination among carriers of CYP2C19 loss-of-function (LOF) alleles after a transient ischemic attack (TIA) or minor ischemic stroke." | 5.69 | Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial. ( Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, Y; Xie, X; Xu, A; Xu, Q; Zhao, X, 2023) |
| "In this secondary analysis of a randomized controlled trial involving patients with minor ischemic stroke or TIA, compared with clopidogrel-ASA, patients with obesity received more clinical benefit from ticagrelor-ASA therapy than those without obesity." | 5.69 | Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack. ( Jiang, Y; Jing, J; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, Y; Xie, X; Zhang, J; Zhao, X, 2023) |
| "The aim of this study is to investigate the effect of gradual dipyridamole titration and the incidence of dipyridamole-induced headache in patients with ischemic stroke or transient ischemic attack (TIA)." | 5.51 | Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial. ( Cha, JK; Chang, DI; Chang, JY; Chung, JW; Hong, KS; Jung, KH; Kang, MK; Kim, BK; Kim, HY; Lee, KY; Lee, SJ; Park, JM; Park, MS; Rha, JH; Shin, DI; Yoon, BW, 2022) |
| "In the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial, acute treatment with clopidogrel-aspirin was associated with significantly reduced risk of recurrent stroke." | 5.51 | Infarct on Brain Imaging, Subsequent Ischemic Stroke, and Clopidogrel-Aspirin Efficacy: A Post Hoc Analysis of a Randomized Clinical Trial. ( de Havenon, A; Easton, JD; Henninger, N; Johnston, SC; Kim, AS; Kvernland, A; Liberman, AL; Mac Grory, B; Rostanski, SK; Yaghi, S, 2022) |
| " Aspirin increased major or CRNM bleeding, particularly in patients without prior stroke/TIA/TE." | 5.51 | Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. ( Alexander, JH; Aronson, R; Bahit, MC; Berwanger, O; Dombrowski, KE; Goodman, SG; Granger, CB; Halvorsen, S; Jordan, JD; Kolls, BJ; Li, Z; Lopes, RD; Mehran, R; Thomas, L; Vinereanu, D; Vora, AN; Windecker, S; Wojdyla, DM, 2022) |
| "Ticagrelor-aspirin was associated with reduced risk of new stroke in patients without hypertension (32 [4." | 5.51 | Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack. ( Bath, PM; Chen, G; Huang, P; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, F; Wang, Y; Xie, X; Zhao, X; Zuo, Y, 2022) |
| "Dual antiplatelet therapy (DAPT) with ticagrelor and aspirin has been found to be effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA) in individuals who carry CYP2C19 loss-of-function (LOF) alleles; however, uncertainties remain about the time course of benefit and risk with ticagrelor and aspirin in these patients." | 5.51 | Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial. ( Bath, PM; Cheng, J; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, Y; Wang, Z; Xie, X; Yang, H; Zhao, X, 2022) |
| "Whether aspirin platelet reactivity affects platelet function and clinical outcomes with different antiplatelet therapies in patients with mild stroke or transient ischemic attack (TIA) remains unclear." | 5.51 | Aspirin platelet reactivity on platelet function and clinical outcome in minor stroke or transient ischemic attack. ( Chen, W; Guo, L; Jiang, L; Liu, L; Pan, Y; Wang, Y; Xu, Y; Yao, D; Zhao, X, 2022) |
| "To identify the ischemic stroke and transient ischemic attack (TIA) prevalence related to length of time of discontinuation of antiplatelet or vitamin K antagonist therapy, in a group of inpatients from a specialized neurological hospital in Brazil." | 5.51 | Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption. ( Kowacs, PA; Macuco, ALB; Nascimento, MTMS; Rizelio, V; Sato, HK; Souza, RKM, 2019) |
| "Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke." | 5.43 | High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016) |
| "In patients with acute mild-moderate ischemic stroke or high-risk transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and Aspirin for Prevention of Stroke and Death) demonstrated that when added to aspirin, ticagrelor reduced stroke or death but increased risk of severe hemorrhage compared with placebo." | 5.41 | Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. ( Amarenco, P; Aunes, M; Denison, H; Evans, SR; Himmelmann, A; Jahreskog, M; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Molina, CA; Nylander, S; Röther, J; Wang, Y, 2021) |
| "Single antiplatelet therapy (SAPT) with aspirin or clopidogrel reduces the risk of recurrent ischemic stroke in patients with non-cardioembolic ischemic stroke or TIA." | 5.41 | Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines. ( Alsbrook, DL; Bhatia, K; Carr, KH; Di Napoli, M; Divani, AA; Hinduja, A; Hosseini Farahabadi, M; Jafarli, A; Ladd, LM; McCullough, LD; Ortiz Garcia, JG; Sabbagh, SY; Saver, JL, 2023) |
| "Ticagrelor is slightly better than clopidogrel and aspirin in preventing stroke, especially ischemic stroke, with significant safety risks." | 5.41 | Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis. ( Chen, Y; Li, D; Liu, S; Ma, X; Zhong, P, 2023) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel was recommended as the secondary prevention of minor ischemic stroke or transient ischaemic attack (TIA)." | 5.41 | Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis. ( Ge, F; Li, M; Lin, H; Shi, J; Yang, Q; Zhang, X, 2023) |
| "The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain." | 5.41 | A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. ( Almeida, AP; Ardito, RV; Atik, FA; Barreto, DO; Berwanger, O; Campos, VB; Cavalcante, MA; Cavalcanti, AB; D'Oliveira Vieira, R; Damiani, L; de Barros E Silva, PGM; de Lima, CEB; de Souza Neto, JD; Dos Santos, JRY; Farias, FR; Ferreira, JFM; Figueira, FAMS; Fonseca, FH; Guimarães, HP; Hoffmann-Filho, CR; Junior, RA; Kalil, PSA; Kojima, F; Lamprea, D; Laranjeira, L; Leiria, TLL; Liporace, IL; Lopes, RD; Magalhães, CC; Maldonado, JGA; Mesas, CE; Moisés, VA; Nakagawa, RH; Paiva, MSMO; Paixão, M; Patriota, R; Pavanello, R; Pinto, IM; Precoma, DB; Sampaio, BS; Sampaio, RO; Saraiva, JFK; Silveira, FS; Tarasoutchi, F; Zilli, AC, 2021) |
| "Clopidogrel and aspirin are key intervention for acute ischemic stroke (AIS) and transient ischemic attack (TIA)." | 5.41 | Personalized antiplatelet therapy based on clopidogrel/aspirin resistance tests in acute ischemic stroke and transient ischemic attack: Study protocol of a multi-center, single-blinded and randomized controlled trial. ( Chen, J; Gao, P; Han, M; Jia, W; Kuang, J; Peng, C; Starcevich, K; Tu, J; Wang, J; Wu, Y; Yi, Y; Yin, S; Zhang, X, 2021) |
| "Stroke is the second leading cause of death." | 5.39 | Neuroprotective effect of a new synthetic aspirin-decursinol adduct in experimental animal models of ischemic stroke. ( Ahn, JH; Cho, JH; Choi, JH; Her, S; Hwang, IK; Hyun, BH; Jun, JG; Kim, CK; Kim, IH; Kim, JS; Kim, YM; Kwon, SH; Kwon, YG; Lee, CH; Lee, JC; Lee, YL; Park, JH; Shin, BN; Suh, HW; Won, MH; Yan, BC; Yoo, KY, 2013) |
| " Approach and Results: The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) randomized patients with acute minor ischemic stroke or high-risk transient ischemic attack to clopidogrel plus aspirin or aspirin alone from October 1, 2009, to July 30, 2012, in China." | 5.34 | Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial. ( Li, H; Li, J; Lin, J; Liu, L; Wang, A; Wang, Y; Zhao, X; Zuo, Z, 2020) |
| "Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke or transient ischemic attack (TIA)." | 5.34 | Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Molina, CA; Wang, Y, 2020) |
| "We performed an exploratory analysis of the interaction of the treatment effects of aspirin plus clopidogrel versus aspirin monotherapy, stratified by presence of ipsilateral nonstenotic carotid disease in patients with minor ischemic stroke in the POINT trial." | 5.34 | Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial. ( Brorson, JR; Bulwa, Z; Pinto, CB; Saleh Velez, FG, 2020) |
| "The European/Australasian stroke prevention in reversible ischaemia trial (ESPRIT) confirms that long-term administration of the combination acetylsalicylic acid and dipyridamole is more effective than acetylsalicylic acid in reducing the risk of vascular events after cerebral ischaemia of arterial origin." | 5.33 | [The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed]. ( De Keyser, JH; Luijckx, GJ, 2006) |
| "In patients with acute cerebral ischemia, the rate of stroke, myocardial infarction, or death during 90 days was reported to be non-significantly lower with ticagrelor compared with aspirin, with no increase in major hemorrhage." | 5.30 | The Acute S ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Molina, CA; Wang, Y, 2019) |
| "Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone." | 5.30 | Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. ( Barsan, W; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY; Tillman, H, 2019) |
| "SOCRATES compared ticagrelor and aspirin in 13,199 patients with acute minor stroke or high-risk transient ischemic attack." | 5.30 | Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Johnston, SC; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KL, 2019) |
| "Antiplatelet therapy combining aspirin and clopidogrel is considered to be a key intervention for acute ischaemic minor stroke (AIMS) and transient ischaemic attack (TIA)." | 5.30 | Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial. ( Hu, L; Jiang, HY; Li, ZZ; Xue, J; Yue, YH; Zhang, XG; Zhu, XQ, 2019) |
| "Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin has been suggested by American Heart Association/American Stroke Association guidelines for minor stroke (MS) and transient ischemic attack (TIA) patients." | 5.30 | Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile. ( Chen, W; Chen, Z; Dai, L; Li, H; Meng, X; Mo, J; Wang, A; Wang, Y; Wangqin, R; Xian, Y; Xu, J; Zhao, X, 2019) |
| "In patients with acute minor ischemic stroke or high-risk transient ischemic attack enrolled in the POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke [POINT] Trial), the combination of clopidogrel and aspirin for 90 days reduced major ischemic events but increased major hemorrhage in comparison to aspirin alone." | 5.30 | Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. ( Albers, GW; Barsan, WG; Cucchiara, BL; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Kleindorfer, DO; Lindblad, AS; Lutsep, HL; Palesch, YY; Pearson, C; Sethi, P; Vora, N; Zurita, KG, 2019) |
| "The objective was to assess whether rivaroxaban is superior to acetylsalicylic acid (ASA) in reducing the risk of clinically overt stroke, systemic embolism, or covert stroke among patients without apparent recurrent atrial arrhythmias for at least 1 year after their most recent AF ablation procedure." | 5.27 | The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. ( Birnie, DH; Champagne, J; Essebag, V; Gupta, D; Ha, ACT; Healey, JS; Heidbuchel, H; Hill, MD; Hindricks, G; Kirchhof, P; Sanders, P; Sharma, M; Verma, A; Wells, G; Wyse, DG, 2018) |
| " ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing rivaroxaban versus aspirin in patients with recent ESUS." | 5.27 | Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. ( Amarenco, P; Ameriso, SF; Arauz, A; Bereczki, D; Berkowitz, SD; Bornstein, N; Brouns, R; Connolly, SJ; Cunha, L; Czlonkowska, A; Dávalos, A; DeVries Basson, MM; Eckstein, J; Endres, M; Gagliardi, R; Hankey, GJ; Hart, RG; Kasner, SE; Kirsch, B; Lang, W; Lavados, P; Lindgren, A; Mikulik, R; Muir, K; Mundl, H; Ntaios, G; O'Donnell, M; Ozturk, S; Pare, G; Pater, C; Peacock, WF; Peters, G; Shamalov, N; Sharma, M; Shoamanesh, A; Swaminathan, B; Tatlisumak, T; Themeles, E; Toni, DS; Uchiyama, S; Veltkamp, R; Wang, Y; Weitz, J; Yoon, BW, 2018) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 5.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death." | 5.24 | Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi ( Al-Qoofi, F; Chamandi, C; Côté, M; Dumont, E; Garcia Del Blanco, B; Généreux, P; Maluenda, G; Masson, JB; Paradis, JM; Pelletier, M; Rodés-Cabau, J; Serra, V; Thoenes, M; Webb, JG; Welsh, RC, 2017) |
| "Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis." | 5.24 | Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "In the SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), ticagrelor was not superior to aspirin." | 5.24 | Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS, 2017) |
| "Ticagrelor is an effective antiplatelet therapy for patients with coronary atherosclerotic disease and might be more effective than aspirin in preventing recurrent stroke and cardiovascular events in patients with acute cerebral ischaemia of atherosclerotic origin." | 5.24 | Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is effective in preventing recurrent strokes after minor ischemic stroke or transient ischemic attack (TIA)." | 5.22 | Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Zitikyte, G, 2022) |
| "This systematic review aimed to compare early use of P2Y12 inhibitors (clopidogrel/ticagrelor) plus aspirin to aspirin alone for acute treatment and secondary prevention in acute non-cardioembolic minor ischemic stroke or TIA." | 5.22 | P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: A systematic review and meta-analysis. ( Bellesini, M; Galli, E; Maroni, L; Pomero, F; Squizzato, A, 2022) |
| "It was found that the effectiveness of dual antiplatelet therapy in patients with minor ischaemic stroke or high risk transient ischaemic attack does not significantly differ in patients with prior aspirin exposure; therefore there should be no influence on the decision to use dual antiplatelet therapy." | 5.22 | Does prior use of antiplatelet therapy modify the effect of dual antiplatelet therapy in transient ischaemic attack/minor ischaemic stroke: A systematic review and meta-analysis. ( Clarke, A; Murphy, R; O'Donnell, MJ; Reddin, C, 2022) |
| " Cilostazol proved to be the most efficacious in reducing stroke recurrence and the risk of bleeding (RR = 0." | 5.22 | Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials. ( Bálint, A; El Abdallaoui, OEA; Komócsi, A; Kupó, P; Szapáry, L; Szapáry, LB; Tornyos, D, 2022) |
| "P2Y12 receptor inhibitor plus aspirin vs aspirin given within 24 h after acute noncardioembolic ischemic stroke or TIA reduces the risk of subsequent stroke." | 5.22 | P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis. ( Huang, WY; Lee, M; Ovbiagele, B, 2022) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 5.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "Ticagrelor may be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and cardiovascular events in patients with acute cerebral ischemia." | 5.22 | Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS, 2016) |
| "Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone." | 5.22 | Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016) |
| "Dual clopidogrel-aspirin therapy was associated with a marked reduction in new strokes compared with the therapy of aspirin alone in patients with normal renal function (hazard ratio, 0." | 5.22 | Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Wu, Y; Zhao, X; Zhou, Y, 2016) |
| "Participants in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) trials with HF, but not randomized to oral anticoagulation, were categorized as having preserved versus reduced ejection fraction." | 5.20 | Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. ( Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S, 2015) |
| "The Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events trial randomized minor ischemic stroke or TIA patients to antiplatelet therapy of clopidogrel plus aspirin or aspirin alone." | 5.20 | Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke. ( Li, J; Lin, J; Liu, L; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| "The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreases the 90-day risk of stroke without increasing hemorrhage in comparison with aspirin alone, but provided insufficient data to establish whether the benefit persisted over a longer period of time beyond the trial termination." | 5.20 | Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| "We compared the effect of clopidogrel plus aspirin vs aspirin alone on functional outcome and quality of life in the Clopidogrel in High-risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial of aspirin-clopidogrel vs aspirin alone after acute minor stroke or TIA." | 5.20 | Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. ( Fang, J; Hu, B; Johnston, SC; Li, H; Liu, L; Meng, X; Wang, A; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Zhao, X, 2015) |
| "To study whether Clopidogrel-Aspirin combined treatment for high risk transient ischaemic attack (TIA) or minor stroke results in increased number of lesions associated with anti-thrombotic cerebral haemorrhage or cerebral micro-bleeds (CMB) than aspirin alone treatment." | 5.20 | Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds. ( Wang, P; Wang, Y; Wang, Z; Xin, H; Xu, C, 2015) |
| " Treatment with rivaroxaban may prevent more cerebrovascular events with an acceptable risk profile after TIA or minor stroke, compared with aspirin, thus helping to improve the outcome of the disease." | 5.20 | Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial. ( Bai, Y; Han, J; Jiang, W; Liu, X; Yang, F; Zhang, G; Zhao, G, 2015) |
| "We examined the efficacy and safety of dual antiplatelets in patients with transient ischemic attack or minor stroke, defined as National Institute of Health Stroke Scale scores 0-3, in a subgroup analysis of Clopidogrel plus aspirin versus Aspirin alone for Reducing embolization in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR) study." | 5.19 | Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study. ( Chen, C; Fu, J; Han, Z; Huang, Y; Lau, AY; Leung, TW; Markus, HS; Ratanakorn, D; Suwanwela, NC; Tan, KS; Wong, KS; Zhao, Y, 2014) |
| "We showed that slower than standard dose escalation of dipyridamole in combination therapy with acetylsalicylic acid does not reduce headaches as a side effect." | 5.19 | The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE). ( de Vogel, EM; de Vos-Koppelaar, NC; Dieleman, HG; Kerkhoff, H; Zock, E, 2014) |
| "Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage." | 5.17 | Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013) |
| "The aim of POINT is to determine whether clopidogrel plus aspirin taken <12 h after transient ischemic attack or minor ischemic stroke symptom onset is more effective in preventing major ischemic vascular events at 90 days in the high-risk, and acceptably safe, compared with aspirin alone." | 5.17 | Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. ( Barsan, W; Battenhouse, H; Conwit, R; Dillon, C; Easton, JD; Elm, J; Farrant, M; Johnston, SC; Lindblad, A; Morgenstern, L; Palesch, Y; Poisson, SN, 2013) |
| " Patients were assessed at baseline [≤ 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke], and at 14 days and ≥ 90 days after changing treatment from (i) no medication to aspirin monotherapy (N = 26) or (ii) aspirin to clopidogrel monotherapy (N = 22)." | 5.17 | High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study. ( Collins, DR; Coughlan, T; Egan, B; Feeley, TM; Kinsella, JA; McCabe, DJ; Murphy, RP; O'Neill, D; Tierney, S; Tobin, WO, 2013) |
| "In AVERROES, 5599 patients (mean age 70 years) with atrial fibrillation who were at increased risk of stroke and unsuitable for vitamin K antagonist therapy were randomly assigned to receive apixaban (5 mg twice daily) or aspirin (81-324 mg per day)." | 5.16 | Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. ( Connolly, SJ; Diener, HC; Eikelboom, J; Hankey, GJ; Hart, RG; Hohnloser, SH; Joyner, CD; Lip, GY; O'Donnell, M; Shestakovska, O; Yusuf, S, 2012) |
| " Platelet surface marker expression, leucocyte-platelet complex formation and inhibition of platelet function at high shear stress as detected by the PFA-100® Collagen-Adenosine-diphosphate (C-ADP) and Collagen-Epinephrine cartridges was assessed in 52 patients within 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke on aspirin, and then 14 d (14 d) and >90 d (90 d) after adding dipyridamole." | 5.15 | Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study. ( Collins, DR; Coughlan, T; Egan, B; Feeley, TM; Kinsella, JA; McCabe, DJ; Murphy, RP; O'Neill, D; Tierney, S; Tobin, WO, 2011) |
| " Patients who had an ischaemic stroke in the previous 3 months or a TIA in the previous 8 days were randomly allocated with a central interactive response system to 30 mg per day terutroban or 100 mg per day aspirin." | 5.15 | Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. ( Amarenco, P; Bousser, MG; Chamorro, A; de Cordoüe, A; Fisher, M; Ford, I; Fox, KM; Fratacci, MD; Hennerici, MG; Mattle, HP; Rothwell, PM, 2011) |
| "We compared baseline features and the rates of stroke or vascular death and stroke in the territory of the symptomatic artery between patients ON (n=299) versus OFF (n=269) antithrombotics at the time of their qualifying event for the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial." | 5.14 | Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. ( Chimowitz, MI; Cotsonis, G; Levine, SR; Lynn, MJ; Maidan, L; Romano, JG; Turan, TN, 2009) |
| "The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study is an international double-blind, randomized controlled trial designed to investigate the superiority of the specific TP receptor antagonist terutroban (30 mg/day) over aspirin (100 mg/day), in reducing cerebrovascular and cardiovascular events in patients with a recent history of ischemic stroke or transient ischemic attack." | 5.14 | The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, M; Mattle, HP; Rothwell, PM, 2009) |
| "Secondary pharmacological prevention of ischemic stroke or transient ischemic attack (TIA) is often provided with acetylsalicylic acid (ASA), dipyridamole (DP) or a combination of the two." | 5.14 | Dipyridamole-associated headache in stroke patients--interindividual differences? ( Lökk, J, 2009) |
| "We quantified visit-to-visit variability in BP and explored potential confounding factors by analysing repeat measurements obtained every few months during follow-up in two large trials in patients with a transient ischaemic attack (TIA) or minor ischaemic stroke: the UK-TIA Aspirin Trial (effect of aspirin, effect of season and day of the week of measurement) and the European Carotid Surgery Trial (ECST - effect of carotid endarterectomy)." | 5.14 | Reproducibility of measures of visit-to-visit variability in blood pressure after transient ischaemic attack or minor stroke. ( Howard, SC; Rothwell, PM, 2009) |
| "The clopidogrel plus aspirin for infarction reduction in acute stroke or transient ischaemic attack patients with large artery stenosis and microembolic signals (CLAIR) trial was a randomised, open-label, blinded-endpoint trial." | 5.14 | Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. ( Chang, HM; Chen, C; Chollate, P; Fu, J; Han, Z; Hao, Q; Huang, YN; Koh, A; Markus, HS; Ratanakorn, D; Suwanwela, NC; Tan, KS; Wong, KS; Zhao, Y, 2010) |
| "The study will randomize 5,100 Chinese patients with acute TIA or minor stroke to receive a 3-month regimen of clopidogrel initiated with a loading dose of 300 mg followed by 75 mg/d, combined with aspirin 75 mg/d during the first 21 days, or a 3-month regimen of aspirin 75 mg/d alone." | 5.14 | Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. ( Johnston, SC; Wang, Y, 2010) |
| "We extended the follow-up of 2473 patients from the Dutch TIA Trial (recruitment March 1986 to March 1989, all treated with aspirin; CIAO) and 186 Dutch participants of the European Atrial Fibrillation Trial (recruitment June 1988 to May 1992, 26% on anticoagulants during the trial; CIAF)." | 5.13 | Long-term occurrence of death and cardiovascular events in patients with transient ischaemic attack or minor ischaemic stroke: comparison between arterial and cardiac source of the index event. ( Algra, A; Gorter, JW; Kappelle, LJ; Koudstaal, PJ; van Gijn, J; van Wijk, I, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 5.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Patients experiencing acute ischemic stroke or transient ischemic attack are commonly treated with clopidogrel and/or aspirin (mono- and dual-antiplatelet therapy) to minimize the risk for recurrent stroke." | 5.12 | Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis. ( Huang, Z; Yang, Y; Zhang, X, 2021) |
| "As compared to aspirin alone, short-term DAPT within 24 hours of high-risk transient ischemic attack or mild-moderate ischemic stroke reduces the risk of recurrent stroke at the expense of higher risk of major bleeding." | 5.12 | Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials. ( Aggarwal, D; Arora, S; Bhatia, K; Hussain, Z; Jain, V; Qamar, A; Ricciardi, M; Tafur, A; Uberoi, G; Vaduganathan, M; Zhang, C, 2021) |
| "In patients with noncardioembolic mild stroke or high-risk transient ischemic attack, DAPT with aspirin and clopidogrel/ticagrelor is more effective than aspirin alone for recurrent stroke prevention with a small absolute increase in the risk of severe or moderate bleeding." | 5.12 | P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack. ( Fisher, M; Gu, HQ; Johnston, SC; Li, ZX; Wang, YJ; Xian, Y; Xiong, Y, 2021) |
| "gov databases, main international conference proceedings were searched for randomized controlled trials comparing DAPT versus aspirin monotherapy in patients with acute ischemic stroke or TIA not eligible for thrombolysis or thrombectomy presenting in the first 24 hours after the acute event." | 5.12 | Clinical Effects of Dual Antiplatelet Therapy or Aspirin Monotherapy after Acute Minor Ischemic Stroke or Transient Ischemic Attack, a Meta-Analysis. ( Condello, F; Ferrante, G; Liccardo, G, 2021) |
| " Orbofiban, despite no significant excess risk of ICH, was not effective in preventing ischemic stroke or TIA." | 5.12 | Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. ( Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE, 2006) |
| "Results of trials of aspirin and dipyridamole combined versus aspirin alone for the secondary prevention of vascular events after ischaemic stroke of presumed arterial origin are inconsistent." | 5.12 | Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2006) |
| "Combination of low-dose aspirin and modified-release dipyridamole (ASA+MR-DP) provides a significantly increased benefit in stroke prevention over aspirin alone." | 5.12 | Dose titration to reduce dipyridamole-related headache. ( Chang, YJ; Lee, TH; Ryu, SJ, 2006) |
| "Oral anticoagulants are better than aspirin for secondary prevention after myocardial infarction and after cerebral ischaemia in combination with non-rheumatic atrial fibrillation." | 5.12 | Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2007) |
| "Immediately after TIA or minor stroke, patients are at high risk of stroke, which might be reduced by using clopidogrel in addition to aspirin." | 5.12 | Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. ( Buchan, AM; Demchuk, AM; Eliasziw, M; Hill, MD; Kennedy, J; Ryckborst, KJ, 2007) |
| "Aspirin is used commonly to prevent ischemic strokes and other vascular events." | 5.11 | Antiplatelet effect of aspirin in patients with cerebrovascular disease. ( Alberts, MJ; Bergman, DL; Jovanovic, BD; Molner, E; Teruya, J; Ushiwata, I, 2004) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 5.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "Atrial fibrillation patients with TIA have a lower long-term risk of subsequent stroke than those with prior stroke, but their stroke risk during aspirin therapy is still high." | 5.11 | Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. ( Hart, RG; Koudstaal, PJ; Pearce, LA, 2004) |
| "There is still worldwide disagreement about the optimal lowest dose of aspirin to be used in patients after a transient ischemic attack (TIA) or nondisabling stroke." | 5.11 | What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? ( Dippel, DW; Koudstaal, PJ; Leebeek, FW; Li, SS; Mehicevic, A; Van Kooten, F; van Vliet, HH, 2004) |
| "This pilot trial has not found differences between triflusal and aspirin in the prevention of vascular complications after TIA or ischemic stroke, although given the wide CI, potentially important group differences could not be ruled out." | 5.11 | Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. ( Abiusi, G; Bauso-Tosselli, L; Culebras, A; Domínguez, R; Famulari, A; Ferrari, J; Gori, H; Reich, E; Rey, R; Rotta-Escalante, R; Vila, J, 2004) |
| "We randomly assigned patients with transient ischemic attack or stroke caused by angiographically verified 50 to 99 percent stenosis of a major intracranial artery to receive warfarin (target international normalized ratio, 2." | 5.11 | Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. ( Benesch, CG; Chaturvedi, S; Chimowitz, MI; Frankel, MR; Hertzberg, VS; Howlett-Smith, H; Jovin, TG; Kasner, SE; Levine, SR; Lynn, MJ; Romano, JG; Sila, CA; Stern, BJ, 2005) |
| "Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis." | 5.11 | Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005) |
| "To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan." | 5.10 | Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003) |
| "The second European Stroke Prevention Study investigated the prevention of stroke and/or death in 6602 patients with transient ischaemic attack or stroke with aspirin (25 mg b." | 5.09 | Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). ( Bertrand-Hardy, JM; Darius, H; Diener, HC; Humphreys, M, 2001) |
| "The Coumadin Aspirin Reinfarction Study demonstrated that combination treatment with fixed dose warfarin (1 or 3 mg) + aspirin 80 mg was not superior to aspirin 160 mg alone after myocardial infarction for reducing nonfatal reinfarction, nonfatal stroke, and cardiovascular death." | 5.09 | Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). ( Berkowitz, SD; Califf, RM; Daly, R; Fuster, V; Gattis, WA; Gheorghiade, M; Harrington, RA; Hellkamp, AS; Kopecky, SL; Langer, A; Larsen, RL; O'Connor, CM; O'Gara, PT, 2001) |
| "Combination therapy with dipyridamole and aspirin reduces not only the risk of cerebrovascular ischemic events but also the risk of myocardial infarction." | 5.07 | Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event. ( Laakso, M; Lowenthal, A; Riekkinen, PJ; Sivenius, J; Smets, P, 1993) |
| "Mortality rates in this group were not significantly different for patients not taking aspirin as compared with the rates for those taking aspirin, although patients not taking aspirin had a higher incidence of myocardial infarction (27%) as compared with patients taking aspirin (8%), p < 0." | 5.07 | Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis. ( Hobson, RW; Krupski, WC; Weiss, DG, 1993) |
| ") for secondary prevention of cerebral ischemia were compared with the effects of low-dosage aspirin (300 mg/die)." | 5.07 | [Clinical efficacy of picotamide]. ( de Falco, FA; Mastroroberto, G; Montariello, A; Visconti, OS, 1991) |
| "We compared the outcomes of 2,500 patients who suffered from previous cerebrovascular disorders (transient ischemic attacks, reversible ischemic neurologic deficits, or completed strokes) treated with acetylsalicylic acid plus dipyridamole or matched placebo and followed for 2 years." | 5.06 | European Stroke Prevention Study. ESPS Group. ( , 1990) |
| "In a randomized pilot study we compared the efficacy of temporary anticoagulation with intravenous heparin sodium to the efficacy of aspirin in preventing cerebral infarction in hospitalized patients with recent (less than 7 days) transient ischemic attacks (TIAs)." | 5.06 | A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study. ( Adams, HP; Banwart, KJ; Biller, J; Bruno, A; Godersky, JC; Jones, MP; Loftus, CM; Mitchell, VL, 1989) |
| " An updated meta analysis was done to determine the effect of the various dual antiplatelets vs aspirin alone on recurrence rate of ischemic stroke, cardiovascular morbidity and mortality, and its safety profile as reported through major bleeding." | 5.05 | Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis. ( Albay, CEQ; Cheng, FC; Leyson, FGD, 2020) |
| "Dual antiplatelet therapy with clopidogrel and aspirin is effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA)." | 5.01 | Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and ( Dietrich, D; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Li, H; Liu, L; Meng, X; Meurer, WJ; Pan, Y; Wang, Y; Zhao, X, 2019) |
| "Background and Purpose- The role of aspirin plus clopidogrel (A+C) therapy compared with aspirin monotherapy in patients presenting with acute ischemic stroke (IS) or transient ischemic attack remains uncertain." | 5.01 | Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. ( Hammad, T; Kaluski, E; Khan, SU; Meyer, MA; Nasir, F; Rahman, H, 2019) |
| "The result of Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events and the secondary analysis of Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) have shown that treatment with clopidogrel and aspirin for 21 days reduced the risk of recurrent stroke with no significant increase in bleeding risk." | 5.01 | Early Secondary Prevention in Transient Ischemic Attack (TIA) and Minor Stroke. ( Coutts, SB; Hill, MD; Tse, D, 2019) |
| "For stroke prevention in elderly patients with IS or TIA, DAPT is superior to aspirin monotherapy but appears to be equivalent to clopidogrel monotherapy, and is accompanied by an increased risk of bleeding." | 4.98 | Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis. ( Ding, L; Peng, B, 2018) |
| "To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)." | 4.98 | Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018) |
| "Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain." | 4.95 | Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017) |
| "Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack." | 4.93 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014." | 4.93 | Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016) |
| "Aspirin is recommended for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% reduction in long-term risk of recurrent stroke." | 4.93 | Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. ( Algra, A; Chen, Z; Diener, HC; Mehta, Z; Norrving, B; Rothwell, PM, 2016) |
| "Low-dose aspirin, alone or in combination, is recommended for the secondary prevention of acute non-cardioembolic ischemic stroke and transient ischemic attack, starting soon after the acute event." | 4.93 | Aspirin, stroke and drug-drug interactions. ( Petrucci, G; Rocca, B; Russo, NW, 2016) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 4.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "The safety and efficacy of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in the setting of secondary stroke prevention are reviewed." | 4.91 | Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. ( Davis, KA; Dietrich, E; Miyares, MA, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 4.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| "In the overall population, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in comparison to aspirin monotherapy reduced the relative risk of total stroke by 20% (risk ratio [RR], 0." | 4.90 | Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. ( Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M, 2014) |
| "Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke." | 4.89 | The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013) |
| "We performed meta-analyses to assess the effectiveness and safety of combination therapy with aspirin and dipyridamole (A+D) versus aspirin (A) alone in secondary prevention after transient ischemic attack (TIA) or stroke of presumed arterial origin within one week and six months." | 4.89 | The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. ( Li, X; Zhou, G; Zhou, S; Zhou, X, 2013) |
| "Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0." | 4.89 | Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2013) |
| "We performed a systematic review to identify all published randomized controlled trials of patients with stroke or transient ischemic attack of presumed arterial origin that included an aspirin arm." | 4.85 | Is there a decline in the vascular event rate after transient ischemic attack or stroke in antiplatelet trials? ( Chen, F; Fieuws, S; Lemmens, R; Ni, Y; Thijs, V, 2009) |
| "To study the effect of combination therapy with aspirin and dipyridamole (A+D) over aspirin alone (ASA) in secondary prevention after transient ischaemic attack (TIA) or minor stroke of presumed arterial origin and to perform subgroup analyses to identify patients that might benefit most from secondary prevention with A+D." | 4.84 | Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. ( Algra, A; Bath, PM; Diener, HC; Gray, LJ; Guiraud-Chaumeil, B; Halkes, PH; Yatsu, FM, 2008) |
| "Meta-analyses of randomised clinical trials in patients with TIA and ischaemic stroke of arterial origin indicate that, compared with control, the relative risk reduction (RRR) for recurrent stroke and other serious vascular events is 13% (95% confidence interval [CI] 6% to 19%) with aspirin, 13% (4% to 21%; p = 0." | 4.84 | Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines. ( Hankey, GJ, 2007) |
| "Low dose aspirin is effective in secondary stroke prevention." | 4.84 | Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected]. ( Kirshner, HS, 2007) |
| "This meta-analysis systematically reviewed randomized controlled trials comparing aspirin plus dipyridamole with aspirin alone in patients with stroke and TIA to determine the efficacy of these agents in preventing recurrent cerebral and systemic vascular events." | 4.84 | Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. ( Gorelick, PB; Nguyen, D; Verro, P, 2008) |
| "The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published." | 4.83 | MATCH results: implications for the internist. ( Lutsep, HL, 2006) |
| "Alternative antiplatelet therapy for stroke prevention is indicated for patients who experience transient ischemic attacks (TIAs) while on aspirin therapy (strength of recommendation [SOR]: A, based on 1 meta-analysis and 1 randomized controlled trial)." | 4.83 | Clinical inquiries. What is the best management for patients who have a TIA while on aspirin therapy? ( Ahmed, N; Coffey, JB; Oh, R, 2006) |
| " Increased leptin, dysregulation of adipocyte proteins, increased insulin resistance and C-reactive protein may be factors involved in the increased incidence of cardiovascular morbidity and mortality directly related to obesity." | 4.83 | Stroke prevention in diabetes and obesity. ( Govindarajan, G; Kurukulasuriya, LR; Sowers, J, 2006) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| "Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results." | 4.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "Aspirin is the standard treatment for secondary prevention of stroke and other vascular events." | 4.82 | Triflusal for preventing serious vascular events in people at high risk. ( Alvarez-Sabin, J; Costa, J; Ferro, JM; Matias-Guiu, J; Torres, F, 2005) |
| "Three trials tested aspirin in dosages ranging from 75 mg to 325 mg per day and 125 mg every other day to placebo (in two trials) or control (in one trial) in 1965 AF patients without prior stroke or TIA." | 4.82 | Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. ( Aguilar, M; Hart, R, 2005) |
| " The search terms used were dipyridamole, aspirin, acetylsalicylic acid, ischemic stroke, and cerebrovascular disorders." | 4.81 | Analysis of trials evaluating combinations of acetylsalicylic acid and dipyridamole in the secondary prevention of stroke. ( Redman, AR; Ryan, GJ, 2001) |
| " In the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) Trial, clopidogrel (clopidogrel bisulphate) was superior to acetylsalicylic acid (ASA) in reducing the combined risk of ischaemic stroke (IS), myocardial infarction (MI) or vascular death in patients with symptomatic atherosclerosis." | 4.81 | From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. ( Hacke, W, 2002) |
| " Aspirin modestly reduces the risk for subsequent ischemic stroke after a transient ischemic attack or initial stroke." | 4.80 | Antithrombotic and thrombolytic therapy for ischemic stroke. ( Fisher, M, 1999) |
| "Aspirin is the treatment of first choice for long-term secondary prevention of vascular events in patients with confirmed non-cardioembolic ischaemic stroke or TIA." | 4.80 | Prevention of ischaemic stroke--antiplatelets. ( Brown, MM; McCabe, DJ, 2000) |
| " (1) Proven: one or more TIAs in the past 6 months and carotid stenosis > or = 70% or mild stroke within 6 months and a carotid stenosis > or = 70%; (2) acceptable but not proven: TIAs within the past 6 months and a stenosis 50% to 69%, progressive stroke and a stenosis > or = 70%, mild or moderate stroke in the past 6 months and a stenosis 50% to 69%, or carotid endarterectomy ipsilateral to TIAs and a stenosis > or = 70% combined with required coronary artery bypass grafting; (3) uncertain: TIAs with a stenosis < 50%, mild stroke and stenosis < 50%, TIAs with a stenosis < 70% combined with coronary artery bypass grafting, or symptomatic, acute carotid thrombosis; (4) proven inappropriate: moderate stroke with stenosis < 50%, not on aspirin; single TIA, < 50% stenosis, not on aspirin; high-risk patient with multiple TIAs, not on aspirin, stenosis < 50%; high-risk patient, mild or moderate stroke, stenosis < 50%, not on aspirin; global ischemic symptoms with stenosis < 50%; acute dissection, asymptomatic on heparin." | 4.79 | Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the ad hoc Committee, American Heart Association. ( Barnett, HJ; Beebe, HG; Bernstein, EF; Brener, BJ; Brott, T; Caplan, LR; Day, A; Goldstone, J; Hobson, RW; Moore, WS, 1995) |
| "English-language articles published after 1977 and indexed in MEDLINE under the following Medical Subject Heading terms: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders." | 4.79 | Medical treatment for stroke prevention. ( Barnett, HJ; Feussner, JR; Matchar, DB; McCrory, DC, 1994) |
| "Aspirin given as a platelet antiaggregant has been shown to be effective for secondary prevention both in cardiology (myocardial infarction, uncontrolled angina pectoris, coronary bypass, etc." | 4.79 | [From heart to brain and from brain to heart: impact of an anticoagulant treatment with aspirin in secondary prevention]. ( Chollet, F, 1994) |
| "Warfarin prophylaxis in patients with nonvalvular atrial fibrillation may be one of the most valuable public-health interventions." | 4.79 | Stroke prevention: the emerging strategies. ( Matchar, DB; McCrory, DC, 1996) |
| "The CHANCE-2 study compared 3 weeks of aspirin-ticagrelor to aspirin-clopidogrel in CYP2C19 loss-of-function (LOF) allele carriers following a transient ischemic attack (TIA)/minor stroke and demonstrated a modestly lower risk of stroke recurrence with aspirin-ticagrelor." | 4.31 | Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective. ( Demchuk, AM; Jahn, B; Menon, BK; Micieli, A; Siebert, U; Singh, N, 2023) |
| " In patients administered ticagrelor-aspirin and clopidogrel-aspirin, respectively, stroke recurred in 85 (9." | 4.31 | Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial. ( Bath, PM; Claiborne Johnston, S; Jiang, Y; Jing, J; Li, H; Li, Z; Liu, L; Meng, X; Wang, A; Wang, Y; Xie, X; Xu, Q; Zhao, X, 2023) |
| "Among Chinese minor stroke/transient ischemic attack population, the efficacy of clopidogrel-aspirin therapy was decreased in patients with higher ABCD-GENE score." | 4.12 | Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial. ( Chen, Z; Dai, L; Li, H; Meng, X; Pan, Y; Wang, Y; Xu, J; Yan, H, 2022) |
| "Among patients with TIA or mild ischemic stroke, the combination of cinnamon and aspirin could be superior to aspirin alone for reducing the risk of 90-day recurrent stroke." | 4.12 | Cinnamon and Aspirin for Mild Ischemic Stroke or Transient Ischemic Attack: A Pilot Trial. ( Fan, Y; He, P; He, Z; Li, Z; Liang, J; Wu, Y; Zhang, L, 2022) |
| "The goal of this work was to investigate the short-term time-course benefit and risk of ticagrelor with aspirin in acute mild-moderate ischemic stroke or high-risk TIA in The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial." | 4.12 | Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Li, H; Molina, CA; Pan, Y; Wang, Y, 2022) |
| "Among the 3456 patients included, a total of 10 patients in the Clopidogrel Discontinuation Group and 11 patients in the non-Clopidogrel Discontinuation Group presented ischemic stroke recurrence during the 90-180-day period." | 4.12 | No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke. ( Jing, J; Johnston, SC; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, D; Wang, Y; Zhang, X; Zhao, X, 2022) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 4.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 4.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "Fifty one acute stroke/transient ischemic attack (TIA) patients (ASG) with a history of regular aspirin intake for the previous 7 days or more were included to the study within 24 hours of symptoms onset." | 4.02 | Biochemical aspirin resistance in acute stroke patients and its association with clinical factors: a prospective pilot study. ( Fiszer, U; Kubiak-Balcerewicz, K; Morton, M; Sarnowska, A, 2021) |
| "Patients with ischemic stroke receiving aspirin (100 mg/day) for three months were recruited for a multicenter, prospective, cohort study." | 4.02 | Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions. ( Chen, Y; Deng, W; Huang, W; Jiang, H; Li, J; Liang, Z; Liu, Q; Ou, Z; Ouyang, F; Wu, Z; Xing, S; Zeng, J; Zhang, Y, 2021) |
| " Here we assessed the contribution of clopidogrel versus aspirin to the development of pneumonia during an acute ischemic stroke admission." | 4.02 | Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients. ( Feng, Q; Fu, J; Jin, X; Shan, B; Shen, R; Yu, Z; Zhou, H; Zhu, H, 2021) |
| " We conducted a network meta-analysis to compare ticagrelor with other receptor antagonists (P2Y12) inhibitors and aspirin in monotherapy or combination in the treatment of patients with high risk for cardiovascular or cerebrovascular disease, defined as coronary artery disease, acute coronary syndrome, stroke or transient ischemic attack, or peripheral artery disease." | 4.02 | Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. ( Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021) |
| "We pooled individual patient data from 6 randomized clinical trials (CAPRIE [Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events], ESPS-2 [European Stroke Prevention Study-2], MATCH [Management of Atherothrombosis With Clopidogrel in High-Risk Patients], CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance], ESPRIT [European/Australasian Stroke Prevention in Reversible Ischemia Trial], and PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes]) investigating antiplatelet therapy in the subacute or chronic phase after noncardioembolic transient ischemic attack or stroke." | 4.02 | Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. ( Algra, A; Bath, PM; Csiba, L; Diener, HC; Greving, JP; Hacke, W; Hilkens, NA; Kappelle, LJ; Koudstaal, PJ; Leys, D; Mas, JL; Sacco, RL, 2021) |
| " The methodologies are demonstrated using the acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes study (SOCRATES; NCT01994720), a randomized clinical trial." | 3.96 | Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial. ( Albers, GW; Amarenco, P; Bath, PM; Denison, H; Easton, JD; Evans, SR; Johnston, SC; Jonasson, J; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KL, 2020) |
| " Clopidogrel plus aspirin treatment was associated with reduced risk of new stroke in patients with ABCB1 -154 TT and 3435 CC genotype (hazard ratio [HR], 0." | 3.91 | Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. ( Chen, W; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Simon, T; Wang, D; Wang, Y; Zhao, X, 2019) |
| "The relationship of CYP2C19 genotype and clinical efficacy in stroke or transient ischemic attack (TIA) patients treated with clopidogrel monotherapy or clopidogrel plus aspirin remains unknown." | 3.88 | Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis. ( Cui, M; Gu, ZC; Li, WY; Pan, MM; Yao, JC, 2018) |
| "WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG." | 3.88 | Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. ( Agoritsas, T; Booth, B; Fisch, L; Fobuzi, AC; Fraiz, A; Gorthi, SP; Guyatt, G; Hao, Q; Heen, AF; Horton, E; Jusufovic, M; Katragunta, N; Lytvyn, L; Muller, J; O'Donnell, M; Prasad, K; Rochwerg, B; Siemieniuk, J; Siemieniuk, R; Vandvik, PO, 2018) |
| "From January 2014 to September 2014, a single center continuously enrolled patients with minor ischemic stroke or high-risk TIA and gave them antiplatelet therapy consisting of aspirin with clopidogrel." | 3.85 | The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA. ( Cao, Y; Dong, K; Liu, L; Rao, Z; Wang, A; Wang, F; Wang, Y; Zhao, X; Zheng, H, 2017) |
| "Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds." | 3.85 | Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome ( Albers, GW; Amarenco, P; Aunes, M; Bokelund-Singh, S; Denison, H; Easton, JD; Evans, SR; Held, P; Jahreskog, M; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "Aspirin and clopidogrel are both acceptable antiplatelet options for the secondary prevention of noncardioembolic ischemic stroke." | 3.85 | Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up. ( Dai, H; He, P; Li, W; Lin, H; Ping, Y; Xu, H, 2017) |
| " MIAs were frequently preceded or followed by ocular ischemic events of blurred vision, scotomas, transient flashing of the eyes, and sudden transient partial blindness preceded or followed erythromelalgia in the toes or fingers." | 3.81 | Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ( Berneman, Z; De Raeve, H; Gadisseur, A; Lam, KH; Michiels, JJ; Schroyens, W, 2015) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Treatment with the combination of clopidogrel and aspirin taken soon after a transient ischemic attack (TIA) or minor stroke was shown to reduce the 90-day risk of stroke in a large trial in China, but the cost-effectiveness is unknown." | 3.80 | Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. ( Johnston, SC; Liu, G; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, Y; Zhao, K; Zhao, X, 2014) |
| "We examined 157 aspirin-treated patients with acute stroke or TIA, 128 aspirin-free and 15 aspirin-treated healthy subjects (HS)." | 3.79 | TXA2 synthesis and COX1-independent platelet reactivity in aspirin-treated patients soon after acute cerebral stroke or transient ischaemic attack. ( Lago, A; Moscardo, A; Parkhutik, V; Santos, MT; Tembl, J; Valles, J, 2013) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 3.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "Only 50% of patients who would benefit from warfarin therapy for atrial fibrillation (AF) receive treatment because of clinical concerns regarding chronic anti-coagulation." | 3.78 | Role for the left atrial appendage occlusion device in managing thromboembolic risk in atrial fibrillation. ( Alison, JF; Lockwood, S; Mottram, P; Obeyesekere, MN, 2012) |
| "To examine healthcare costs among patients hospitalized for transient ischemic attack or ischemic stroke (TIA/stroke) and prescribed aspirin plus extended-release dipyridamole (ASA-ERDP) or clopidogrel (CLOPID) within 30 days post-discharge using a retrospective claims database from a large US managed care organization." | 3.78 | One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel. ( Burton, TM; Lacey, M; Lang, K; Liu, F; Monsalvo, ML; Sander, S; Yu, Y, 2012) |
| " In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques." | 3.78 | Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012) |
| "There was a clear impact of aspirin treatment on CMBs associated with intracerebral hemorrhage in Chinese patients." | 3.77 | Aspirin treatment increases the risk of cerebral microbleeds. ( Gao, Y; Ge, L; Guo, D; Han, X; Niu, G; Wu, H; Wu, Q; Zhang, Y, 2011) |
| "Patients who have had a recent transient ischemic attack (TIA) are at high risk for subsequent stroke." | 3.77 | Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly. ( Adams, HP; Gordon, DL, 1991) |
| "Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain." | 3.76 | Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010) |
| "The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke." | 3.76 | Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010) |
| "(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months." | 3.75 | Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009) |
| "In primary prevention, aspirin reduces the risk of stroke but not of myocardial infarction in women while in men only the risk of myocardial infarction but not stroke could be significantly reduced." | 3.75 | Antiplatelet agents in stroke prevention: acute and long-term treatment strategies. ( Diener, HC; Weber, R; Weimar, C, 2009) |
| "Data from the Aspirin in Transient Ischemic Attack (AITIA) study, an ongoing study of two platelet antiaggregant drugs, and other published therapeutic trials were reviewed to determine whether the severity of stroke is reduced in patients taking platelet antiaggregants." | 3.75 | Does platelet antiaggregant therapy lessen the severity of stroke? ( Fields, WS; Gary, H; Grotta, JC; Lemak, NA; Vital, D, 1985) |
| "The authors prospectively included acute ischemic stroke/TIA patients who were treated at Thammasat Hospital from August, 2006 to July, 2007 and had already been on aspirin." | 3.74 | Aspirin non-responders in Thai ischemic stroke/TIA patients. ( Dharmasaroja, P, 2008) |
| "To determine the changes in platelet function, manifesting as deviations of their aggregation intensity, in persons with acute ischemic stroke and transient ischemic attacks, to evaluate the effect of aspirin on platelet aggregation, dependent upon degree of cerebral blood flow disturbances and patient's gender, and to compare these changes with those in healthy persons." | 3.74 | [The impact of acute cerebral blood flow disturbances on platelet aggregation]. ( Gaigalaite, V; Grybauskas, P; Ptasekas, J; Sabaliauskiene, Z, 2008) |
| "In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)." | 3.74 | [Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007) |
| " Hypertension, diabetes mellitus, transient ischemic attack (TIA), hyperlipemia and mural thrombus in left atrium were significantly correlated with the recurrence rate by univariate Cox proportional hazards regression analysis; but aspirin therapy, warfarin therapy and hypertension control were protective factors for the recurrence of ischemic stroke in patients with NVAF." | 3.74 | [A study on the recurrence of ischemic stroke in nonvalvular atrial fibrillation]. ( Cai, YY; Hu, Y; Luo, M; Quan, HB; Xie, RM, 2007) |
| " We report a patient, having used aspirin for secondary stroke prevention, who had an acute cerebellar hemorrhage after taking nattokinase 400 mg daily for 7 consecutive days." | 3.74 | Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds. ( Chang, YY; Lai, SL; Lan, MY; Liu, JS; Wu, HS, 2008) |
| "Clopidogrel and dipyridamole-aspirin are used frequently after stroke or transient ischemic attack." | 3.74 | Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack. ( Hills, NK; Johnston, SC, 2008) |
| "Vascular events commonly recur in stroke patients on aspirin, and may reflect incomplete inhibition of platelet function with aspirin therapy." | 3.73 | Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. ( Brown, MM; Harrison, P; Lawrie, AS; Machin, SJ; Mackie, IJ; McCabe, DJ; Purdy, G; Sidhu, PS, 2005) |
| "The rapid and significant decline of MES in our stroke and TIA patients suggests the possible efficacy of dual antiplatelet therapy with aspirin and clopidogrel in patients with MES and symptomatic large-artery occlusive disease." | 3.73 | Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases. ( Chang, HM; Chen, CL; Esagunde, RU; Gan, HY; Lee, MP; Wong, KS; Wong, MC, 2006) |
| "There is substantial interpatient variability in response to aspirin after an ischemic stroke or transient ischemic attack (TIA), as assessed by ex vivo effects of aspirin on platelet aggregation." | 3.73 | Sex difference in the antiplatelet effect of aspirin in patients with stroke. ( Brace, LD; Cavallari, LH; Helgason, CM; Nutescu, EA; Viana, MA, 2006) |
| "Within a cross-sectional study, nested in a cohort we identified 931 patients with a recent ischemic stroke or TIA who were discharged with OAC or with one of the antiplatelet medications aspirin, clopidogrel, or the combination of aspirin and extended-release dipyridamole." | 3.71 | Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry. ( Lalouschek, W; Lang, W; Müllner, M, 2001) |
| "Patients with both patent foramen ovale and atrial septal aneurysm who have had a stroke constitute a subgroup at substantial risk for recurrent stroke, and preventive strategies other than aspirin should be considered." | 3.71 | Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. ( Arquizan, C; Cabanes, L; Coste, J; Derumeaux, G; Lamy, C; Mas, JL; Zuber, M, 2001) |
| "A previous study indicated that diaspirin-crosslinked hemoglobin (DCLHb) decreases cerebral ischemia after subarachnoid hemorrhage." | 3.70 | Subarachnoid molecular hemoglobin after subarachnoid hemorrhage in rats: effect on the area of hypoperfusion. ( Cole, DJ; Cross, LM; Drummond, JC; McKay, LD; Patel, PM, 1998) |
| "Compared with aspirin alone, use of the new antiplatelet regimens, including aspirin combined with dipyridamole and clopidogrel bisulfate, has been found to further reduce the risk of stroke and other vascular events in patients who have experienced stroke or transient ischemic attack." | 3.70 | Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. ( Bounameaux, H; Gaspoz, JM; Sarasin, FP, 2000) |
| "A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented." | 3.69 | Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis: a case report. ( Ashkenazi, E; Israel, Z; Spektor, S, 1995) |
| "The difference in the effectiveness of aspirin for the prevention of stroke and secondary prevention of myocardial infarction was discussed on the basis of inhibition of platelet aggregation." | 3.67 | Experimental basis of platelet aggregation inhibition by acetylsalicylic acid. ( Begent, NA; Born, GV; Görög, P, 1984) |
| "Data from the medical treatment group of the Aspirin in TIA study were reviewed, and prospective analysis of patients with asymptomatic bruits was performed to see whether carotid stenosis (0 to 49% or 50 to 99%) or ulceration produced an increased risk of ipsilateral TIA or infarct." | 3.67 | The significance of carotid stenosis or ulceration. ( Bigelow, RH; Fields, WS; Grotta, JC; Hankins, L; Hu, H, 1984) |
| " Aspirin effectively abolished SPA in 50 patients and relieved the clinical symptoms of patients with recurrent complaints of transient blindness and paraesthesia." | 3.66 | Spontaneous platelet aggregation in cerebrovascular disease. ( Jenkins, CS; Oosterhuis, H; Prenger, D; ten Cate, JW; Vos, J, 1978) |
| "It is unclear whether infarct location affects stroke recurrence after index ischemic stroke." | 3.30 | Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack. ( Jing, J; Li, H; Li, Z; Liu, H; Meng, X; Wang, A; Wang, Y; Xu, Q, 2023) |
| "Bleeding was defined using the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal, major, moderate, minor, none." | 3.30 | Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia. ( Appleton, JP; Bath, PM; Christensen, H; Dineen, RA; England, TJ; James, M; Krishnan, K; Montgomery, AA; Ranta, A; Robinson, TG; Sprigg, N; Woodhouse, LJ, 2023) |
| " We aimed to evaluate the dose-response relationship of milvexian in participants treated with dual antiplatelets." | 3.11 | Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention. ( Amarenco, P; Bereczki, D; Czlonkowska, A; Diener, HC; Donovan, M; Endres, M; Gailani, D; Hankey, GJ; Kahl, A; Kasner, SE; Li, D; Lutsep, HL; Molina, CA; Ntaios, G; Perera, V; Sharma, M; Shuaib, A; Toyoda, K; Tsivgoulis, G, 2022) |
| "Keyword: antiplatelet therapy, acute ischemic stroke, secondary prevention, transient ischemic attack." | 3.01 | Clinical Updates on Antiplatelet Therapy for Secondary Prevention in Acute Ischemic Stroke. ( Chang, YM; Lee, TL; Sung, PS, 2023) |
| "Major bleeding was the primary safety end point." | 2.90 | Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Röther, J; Wang, Y; Wong, KSL, 2019) |
| "Acute minor ischemic stroke (AMIS) or transient ischemic attack (TIA) is a common cerebrovascular event with a considerable high recurrence." | 2.87 | Rationale and Study Design for a Single-Arm Phase IIa Study Investigating Feasibility of Preventing Ischemic Cerebrovascular Events in High-Risk Patients with Acute Non-disabling Ischemic Cerebrovascular Events Using Remote Ischemic Conditioning. ( Feng, WW; Ji, XM; Li, SJ; Liu, SM; Meng, R; Ovbiagele, B; Ren, CH; Song, HQ; Zhao, WL, 2018) |
| "aspirin monotherapy was carried out, to determine optimal peri-operative management with these antiplatelet agents." | 2.82 | Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis. ( Bissacco, D; Chechik, O; Chisci, E; Cusimano, MD; Ku, JC; Larrue, V; Macdonald, RL; Michelagnoli, S; Nasr, N; Pasarikovski, CR; Priola, SM; Rabinovich, Y; Settembrini, PG; Taslimi, S; Yang, VXD; Zuccato, J, 2022) |
| "Acute stroke is the leading cause of disability in the UK and a leading cause of mortality worldwide." | 2.82 | Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician. ( Appleton, JP; Bath, PM; Dawson, J; England, TJ; Eveson, D; Krishnan, K; Law, ZK; Mavilakandy, A; Minhas, JS; Mistri, A; Robinson, TG; Sprigg, N, 2022) |
| "Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) is a randomized, double-blind, event-driven trial and will include an estimated 13,600 participants randomized in 33 countries worldwide to collect 844 primary events." | 2.80 | Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wong, LK, 2015) |
| "60." | 2.79 | Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up. ( Alvarez-Sabín, J; Maisterra, O; Quintana, M; Santamarina, E, 2014) |
| "A cause other than paradoxical embolism was usually apparent in patients with recurrent neurologic events." | 2.77 | Closure or medical therapy for cryptogenic stroke with patent foramen ovale. ( Adams, H; Albers, GW; Felberg, R; Furlan, AJ; Herrmann, H; Kar, S; Landzberg, M; Massaro, J; Mauri, L; Raizner, A; Reisman, M; Wechsler, L, 2012) |
| "Terutroban is a specific TP receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which may be of interest for the secondary prevention of ischemic stroke." | 2.74 | Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, MG; Mattle, HP; Rothwell, PM, 2009) |
| " The number of patients with adverse events and bleeding complications, and their severity, were significantly greater in the triple therapy group (p<0." | 2.73 | A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. ( Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008) |
| "30 patients with transient cerebral ischemia attack in the treatment group were acupunctured at Fengchi (GB 20), Wangu (GB 12) and Tianzhu (BL 10) and given orally leech capsules and centipede capsules." | 2.73 | Clinical observation on 30 cases of transient cerebral ischemia attack treated with acupuncture and medication. ( Feng, L; Sun, Y; Wei, C; Zhang, J, 2007) |
| "In these patients with type 2 diabetes and a history of TIA, patterns of platelet inhibition differed significantly according to whether treatment was with ER-DP+ASA or clopidogrel with or without ASA." | 2.73 | Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-b ( Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL, 2008) |
| "Patients with minor ischemic stroke or transient ischemic attack represent a high-risk population for recurrent stroke." | 2.72 | Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Shorr, R; Zitikyte, G, 2021) |
| " There is no study that assessed the effect of age on adverse event rates in cryptogenic stroke patients with PFO." | 2.71 | Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. ( DiTullio, MR; Homma, S; Mohr, JP; Sacco, RL; Sciacca, RR, 2004) |
| "In patients with symptomatic carotid artery stenosis, high-intensity transient signals detected by transcranial Doppler (TCD) have been related to particulate microemboli originating at the stenotic lesion." | 2.70 | Acetylsalicylic acid and microembolic events detected by transcranial Doppler in symptomatic arterial stenoses. ( Blaser, T; Goertler, M; Krueger, S; Lutze, G; Wallesch, CW, 2001) |
| "Dipyridamole was associated with a slight increase in headache, which resolved in most patients if therapy was continued." | 2.69 | Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. ( Forbes, CD, 1998) |
| "Nine patients with recent transient ischemic attack or minor stroke of arterial origin were investigated." | 2.69 | Rapid decline of cerebral microemboli of arterial origin after intravenous acetylsalicylic acid. ( Baeumer, M; Blaser, T; Goertler, M; Jost, S; Kross, R; Lutze, G; Wallesch, CW, 1999) |
| "One hundred patients with transient ischemic attacks, minor strokes, or residual ischemic neurologic deficits were enrolled in a double-blind, randomized study comparing the effects of aspirin plus vitamin E [0." | 2.68 | Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. ( Glantz, M; Lekos, A; Steiner, M, 1995) |
| "Initially, transient ischemic attack or cerebral infarction occurring in the distribution of the study artery and any transient ischemic attack, stroke, or death occurring in the perioperative period." | 2.68 | Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. ( , 1995) |
| "In addition, 6 transient ischemic attacks and 3 myocardial infarctions could be directly linked to CEA, for a total CEA event rate of 2." | 2.68 | An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study. ( Broderick, JP; Cohen, SN; Dempsey, RJ; Ernst, CB; Hosking, JD; Moore, WS; Robertson, JT; Toole, JF; Young, B, 1996) |
| "Patients with prior stroke or transient ischemic attack (TIA) were randomized to treatment with ASA alone (50 mg daily), modified-release dipyridamole alone (400 mg daily), the two agents in a combined formulation, or placebo." | 2.68 | European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. ( Cunha, L; Diener, HC; Forbes, C; Lowenthal, A; Sivenius, J; Smets, P, 1996) |
| "Aspirin is a safe, though less effective, alternative when anticoagulation is contraindicated; it prevents 40 vascular events each year for every 1000 treated patients." | 2.67 | Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. ( , 1993) |
| "The subjects were 75 patients with cerebral ischemia and 26 control subjects." | 2.67 | Shear-induced platelet aggregation in cerebral ischemia. ( Fukuyama, M; Handa, M; Ikeda, Y; Itagaki, I; Maruyama, S; Uchiyama, S; Yamazaki, M, 1994) |
| "Ticlopidine was more effective than aspirin in both sexes." | 2.66 | A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. ( Adams, HP; Anderson, S; Easton, JD; Hass, WK; Kamm, B; Molony, BA; Pryse-Phillips, W, 1989) |
| "The aspirin effect was the same across all risk-factor groups." | 2.66 | Controlled trial of aspirin in cerebral ischemia: an addendum. ( Fields, WS; Gary, HE; Lemak, NA, 1986) |
| "Of the 5 cerebral infarcts, 4 occurred in the control group, 3 patients died." | 2.65 | [The treatment of transitory ischemic attacks with acetylsalicylic acid: results of a double-blind-study (author's transl)]. ( Dorndorf, W; Loew, D; Reuther, R, 1980) |
| "Of 303 patients who had carotid transient ischemic attacks (TIAs), 125 were selected for carotid reconstructive surgery and were then randomly assigned treatment with aspirin or placebo." | 2.65 | Controlled trial of aspirin in cerebral ischemia. ( Bigelow, RH; Fields, WS; Frankowski, RF; Hardy, RJ; Lemak, NA, 1980) |
| "However, considering that most stroke recurrences occur i n the short term, a time limited double antiplatelet scheme could result in significant benefits to patients with acute ischemic stroke." | 2.61 | [Dual antiplatelet therapy for secondary stroke prevention in patients with acute ischemic stroke. CIERTO group recommendation]. ( Bottaro, F; Caruso, D; Catalano, HN; Izcovich, A; Pollán, J; Saavedra, E; Tisi Baña, M, 2019) |
| "Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke." | 2.61 | Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019) |
| " The combination of clopidogrel and aspirin is not recommended for long-term use (more than two to three years) because of increased bleeding risk." | 2.55 | Recurrent Ischemic Stroke: Strategies for Prevention. ( Garcellano, M; Oza, R; Rundell, K, 2017) |
| "Performance in patients with cerebral ischemia was poor." | 2.53 | Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study. ( Algra, A; Greving, JP; Hilkens, NA, 2016) |
| " Although administration of antiplatelet agents has been confirmed to be one of the major approaches for secondary prevention of noncardioembolic stroke, the short-term or long-term use of aspirin plus clopidogrel for secondary stroke prevention remains to be controversial." | 2.52 | Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention. ( Chen, W; Wang, Y, 2015) |
| "These events, previously called apoplexy, are now called strokes." | 2.50 | Stroke: transient ischemic attack. ( Silver, B; Wulf Silver, R, 2014) |
| "Bleeding is potentially the most significant antiplatelet-associated side effect." | 2.47 | Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. ( Guthrie, R, 2011) |
| "Aspirin has been shown to reduce the risk of recurrent strokes, and the combination of aspirin and dipyridamole has repeatedly been shown to outperform aspirin alone." | 2.46 | Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review. ( Fung, K; Simmons, BB; Yeo, A, 2010) |
| "In the past, transient ischemic attack (TIA) was defined as any sudden, focal cerebral ischemic event with neurological deficit lasting <24 hours." | 2.46 | [New clinical concept and therapeutic strategy for TIA]. ( Urabe, T, 2010) |
| "Many aspects of acute management of transient ischemic attack, such as which patients should be hospitalized and choice of acute antithrombotic therapy, remain controversial because of a lack of evidence from controlled trials." | 2.44 | Transient ischemic attack: risk stratification and treatment. ( Cucchiara, B; Ross, M, 2008) |
| "Stroke is a leading cause of death and the primary cause of serious, long-term disability in the United States." | 2.44 | Combination antiplatelet agents for secondary prevention of ischemic stroke. ( Saseen, JJ; Vande Griend, JP, 2008) |
| "Patients who have transient ischemic attack (TIA) or ischemic stroke are at a high risk of having a first or recurrent stroke." | 2.44 | Antiplatelet agents and randomized trials. ( Diener, HC, 2007) |
| "The short-term risk of stroke after transient ischemic attack (TIA) is about 10% to 20% in the first 3 months, with much of the risk front-loaded in the first week." | 2.43 | Stroke prevention. MATCHing therapy to the patient with TIA. ( Buchan, AM; Demchuk, AM; Hill, MD; Weir, NU, 2005) |
| "Twenty-three children had varicella at age 1." | 2.43 | Post-varicella arteriopathy of childhood: natural history of vascular stenosis. ( Armstrong, D; deVeber, G; Domi, T; Lanthier, S, 2005) |
| "Aspirin is the treatment of choice for stroke prevention in patients who do not require anticoagulation." | 2.42 | Transient ischemic attacks: Part II. Treatment. ( Solenski, NJ, 2004) |
| "Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke." | 2.41 | Update on antiplatelet therapy for stroke prevention. ( Elkind, MS; Sacco, RL, 2000) |
| "Aspirin has a modest effect on reducing stroke." | 2.41 | [Antithrombotic therapy for stroke prevention in patients with atrial fibrillation]. ( Kitabatake, A; Kohya, T; Tomita, F, 2000) |
| "In comparison with transient ischemic attacks in patients with vascular risk factors, the usual neurologic presentation of ET consists of brief attacks of sudden cerebral or visual dysfunction, which can be either well localized or diffuse and entirely nonspecific." | 2.40 | Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin. ( Koudstaal, A; Koudstaal, PJ, 1997) |
| "Four patients presented transient ischemic attacks, one amaurosis fugax, two suffered from a minor stroke, four had non-focalized ischemic cerebral symptoms and two were asymptomatic." | 2.40 | Fibromuscular dysplasia of the internal carotid artery. Personal experience with 13 cases and literature review. ( Limet, R; Sakalihasan, N; Van Damme, H, 1999) |
| "6 studies with a placebo-controlled, double blind, randomized protocol on the effect of acetylsalicylic acid (ASA) in a dosage of higher than 100 mg/day have been published." | 2.39 | [High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia]. ( Hartmann, A, 1995) |
| " There is disagreement over the optimal dosage to prevent a stroke: earlier studies considered > or = 975 mg ASS per day, sometimes in combination with other substances, while more recently, lower dosages of about 300 mg per day or even as low as < or = 100 mg per day have been proposed." | 2.39 | [Aspirin dosage for prevention of cerebral infarct: arguments for low dosage]. ( Hennerici, MG; Meairs, S, 1995) |
| " In cases with severe cardiac disease, however, a high dosage of ASA or anticoagulation therapy may be necessary to prevent further vascular events." | 2.38 | [Low dose acetylsalicylic acid in secondary prevention of stroke]. ( Deecke, L; Zeiler, K, 1993) |
| " The dosage of ASA in the majority of works has been about 1,000 mg daily while isolated investigations have shown good effect from doses as low as 60 mg daily." | 2.38 | [Acetylsalicylic acid in the treatment of arterial thromboembolytic diseases. 2. Clinical documentation]. ( Faergeman, O; Fasting, H; Husted, SE; Krusell, LR; Nielsen, HK, 1989) |
| " The majority of patients were given aspirin 1300 mg daily, but the optimum dosage was not properly evaluated." | 2.37 | The role of arachidonic acid metabolites in cardiovascular homeostasis. Biochemical, histological and clinical cardiovascular effects of non-steroidal anti-inflammatory drugs and their interactions with cardiovascular drugs. ( Goodman, DS, 1987) |
| "Transient ischemic attacks are associated with a 30 to 35 percent risk of stroke within five years of the initial episode." | 2.37 | Carotid surgery in stroke prevention. ( Busuttil, RW; Sheng, FC, 1986) |
| "Dipyridamole can inhibit both platelet adhesion and aggregation by raising the platelet cyclic AMP level through phosphodiesterase inhibition." | 2.37 | Aspirin and other platelet-aggregation inhibiting drugs. ( Gallus, AS, 1985) |
| " The utility of specific 'antithrombotic' treatments is still uncertain, but for long term use aspirin seems to be the most promising." | 2.37 | Transient ischaemic attacks. Current treatment concepts. ( Warlow, C, 1985) |
| " Among the anti-aggregant agents, only Aspirin at high dosage (1 to 1." | 2.37 | [The fate of patients with carotid stenosis. Comparative study, based on the literature, of their natural history and evolution under medical treatment or following endarterectomy]. ( Bachet, P; Ninet, J; Pasquier, J, 1985) |
| "Aspirin has been shown in clinical trials to be an effective agent in treating transient ischemic attacks and preventing infarction." | 2.36 | Aspirin for prevention of stroke: a review. ( Fields, WS, 1983) |
| "Aspirin prescription was associated with a reduced risk." | 1.72 | Long term survival after a first transient ischaemic attack in England: A retrospective matched cohort study. ( Bakbergenuly, I; Brown, B; Chutoo, P; Kulinskaya, E; Pchejetski, D; Steel, N, 2022) |
| "Treating high-risk transient ischemic attack (TIA) with dual antiplatelet therapy (DAPT) reduces subsequent ischemic stroke risk yet current rates of clopidogrel-aspirin treatment are uncertain." | 1.62 | Under Treatment of High-Risk TIA Patients with Clopidogrel-Aspirin in the Emergency Setting. ( Cheng, NT; Esenwa, C; Friedman, BW; Labovitz, DL; Lendaris, AR; Lessen, S; Liberman, AL; Lipton, RB; Prabhakaran, S, 2021) |
| "VWF is critically involved in thrombus formation at sites of stenotic extracranial/intracranial arteries." | 1.62 | The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients. ( Buchtele, N; Gelbenegger, G; Gilbert, JC; Greisenegger, S; Jilma, B; Kovacevic, KD; Langer, A; Pabinger, I; Petroczi, K; Zhu, S, 2021) |
| "The majority presented with recurrent transient ischemic attacks/minor strokes within a single vascular territory over days to weeks." | 1.56 | Focal Cerebral Arteriopathy in Young Adult Patients With Stroke. ( Cronin, S; Fanning, N; McKenna, MC, 2020) |
| "To identify the ischemic stroke and transient ischemic attack (TIA) prevalence related to length of time of discontinuation of antiplatelet or vitamin K antagonist therapy, in a group of inpatients from a specialized neurological hospital in Brazil." | 1.51 | Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption. ( Kowacs, PA; Macuco, ALB; Nascimento, MTMS; Rizelio, V; Sato, HK; Souza, RKM, 2019) |
| "Hemorrhagic stroke is not the only complication of thrombolysis, ischemic stroke can occur even if it is an extremely rare complication." | 1.46 | Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports. ( Arous, S; Bentaoune, T; El Ghali Benouna, M; Habbal, R; Haboub, M, 2017) |
| "All the patients presented with carotid artery stenosis >70% (North American Symptomatic Carotid Endarterectomy Trial [NASCET] criteria), which was symptomatic in 42 patients (transient ischemic attack, n = 32; minor stroke, n = 10) and asymptomatic in 146." | 1.46 | Dual Antiplatelet Therapy Does Not Increase the Risk of Bleeding After Carotid Endarterectomy: Results of a Prospective Study. ( Calio', FG; Illuminati, G; Masci, F; Pizzardi, G; Ricco, JB; Schneider, F, 2017) |
| "The early recurrence of neurological symptoms (NR) after urgent aggressive best medical therapy (BMT) in symptomatic carotid stenosis is not well documented." | 1.43 | Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy. ( Ellemann, K; Gottschalksen, B; Owen-Falkenberg, A; Shahidi, S, 2016) |
| "Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke." | 1.43 | High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016) |
| "Treatment of intracranial fusiform aneurysms is complex and controversial, and is associated with high morbidity and mortality rates." | 1.39 | Using Leo Plus stent as flow diverter and endoluminal remodeling in endovascular treatment of intracranial fusiform aneurysms. ( Ageitos, M; Arias-Rivas, S; Blanco, M; Castiñeira-Mourenza, JA; Masso, A; Pumar, JM; Rodríguez-Yáñez, M; Vazquez-Herrero, F, 2013) |
| "In selected low TE risk patients undergoing ablation for AF, a short period of periprocedural therapeutic anticoagulation with LMWH together with aspirin is an effective and safe strategy to prevent TE events." | 1.39 | Catheter ablation of atrial fibrillation in patients at low thrombo-embolic risk: efficacy and safety of a simplified periprocedural anticoagulation strategy. ( Acena, M; Berte, B; Bun, SS; De Meyer, G; Duytschaever, M; Tavernier, R; Van Heuverswyn, F; Vandekerckhove, Y, 2013) |
| "While a stroke or transient ischemic attack or history of systemic thromboembolism was detected in 15." | 1.39 | Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study. ( Acar, G; Akıl, MA; Arıbaş, A; Aydın, M; Bilik, MZ; Bulur, S; Cağlıyan, CE; Ergene, O; Ertaş, F; Gedik, S; Gül, M; Kahya Eren, N; Kanadaşı, M; Kaya, H; Kaya, Z; Köroğlu, B; Köse, N; Oylumlu, M; Ozhan, H; Simşek, Z; Ulgen, MS; Vatan, B; Yeter, E; Yıldız, A; Yılmaz, R; Yüksel, M, 2013) |
| "Stroke is the second leading cause of death." | 1.39 | Neuroprotective effect of a new synthetic aspirin-decursinol adduct in experimental animal models of ischemic stroke. ( Ahn, JH; Cho, JH; Choi, JH; Her, S; Hwang, IK; Hyun, BH; Jun, JG; Kim, CK; Kim, IH; Kim, JS; Kim, YM; Kwon, SH; Kwon, YG; Lee, CH; Lee, JC; Lee, YL; Park, JH; Shin, BN; Suh, HW; Won, MH; Yan, BC; Yoo, KY, 2013) |
| "The risk for preeclampsia increased in patients who were positive for multiple antiphospholipid antibodies (aPL) (odds ratio (OR) 3." | 1.38 | Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. ( Brinks, R; Fischer-Betz, R; Schneider, M; Specker, C, 2012) |
| "Intracranial arterial stenosis (IAS) is thought to be responsible for 8% of all ischemic stroke subtypes." | 1.37 | The role of transcranial Doppler embolic monitoring in the management of intracranial arterial stenosis. ( Derksen, C; Khan, K; Saqqur, M; Sebastian, J, 2011) |
| "Incidence of postoperative hemorrhage (early and delayed) was not significant (P = ." | 1.37 | Stopping anticoagulation before TURP does not appear to increase perioperative cardiovascular complications. ( Bariol, SV; Brooks, AJ; Drummond, M; Lau, HM; McDonald, C; Patel, MI; Raj, MD; Wang, AC; Woo, HH, 2011) |
| "Over all, he had 15 times of transient ischemic attack with no lasting deficit." | 1.36 | [Case of branch atheromatous disease presenting capsular warning syndrome]. ( Dougu, N; Nukui, T; Taguchi, Y; Takashima, S; Tanaka, K; Toyoda, S, 2010) |
| "Ischemic stroke was reported in 57." | 1.35 | [Secondary prevention with clopidogrel or acetylsalicylic acid after acute cerebrovascular event. Health services research study of private primary care specialists]. ( Diehm, C; Köfüncü, E; Pittrow, D; Sander, D; Schwertfeger, M, 2008) |
| "None experienced strokes or transient ischemic attacks." | 1.35 | Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device. ( Dia, M; Gallagher, C; Silver, MA; Slaughter, MS; Sobieski, MA, 2008) |
| "We report a patient who presented with transient ischemic attack (TIA) associated with stenosis of the accessory MCA ostium." | 1.35 | Transient ischemic attack associated with stenosis of accessory middle cerebral artery: a case report. ( Gao, F; Jiang, WJ, 2009) |
| "Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke of between 5% and 20% per year." | 1.33 | Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? ( Diener, HC, 2006) |
| "To report procedure-related complications and neurological adverse events of unprotected over-the-wire (OTW) and protected rapid exchange (RX) carotid artery stenting (CAS) in a single-center patient series during an 8-year period." | 1.33 | Procedure-related complications and early neurological adverse events of unprotected and protected carotid stenting: temporal trends in a consecutive patient series. ( Ahmadi, A; Amighi, J; Boltuch, J; Dick, P; Minar, E; Mlekusch, W; Sabeti, S; Schillinger, M; Schlager, O, 2005) |
| "The European/Australasian stroke prevention in reversible ischaemia trial (ESPRIT) confirms that long-term administration of the combination acetylsalicylic acid and dipyridamole is more effective than acetylsalicylic acid in reducing the risk of vascular events after cerebral ischaemia of arterial origin." | 1.33 | [The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed]. ( De Keyser, JH; Luijckx, GJ, 2006) |
| "However, the relationship between LA thrombus and transient ischemic attack (TIA) in patients with AF is less well established." | 1.32 | Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. ( Dawn, B; Longaker, RA; Singh, P; Stoddard, MF, 2003) |
| "Treatment of dissecting pseudoaneurysms of the distal cervical internal carotid artery with preservation of the parent artery by using stents or coils has become routine." | 1.32 | Stent-coil treatment of a distal internal carotid artery dissecting pseudoaneurysm on a redundant loop by use of a flexible, dedicated nitinol intracranial stent. ( Graybeal, CL; Pride, GL; Purdy, P; Rappard, G; Replogle, RE; White, J, 2004) |
| "Patients suffering from a transient ischemic attack (TIA) or ischemic stroke are at high risk of a recurrent stroke." | 1.32 | [Secondary prevention of stroke with antiplatelet drugs]. ( Diener, HC, 2004) |
| "Unfortunately, VBA transient ischemic attacks (TIAs) herald a lethal or devastating event within 5 years in 25 to 30% of patients." | 1.31 | Stent-assisted angioplasty of intracranial vertebrobasilar atherosclerosis: an initial experience. ( Barr, JD; Furlan, AJ; Katzan, I; Krieger, D; Markarian, GZ; Masaryk, TJ; Perl, J; Rasmussen, PA; Sila, C, 2000) |
| "Aspirin treatment improved survival ratio and stroke index, and decreased ischemically injured cell numbers in cortex." | 1.31 | Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia. ( Hosomi, N; Kohno, M; Mizushige, K; Ohyama, H; Takahashi, T, 2001) |
| "She was diagnosed as having transient ischemic attacks (TIAs)." | 1.30 | [Disappearance of embolic signals on transcranial Doppler sonography following antiplatelet therapy in a patient with transient ischemic attacks]. ( Akiyama, H; Minematsu, K; Moriyasu, H; Takada, T; Yamaguchi, T, 1998) |
| "To determine whether anticoagulation practices have changed when heparin and warfarin are used to treat cerebrovascular disease, and to determine the dosage of aspirin used to treat carotid territory transient ischemic attacks (TIAs)." | 1.29 | A follow-up survey of clinical practices for the use of heparin, warfarin, and aspirin. ( Alberts, MJ; Dawson, DV; Massey, EW, 1994) |
| "Advanced age, previous stroke or transient ischemic attack (TIA), hypertension and diabetes were all found to be risk factors for stroke in patients with atrial fibrillation." | 1.29 | [Atrial fibrillation and apoplexy--risks and prevention]. ( Gulløv, AL; Koefoed, BG; Petersen, P, 1996) |
| "The value of treatment of hyperlipidemia in reducing the incidence of a first stroke remains to be demonstrated." | 1.28 | Ischemic stroke. How to keep the first one from happening. ( Bundlie, SR, 1991) |
| "Patients with transient ischemic attacks (TIA) were previously shown to have high plasma values of thiobarbituric acid-reactive substances (TBA-RS)." | 1.28 | Blood lipid peroxides in TIA: relation to platelet function and metabolic profile. ( Alessandri, C; Balsano, F; Caliendo, C; Censi, C; Germani, M; Ghiselli, A; Servi, M; Violi, F, 1989) |
| "In patients with transient ischemic attack (TIA), the risk of stroke increases greatly, especially in the months immediately following the initial attack." | 1.27 | Transient ischemic attacks. Strategies for minimizing stroke risk. ( Furlan, AJ, 1984) |
| "62 patients with transient ischemic attack (TIA), 60 with reversible ischemic neurologic deficit (RIND) and 57 with stroke with minimum residuum (SMR) were followed, in a retrospective survey, from the first 7 days to the 3rd month of evolution." | 1.27 | Short-term outcome of medically treated patients with transient ischemic attacks, reversible ischemic neurologic deficits and strokes with minimum residuum. ( Calandre, L; Molina, JA, 1985) |
| "The different effect of ASA in TIAs and migraine indicates that the platelet activation in TIA patients is due not only to cyclo-oxygenase pathway but also to other in vivo pathways." | 1.27 | Drugs and platelet activation in migraine and transient ischemic attacks. ( Canazi, A; D'Andrea, G; Ferro-Milone, F; Toldo, M, 1985) |
| "Aspirin treatment reduced baseline [Cai2+] as well as thrombin- and collagen-induced [Cai2+] changes." | 1.27 | Baseline and activated platelet cytoplasmic ionized calcium in acute ischemic stroke. Effect of aspirin. ( D'Andrea, G; Grunfeld, S; Joseph, R; Oster, SB; Welch, KM, 1988) |
| "A patient is reported who sustained a cerebral infarction from carotid artery disease and was treated with aspirin." | 1.27 | Aspirin, anticoagulants, and hemorrhagic conversion of ischemic infarction: hypothesis and implications. ( Fisher, M, 1986) |
| "Recurrent transient ischemic attack or amaurosis fugax occurred more frequently (P less than 0." | 1.27 | Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks. ( Eriksson, SE, 1985) |
| "Aspirin, known to inhibit platelet function markedly, seems to have little effect on isolated vascular smooth muscle." | 1.26 | Cerebral vasospasm: effects of prostaglandin synthetase inhibitors in vitro. ( Chapleau, CE; Robertson, JT; White, RP, 1980) |
| "Phentolamine was ineffective." | 1.26 | Mechanism of cerebral arterial contraction induced by blood constituents. ( Ohta, T; Shimizu, K; Toda, N, 1980) |
| "The authors report 22 cases of transient ischemic attacks (TIA's) manifested by amaurosis fugax or hemiparesis or paresthesia of less than 24 hours' duration." | 1.26 | Transient ischemic attacks due to increased platelet aggregation and adhesiveness. Ultrastructural and functional correlation. ( al-Mefty, O; Marano, G; Nugent, GR; Raiaraman, S; Rodman, N, 1979) |
| "Sulfinpyrazone treatment of patients with myocardial infarction (Killip--classification I and II), starting 25--35 days after the acute myocardial infarction, reduces cardiac mortality and incidence of sudden death for a period of two years." | 1.26 | [Action mechanism and clinical indications for thrombocyte aggregation inhibitors]. ( Oelz, O, 1979) |
| "and sulfinpyrazone have been tested in several large scale clinical trials." | 1.26 | [Antiplatelet drugs (author's transl)]. ( Dechavanne, M; Follea, G; Trzeciak, MC, 1979) |
| "Eight patients with transient ischemic attacks, and three with partial nonprogressive strokes associated with mitral valve prolapse, are reported." | 1.26 | TIA, stroke, and mitral valve prolapse. ( Watson, RT, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 215 (26.16) | 18.7374 |
| 1990's | 137 (16.67) | 18.2507 |
| 2000's | 185 (22.51) | 29.6817 |
| 2010's | 192 (23.36) | 24.3611 |
| 2020's | 93 (11.31) | 2.80 |
| Authors | Studies |
|---|---|
| Johnston, SC | 55 |
| Amarenco, P | 23 |
| Aunes, M | 2 |
| Denison, H | 13 |
| Evans, SR | 12 |
| Himmelmann, A | 4 |
| Jahreskog, M | 2 |
| James, S | 4 |
| Knutsson, M | 7 |
| Ladenvall, P | 9 |
| Molina, CA | 15 |
| Nylander, S | 1 |
| Röther, J | 3 |
| Wang, Y | 99 |
| Morton, M | 1 |
| Kubiak-Balcerewicz, K | 1 |
| Sarnowska, A | 1 |
| Fiszer, U | 1 |
| Lendaris, AR | 1 |
| Lessen, S | 1 |
| Cheng, NT | 1 |
| Friedman, BW | 1 |
| Esenwa, C | 1 |
| Labovitz, DL | 2 |
| Prabhakaran, S | 2 |
| Lipton, RB | 1 |
| Liberman, AL | 2 |
| Dai, L | 3 |
| Xu, J | 9 |
| Yan, H | 4 |
| Chen, Z | 3 |
| Pan, Y | 23 |
| Meng, X | 35 |
| Li, H | 33 |
| Wang, A | 24 |
| Xie, X | 11 |
| Bath, PM | 20 |
| Dong, Q | 2 |
| Xu, A | 3 |
| Jing, J | 19 |
| Lin, J | 15 |
| Niu, S | 1 |
| Zhao, X | 35 |
| Li, Z | 16 |
| Jiang, Y | 10 |
| Li, W | 3 |
| Liu, L | 35 |
| Chang, L | 1 |
| Wang, L | 1 |
| Zhuang, X | 1 |
| Zhao, J | 1 |
| Feng, Y | 1 |
| Man, H | 1 |
| Li, G | 1 |
| Wang, B | 2 |
| Barry, HC | 1 |
| Lun, R | 2 |
| Dhaliwal, S | 2 |
| Zitikyte, G | 2 |
| Roy, DC | 2 |
| Hutton, B | 2 |
| Dowlatshahi, D | 3 |
| Yang, Y | 3 |
| Huang, Z | 2 |
| Zhang, X | 5 |
| Tian, X | 4 |
| Zuo, Y | 3 |
| Wang, F | 5 |
| Li, Y | 3 |
| Liu, J | 1 |
| Kang, MK | 1 |
| Cha, JK | 1 |
| Chang, DI | 1 |
| Kim, HY | 1 |
| Chung, JW | 1 |
| Jung, KH | 1 |
| Hong, KS | 3 |
| Chang, JY | 1 |
| Rha, JH | 1 |
| Park, JM | 1 |
| Kim, BK | 1 |
| Lee, SJ | 1 |
| Park, MS | 1 |
| Lee, KY | 1 |
| Shin, DI | 1 |
| Yoon, BW | 2 |
| Rostanski, SK | 2 |
| Kvernland, A | 1 |
| de Havenon, A | 4 |
| Henninger, N | 2 |
| Mac Grory, B | 3 |
| Kim, AS | 9 |
| Easton, JD | 24 |
| Yaghi, S | 4 |
| Piccini, JP | 1 |
| Poli, S | 1 |
| Weiss, M | 1 |
| Xian, Y | 7 |
| Feng, W | 1 |
| Ku, JC | 1 |
| Taslimi, S | 1 |
| Zuccato, J | 1 |
| Pasarikovski, CR | 1 |
| Nasr, N | 1 |
| Chechik, O | 1 |
| Chisci, E | 1 |
| Bissacco, D | 1 |
| Larrue, V | 2 |
| Rabinovich, Y | 1 |
| Michelagnoli, S | 1 |
| Settembrini, PG | 1 |
| Priola, SM | 1 |
| Cusimano, MD | 1 |
| Yang, VXD | 1 |
| Macdonald, RL | 1 |
| Pomero, F | 1 |
| Galli, E | 1 |
| Bellesini, M | 1 |
| Maroni, L | 1 |
| Squizzato, A | 1 |
| Xu, H | 2 |
| Smith, EE | 2 |
| Fonarow, GC | 1 |
| Bhatt, DL | 3 |
| Schwamm, LH | 3 |
| Peterson, ED | 1 |
| Zhang, L | 3 |
| Wu, Y | 4 |
| Fan, Y | 1 |
| He, Z | 1 |
| He, P | 2 |
| Liang, J | 1 |
| Shah, J | 1 |
| Liu, S | 2 |
| Yu, W | 1 |
| Venketasubramanian, N | 1 |
| Ebell, MH | 1 |
| Bahit, MC | 1 |
| Vora, AN | 1 |
| Wojdyla, DM | 1 |
| Thomas, L | 1 |
| Goodman, SG | 1 |
| Aronson, R | 1 |
| Jordan, JD | 1 |
| Kolls, BJ | 1 |
| Dombrowski, KE | 1 |
| Vinereanu, D | 1 |
| Halvorsen, S | 1 |
| Berwanger, O | 2 |
| Windecker, S | 1 |
| Mehran, R | 1 |
| Granger, CB | 1 |
| Alexander, JH | 1 |
| Lopes, RD | 2 |
| Clarke, A | 1 |
| Reddin, C | 1 |
| Murphy, R | 1 |
| O'Donnell, MJ | 2 |
| Huang, P | 1 |
| Chen, G | 2 |
| Wang, D | 14 |
| Jin, A | 1 |
| Yang, H | 1 |
| Cheng, J | 2 |
| Wang, Z | 3 |
| Micieli, A | 1 |
| Singh, N | 1 |
| Jahn, B | 1 |
| Siebert, U | 1 |
| Menon, BK | 1 |
| Demchuk, AM | 3 |
| Wang, X | 4 |
| Zhu, Q | 1 |
| Deng, X | 1 |
| Zhang, Z | 1 |
| Ma, Y | 2 |
| Shi, T | 1 |
| Kostev, K | 1 |
| Tanislav, C | 1 |
| Chutoo, P | 1 |
| Kulinskaya, E | 1 |
| Bakbergenuly, I | 1 |
| Steel, N | 1 |
| Pchejetski, D | 1 |
| Brown, B | 1 |
| Xu, Y | 2 |
| Chen, W | 10 |
| Jiang, L | 1 |
| Yao, D | 1 |
| Guo, L | 1 |
| Tornyos, D | 2 |
| Komócsi, A | 2 |
| Bálint, A | 2 |
| Kupó, P | 2 |
| El Abdallaoui, OEA | 1 |
| Szapáry, L | 1 |
| Szapáry, LB | 1 |
| Lim, ST | 1 |
| Murphy, SJX | 1 |
| Murphy, SM | 1 |
| Coughlan, T | 6 |
| O'Neill, D | 6 |
| Tierney, S | 5 |
| Egan, B | 5 |
| Collins, DR | 5 |
| McCarthy, AJ | 1 |
| Lim, SY | 1 |
| Smith, DR | 1 |
| Cox, D | 2 |
| McCabe, DJH | 1 |
| Scalia, L | 1 |
| Calderone, D | 1 |
| Capodanno, D | 1 |
| Sharma, M | 4 |
| Toyoda, K | 1 |
| Bereczki, D | 2 |
| Kasner, SE | 5 |
| Lutsep, HL | 7 |
| Tsivgoulis, G | 2 |
| Ntaios, G | 3 |
| Czlonkowska, A | 2 |
| Shuaib, A | 2 |
| Endres, M | 2 |
| Diener, HC | 24 |
| Gailani, D | 1 |
| Kahl, A | 1 |
| Donovan, M | 1 |
| Perera, V | 1 |
| Li, D | 2 |
| Hankey, GJ | 10 |
| Mele, F | 1 |
| Gendarini, C | 1 |
| Pantoni, L | 1 |
| Aref, HM | 3 |
| El-Khawas, H | 3 |
| Elbassiouny, A | 3 |
| Shokri, HM | 3 |
| Zeinhom, MG | 3 |
| Roushdy, TM | 3 |
| Suo, Y | 2 |
| Krishnan, K | 4 |
| Law, ZK | 2 |
| Minhas, JS | 2 |
| Robinson, TG | 4 |
| Sprigg, N | 5 |
| Mavilakandy, A | 2 |
| England, TJ | 4 |
| Eveson, D | 2 |
| Mistri, A | 2 |
| Dawson, J | 3 |
| Appleton, JP | 4 |
| Cao, M | 1 |
| Li, J | 8 |
| Xu, Q | 5 |
| Gao, Y | 3 |
| Han, S | 1 |
| Wang, C | 15 |
| Wang, T | 1 |
| Liu, H | 2 |
| Lang, AE | 1 |
| Shu, L | 1 |
| Furie, KL | 1 |
| Kim, A | 1 |
| Bhatia, K | 2 |
| Ladd, LM | 1 |
| Carr, KH | 1 |
| Di Napoli, M | 1 |
| Saver, JL | 3 |
| McCullough, LD | 1 |
| Hosseini Farahabadi, M | 1 |
| Alsbrook, DL | 1 |
| Hinduja, A | 1 |
| Ortiz Garcia, JG | 1 |
| Sabbagh, SY | 1 |
| Jafarli, A | 1 |
| Divani, AA | 1 |
| Ma, X | 1 |
| Chen, Y | 2 |
| Zhong, P | 1 |
| Zhang, J | 4 |
| Woodhouse, LJ | 2 |
| Christensen, H | 2 |
| Dineen, RA | 2 |
| James, M | 2 |
| Montgomery, AA | 2 |
| Ranta, A | 2 |
| Claiborne Johnston, S | 1 |
| Li, M | 4 |
| Yang, Q | 1 |
| Shi, J | 1 |
| Lin, H | 3 |
| Ge, F | 2 |
| Lee, TL | 1 |
| Chang, YM | 1 |
| Sung, PS | 1 |
| Brorson, JR | 2 |
| Giurcanu, M | 1 |
| Jia, W | 2 |
| Chen, M | 1 |
| Yang, T | 1 |
| Ruan, Z | 2 |
| Su, J | 1 |
| Xing, Y | 1 |
| Elm, JJ | 5 |
| Farrant, M | 6 |
| Meurer, WJ | 1 |
| Dietrich, D | 1 |
| Izcovich, A | 1 |
| Caruso, D | 1 |
| Tisi Baña, M | 1 |
| Bottaro, F | 1 |
| Pollán, J | 1 |
| Saavedra, E | 1 |
| Catalano, HN | 1 |
| Adelman, EE | 1 |
| Cucchiara, BL | 2 |
| Barsan, WG | 2 |
| Tillman, HJ | 1 |
| Lindblad, AS | 4 |
| Palesch, YY | 4 |
| Zhao, W | 1 |
| Pauls, K | 1 |
| Walsh, KB | 1 |
| Martí-Fàbregas, J | 2 |
| Bernstein, RA | 3 |
| Sagris, D | 1 |
| Georgiopoulos, G | 1 |
| Perlepe, K | 1 |
| Pateras, K | 1 |
| Korompoki, E | 1 |
| Makaritsis, K | 1 |
| Vemmos, K | 1 |
| Milionis, H | 1 |
| D'Ascenzo, F | 1 |
| Gili, S | 1 |
| Bertaina, M | 1 |
| Iannaccone, M | 1 |
| Cammann, VL | 1 |
| Di Vece, D | 1 |
| Kato, K | 1 |
| Saglietto, A | 1 |
| Szawan, KA | 1 |
| Frangieh, AH | 1 |
| Boffini, B | 1 |
| Annaratone, M | 1 |
| Sarcon, A | 1 |
| Levinson, RA | 1 |
| Franke, J | 1 |
| Napp, LC | 1 |
| Jaguszewski, M | 1 |
| Noutsias, M | 1 |
| Münzel, T | 1 |
| Knorr, M | 1 |
| Heiner, S | 1 |
| Katus, HA | 1 |
| Burgdorf, C | 1 |
| Schunkert, H | 1 |
| Thiele, H | 1 |
| Bauersachs, J | 1 |
| Tschöpe, C | 1 |
| Pieske, BM | 1 |
| Rajan, L | 1 |
| Michels, G | 1 |
| Pfister, R | 1 |
| Cuneo, A | 1 |
| Jacobshagen, C | 1 |
| Hasenfuß, G | 1 |
| Karakas, M | 1 |
| Koenig, W | 1 |
| Rottbauer, W | 1 |
| Said, SM | 1 |
| Braun-Dullaeus, RC | 1 |
| Banning, A | 1 |
| Cuculi, F | 1 |
| Kobza, R | 1 |
| Fischer, TA | 1 |
| Vasankari, T | 1 |
| Airaksinen, KEJ | 1 |
| Opolski, G | 1 |
| Dworakowski, R | 1 |
| MacCarthy, P | 1 |
| Kaiser, C | 1 |
| Osswald, S | 1 |
| Galiuto, L | 1 |
| Crea, F | 1 |
| Dichtl, W | 1 |
| Franz, WM | 1 |
| Empen, K | 1 |
| Felix, SB | 1 |
| Delmas, C | 1 |
| Lairez, O | 1 |
| El-Battrawy, I | 1 |
| Akin, I | 1 |
| Borggrefe, M | 1 |
| Horowitz, JD | 1 |
| Kozel, M | 1 |
| Tousek, P | 1 |
| Widimský, P | 1 |
| Gilyarova, E | 1 |
| Shilova, A | 1 |
| Gilyarov, M | 1 |
| Biondi-Zoccai, G | 1 |
| Winchester, DE | 1 |
| Ukena, C | 1 |
| Neuhaus, M | 1 |
| Bax, JJ | 1 |
| Prasad, A | 2 |
| Di Mario, C | 1 |
| Böhm, M | 1 |
| Gasparini, M | 1 |
| Ruschitzka, F | 1 |
| Bossone, E | 1 |
| Citro, R | 1 |
| Rinaldi, M | 1 |
| De Ferrari, GM | 1 |
| Lüscher, T | 1 |
| Ghadri, JR | 1 |
| Templin, C | 1 |
| Zuo, Z | 1 |
| Cucchiara, B | 2 |
| Elm, J | 2 |
| Coutts, SB | 2 |
| Willey, JZ | 1 |
| Biros, MH | 1 |
| Ross, MA | 1 |
| Kamel, H | 1 |
| Zhang, C | 4 |
| Kleindorfer, DO | 2 |
| Levitan, EB | 1 |
| Howard, VJ | 1 |
| Howard, G | 1 |
| Soliman, EZ | 1 |
| Zhuang, M | 1 |
| Bao, G | 1 |
| Zhai, Y | 1 |
| Yang, GY | 1 |
| Xue, G | 1 |
| Li, Q | 1 |
| Bell, H | 1 |
| Steinfort, B | 1 |
| Pasalic, L | 1 |
| Dexter, M | 1 |
| McKenna, MC | 1 |
| Fanning, N | 1 |
| Cronin, S | 1 |
| Albay, CEQ | 1 |
| Leyson, FGD | 1 |
| Cheng, FC | 1 |
| Kalladka, D | 1 |
| Rounis, E | 1 |
| Albers, GW | 13 |
| Jonasson, J | 7 |
| Minematsu, K | 10 |
| Wong, KL | 2 |
| Slivka, A | 2 |
| Rink, C | 1 |
| Paoletto, D | 1 |
| Sen, CK | 1 |
| Ou, Z | 1 |
| Zhang, Y | 2 |
| Liang, Z | 1 |
| Deng, W | 1 |
| Huang, W | 1 |
| Wu, Z | 1 |
| Jiang, H | 1 |
| Liu, Q | 1 |
| Ouyang, F | 1 |
| Xing, S | 1 |
| Zeng, J | 2 |
| Xiong, Y | 2 |
| Yu, Z | 1 |
| Zhou, H | 2 |
| Shan, B | 1 |
| Fu, J | 3 |
| Zhu, H | 1 |
| Feng, Q | 1 |
| Shen, R | 1 |
| Jin, X | 1 |
| Guimarães, HP | 1 |
| de Barros E Silva, PGM | 1 |
| Liporace, IL | 1 |
| Sampaio, RO | 1 |
| Tarasoutchi, F | 1 |
| Paixão, M | 1 |
| Hoffmann-Filho, CR | 1 |
| Patriota, R | 1 |
| Leiria, TLL | 1 |
| Lamprea, D | 1 |
| Precoma, DB | 1 |
| Atik, FA | 1 |
| Silveira, FS | 1 |
| Farias, FR | 1 |
| Barreto, DO | 1 |
| Almeida, AP | 1 |
| Zilli, AC | 1 |
| de Souza Neto, JD | 1 |
| Cavalcante, MA | 1 |
| Figueira, FAMS | 1 |
| Junior, RA | 1 |
| Moisés, VA | 1 |
| Mesas, CE | 1 |
| Ardito, RV | 1 |
| Kalil, PSA | 1 |
| Paiva, MSMO | 1 |
| Maldonado, JGA | 1 |
| de Lima, CEB | 1 |
| D'Oliveira Vieira, R | 1 |
| Laranjeira, L | 1 |
| Kojima, F | 1 |
| Damiani, L | 1 |
| Nakagawa, RH | 1 |
| Dos Santos, JRY | 1 |
| Sampaio, BS | 1 |
| Campos, VB | 1 |
| Saraiva, JFK | 1 |
| Fonseca, FH | 1 |
| Pinto, IM | 1 |
| Magalhães, CC | 1 |
| Ferreira, JFM | 1 |
| Pavanello, R | 1 |
| Cavalcanti, AB | 1 |
| Bulwa, Z | 1 |
| Saleh Velez, FG | 1 |
| Pinto, CB | 1 |
| Kaushik, A | 1 |
| Deora, S | 1 |
| Choudhary, R | 1 |
| Pei, LL | 1 |
| Chen, P | 1 |
| Fang, H | 1 |
| Cao, Y | 4 |
| Guo, YN | 1 |
| Zhang, R | 1 |
| Zhao, L | 2 |
| Wu, J | 1 |
| Sun, SL | 1 |
| Wang, XY | 1 |
| Lo, EH | 1 |
| Buonanno, FS | 1 |
| Ning, MM | 1 |
| Xu, YM | 1 |
| Song, B | 1 |
| Kargiotis, O | 1 |
| Hill, MD | 8 |
| Ullah, W | 1 |
| Zghouzi, M | 1 |
| Ahmad, B | 1 |
| Biswas, S | 1 |
| Zaher, N | 1 |
| Sattar, Y | 1 |
| Pacha, HM | 1 |
| Goldsweig, AM | 1 |
| Velagapudi, P | 1 |
| Fichman, DL | 1 |
| Alraies, MC | 1 |
| Kovacevic, KD | 1 |
| Greisenegger, S | 1 |
| Langer, A | 2 |
| Gelbenegger, G | 1 |
| Buchtele, N | 1 |
| Pabinger, I | 1 |
| Petroczi, K | 1 |
| Zhu, S | 1 |
| Gilbert, JC | 1 |
| Jilma, B | 1 |
| Xue, X | 1 |
| Zhou, L | 1 |
| Clarkson, SA | 1 |
| Heindl, B | 1 |
| Cai, A | 1 |
| Beasley, M | 1 |
| Dillon, C | 2 |
| Limdi, N | 1 |
| Brown, TM | 1 |
| Scavasine, VC | 1 |
| Barbosa, RM | 1 |
| Lopes Neto, FDN | 1 |
| Germininani, FMB | 1 |
| Bazan, R | 1 |
| Zétola, VF | 1 |
| Massaro, AR | 1 |
| Lange, MC | 1 |
| Ma, L | 1 |
| Jain, V | 1 |
| Aggarwal, D | 1 |
| Vaduganathan, M | 1 |
| Arora, S | 1 |
| Hussain, Z | 1 |
| Uberoi, G | 1 |
| Tafur, A | 1 |
| Ricciardi, M | 1 |
| Qamar, A | 1 |
| Shorr, R | 1 |
| Li, ZX | 1 |
| Gu, HQ | 1 |
| Fisher, M | 8 |
| Wang, YJ | 2 |
| Sheth, KN | 1 |
| Lansberg, M | 1 |
| Tirschwell, D | 1 |
| Mistry, E | 1 |
| El Alaoui El Abdallaoui, O | 1 |
| Medranda, GA | 1 |
| Doros, G | 1 |
| Yerasi, C | 1 |
| Case, BC | 1 |
| Weintraub, WS | 1 |
| Waksman, R | 1 |
| Wang, J | 1 |
| Han, M | 1 |
| Kuang, J | 1 |
| Tu, J | 1 |
| Starcevich, K | 1 |
| Gao, P | 2 |
| Peng, C | 1 |
| Yin, S | 1 |
| Chen, J | 1 |
| Yi, Y | 1 |
| Hilkens, NA | 2 |
| Algra, A | 21 |
| Csiba, L | 2 |
| Hacke, W | 4 |
| Kappelle, LJ | 10 |
| Koudstaal, PJ | 16 |
| Leys, D | 3 |
| Mas, JL | 5 |
| Sacco, RL | 5 |
| Greving, JP | 2 |
| Condello, F | 1 |
| Liccardo, G | 1 |
| Ferrante, G | 1 |
| Wu, B | 1 |
| Lin, L | 1 |
| Ding, Y | 1 |
| Zhong, B | 1 |
| Lin, M | 1 |
| Xu, DP | 1 |
| Huang, WY | 1 |
| Ovbiagele, B | 4 |
| Lee, M | 3 |
| Rao, Z | 2 |
| Zheng, H | 4 |
| Dong, K | 2 |
| Rodés-Cabau, J | 1 |
| Masson, JB | 1 |
| Welsh, RC | 1 |
| Garcia Del Blanco, B | 1 |
| Pelletier, M | 1 |
| Webb, JG | 1 |
| Al-Qoofi, F | 1 |
| Généreux, P | 1 |
| Maluenda, G | 1 |
| Thoenes, M | 1 |
| Paradis, JM | 1 |
| Chamandi, C | 1 |
| Serra, V | 1 |
| Dumont, E | 1 |
| Côté, M | 1 |
| Arous, S | 1 |
| Haboub, M | 1 |
| El Ghali Benouna, M | 1 |
| Bentaoune, T | 1 |
| Habbal, R | 1 |
| Tao, Y | 1 |
| Gu, H | 1 |
| Bokelund-Singh, S | 1 |
| Held, P | 7 |
| Wong, KSL | 4 |
| Morris, JG | 1 |
| Carter, EL | 1 |
| Martin, SA | 1 |
| Rao, NM | 2 |
| Wu, YL | 2 |
| Sun, H | 1 |
| Ming, T | 1 |
| Liu, X | 2 |
| Cong, Y | 1 |
| Li, F | 1 |
| Mahajan, K | 1 |
| Negi, P | 1 |
| Merwaha, R | 1 |
| Gui, L | 1 |
| Dong, Y | 1 |
| Li, S | 1 |
| Liu, LP | 1 |
| Wang, YL | 1 |
| Wang, G | 1 |
| Zhao, XQ | 1 |
| Oza, R | 1 |
| Rundell, K | 1 |
| Garcellano, M | 1 |
| Gutierrez, J | 1 |
| Lekic, T | 1 |
| Beridze, M | 1 |
| Duley, L | 1 |
| Flaherty, K | 1 |
| Havard, D | 1 |
| Heptinstall, S | 1 |
| Markus, HS | 4 |
| Pocock, SJ | 1 |
| Randall, M | 1 |
| Scutt, P | 1 |
| Venables, GS | 2 |
| Liu, SM | 1 |
| Zhao, WL | 1 |
| Song, HQ | 1 |
| Meng, R | 1 |
| Li, SJ | 1 |
| Ren, CH | 1 |
| Ji, XM | 1 |
| Feng, WW | 1 |
| Verma, A | 1 |
| Ha, ACT | 1 |
| Kirchhof, P | 1 |
| Hindricks, G | 1 |
| Healey, JS | 2 |
| Wyse, DG | 1 |
| Champagne, J | 1 |
| Essebag, V | 1 |
| Wells, G | 1 |
| Gupta, D | 1 |
| Heidbuchel, H | 1 |
| Sanders, P | 1 |
| Birnie, DH | 1 |
| Dhamoon, MS | 1 |
| Wangqin, R | 2 |
| Lavados, P | 1 |
| Dávalos, A | 2 |
| Shamalov, N | 1 |
| Cunha, L | 3 |
| Lindgren, A | 1 |
| Mikulik, R | 1 |
| Arauz, A | 1 |
| Lang, W | 2 |
| Eckstein, J | 1 |
| Gagliardi, R | 1 |
| Ameriso, SF | 1 |
| Tatlisumak, T | 1 |
| Veltkamp, R | 1 |
| Toni, DS | 1 |
| Uchiyama, S | 4 |
| Brouns, R | 1 |
| DeVries Basson, MM | 1 |
| Muir, K | 1 |
| Bornstein, N | 1 |
| Ozturk, S | 1 |
| O'Donnell, M | 4 |
| Mundl, H | 1 |
| Pater, C | 1 |
| Weitz, J | 1 |
| Peacock, WF | 1 |
| Swaminathan, B | 1 |
| Kirsch, B | 1 |
| Berkowitz, SD | 2 |
| Peters, G | 1 |
| Pare, G | 1 |
| Themeles, E | 1 |
| Shoamanesh, A | 1 |
| Connolly, SJ | 3 |
| Hart, RG | 9 |
| Barsan, W | 3 |
| Conwit, RA | 1 |
| Ding, L | 1 |
| Peng, B | 1 |
| Fyfe, I | 1 |
| Yao, JC | 1 |
| Cui, M | 1 |
| Pan, MM | 1 |
| Gu, ZC | 1 |
| Li, WY | 1 |
| Zhang, N | 1 |
| Ma, C | 1 |
| Jia, L | 1 |
| Ji, H | 1 |
| Li, R | 1 |
| Yin, X | 1 |
| Kheiri, B | 1 |
| Osman, M | 1 |
| Abdalla, A | 1 |
| Haykal, T | 1 |
| Swaid, B | 1 |
| Ahmed, S | 1 |
| Chahine, A | 1 |
| Hassan, M | 1 |
| Bachuwa, G | 1 |
| Al Qasmi, M | 1 |
| Hao, Q | 3 |
| Tampi, M | 1 |
| Foroutan, F | 1 |
| Siemieniuk, RA | 1 |
| Guyatt, G | 2 |
| Prasad, K | 1 |
| Siemieniuk, R | 1 |
| Lytvyn, L | 1 |
| Heen, AF | 1 |
| Agoritsas, T | 1 |
| Vandvik, PO | 2 |
| Gorthi, SP | 1 |
| Fisch, L | 1 |
| Jusufovic, M | 1 |
| Muller, J | 1 |
| Booth, B | 1 |
| Horton, E | 1 |
| Fraiz, A | 1 |
| Siemieniuk, J | 1 |
| Fobuzi, AC | 1 |
| Katragunta, N | 1 |
| Rochwerg, B | 1 |
| Masjuan, J | 1 |
| Salido, L | 1 |
| DeFelipe, A | 1 |
| Hernández-Antolín, R | 1 |
| Fernández-Golfín, C | 1 |
| Cruz-Culebras, A | 1 |
| Matute, C | 1 |
| Vera, R | 1 |
| Pérez-Torre, P | 1 |
| Zamorano, JL | 1 |
| Simon, T | 1 |
| Rahman, H | 1 |
| Khan, SU | 1 |
| Nasir, F | 1 |
| Hammad, T | 1 |
| Meyer, MA | 1 |
| Kaluski, E | 1 |
| Liu, Y | 2 |
| Du, F | 1 |
| Uchino, K | 1 |
| Tillman, H | 1 |
| Tse, D | 1 |
| Zhang, XG | 1 |
| Zhu, XQ | 1 |
| Xue, J | 1 |
| Li, ZZ | 1 |
| Jiang, HY | 1 |
| Hu, L | 1 |
| Yue, YH | 1 |
| Mo, J | 1 |
| Zurita, KG | 1 |
| Pearson, C | 1 |
| Sethi, P | 1 |
| Vora, N | 1 |
| Rizelio, V | 1 |
| Macuco, ALB | 1 |
| Sato, HK | 1 |
| Nascimento, MTMS | 1 |
| Souza, RKM | 1 |
| Kowacs, PA | 1 |
| Lau, AY | 2 |
| Zhao, Y | 2 |
| Chen, C | 3 |
| Leung, TW | 2 |
| Huang, Y | 2 |
| Suwanwela, NC | 2 |
| Han, Z | 2 |
| Tan, KS | 2 |
| Ratanakorn, D | 2 |
| Wong, KS | 6 |
| Pumar, JM | 1 |
| Arias-Rivas, S | 1 |
| Rodríguez-Yáñez, M | 1 |
| Blanco, M | 1 |
| Ageitos, M | 1 |
| Vazquez-Herrero, F | 1 |
| Castiñeira-Mourenza, JA | 1 |
| Masso, A | 1 |
| Duytschaever, M | 1 |
| Berte, B | 1 |
| Acena, M | 1 |
| De Meyer, G | 1 |
| Bun, SS | 1 |
| Van Heuverswyn, F | 1 |
| Vandekerckhove, Y | 1 |
| Tavernier, R | 1 |
| Liptai, Z | 1 |
| Ivády, B | 1 |
| Barsi, P | 1 |
| Várallyay, G | 1 |
| Rudas, G | 1 |
| Fogarasi, A | 1 |
| Ertaş, F | 1 |
| Kaya, H | 1 |
| Kaya, Z | 1 |
| Bulur, S | 1 |
| Köse, N | 1 |
| Gül, M | 1 |
| Kahya Eren, N | 1 |
| Cağlıyan, CE | 1 |
| Köroğlu, B | 1 |
| Vatan, B | 1 |
| Acar, G | 1 |
| Yüksel, M | 1 |
| Bilik, MZ | 1 |
| Gedik, S | 1 |
| Simşek, Z | 1 |
| Akıl, MA | 1 |
| Yılmaz, R | 1 |
| Oylumlu, M | 1 |
| Arıbaş, A | 1 |
| Yıldız, A | 1 |
| Aydın, M | 1 |
| Yeter, E | 1 |
| Kanadaşı, M | 1 |
| Ergene, O | 1 |
| Ozhan, H | 1 |
| Ulgen, MS | 1 |
| Kono, K | 1 |
| Shintani, A | 1 |
| Yoshimura, R | 1 |
| Okada, H | 1 |
| Tanaka, Y | 1 |
| Fujimoto, T | 1 |
| Tomura, N | 1 |
| Terada, T | 1 |
| Zuurbier, SM | 1 |
| Vermeer, SE | 1 |
| Hilkens, PH | 1 |
| Roos, YB | 1 |
| Cui, L | 1 |
| Jia, J | 1 |
| Xia, H | 1 |
| Conrad, MF | 2 |
| Boulom, V | 1 |
| Baloum, V | 1 |
| Mukhopadhyay, S | 1 |
| Garg, A | 1 |
| Patel, VI | 2 |
| Cambria, RP | 2 |
| Edwards, D | 1 |
| Fletcher, K | 1 |
| Deller, R | 1 |
| McManus, R | 1 |
| Lasserson, D | 1 |
| Giles, M | 1 |
| Sims, D | 1 |
| Norrie, J | 1 |
| McGuire, G | 1 |
| Cohn, S | 1 |
| Whittle, F | 1 |
| Hobbs, V | 1 |
| Weir, C | 1 |
| Mant, J | 1 |
| Valles, J | 1 |
| Lago, A | 1 |
| Moscardo, A | 1 |
| Tembl, J | 1 |
| Parkhutik, V | 1 |
| Santos, MT | 1 |
| Li, JY | 1 |
| Xia, YP | 1 |
| Mao, L | 1 |
| Hu, B | 2 |
| Li, X | 1 |
| Zhou, G | 1 |
| Zhou, X | 1 |
| Zhou, S | 1 |
| Battenhouse, H | 1 |
| Conwit, R | 1 |
| Lindblad, A | 1 |
| Morgenstern, L | 1 |
| Poisson, SN | 1 |
| Palesch, Y | 1 |
| Lane, DA | 1 |
| Raichand, S | 1 |
| Moore, D | 1 |
| Connock, M | 1 |
| Fry-Smith, A | 1 |
| Fitzmaurice, DA | 1 |
| Liu, T | 1 |
| Yan, BC | 1 |
| Park, JH | 2 |
| Shin, BN | 1 |
| Ahn, JH | 1 |
| Kim, IH | 1 |
| Lee, JC | 1 |
| Yoo, KY | 1 |
| Hwang, IK | 1 |
| Choi, JH | 1 |
| Lee, YL | 1 |
| Suh, HW | 1 |
| Jun, JG | 1 |
| Kwon, YG | 1 |
| Kim, YM | 1 |
| Kwon, SH | 1 |
| Her, S | 1 |
| Kim, JS | 1 |
| Hyun, BH | 1 |
| Kim, CK | 1 |
| Cho, JH | 1 |
| Lee, CH | 1 |
| Won, MH | 1 |
| Ding, D | 1 |
| Held, VE | 1 |
| Wolf, ME | 1 |
| Hennerici, MG | 5 |
| Derdeyn, CP | 3 |
| Chimowitz, MI | 5 |
| Lynn, MJ | 5 |
| Fiorella, D | 3 |
| Turan, TN | 4 |
| Janis, LS | 3 |
| Montgomery, J | 2 |
| Nizam, A | 1 |
| Lane, BF | 3 |
| Barnwell, SL | 2 |
| Waters, MF | 3 |
| Hoh, BL | 3 |
| Hourihane, JM | 2 |
| Levy, EI | 2 |
| Alexandrov, AV | 2 |
| Harrigan, MR | 2 |
| Chiu, D | 2 |
| Klucznik, RP | 2 |
| Clark, JM | 2 |
| McDougall, CG | 2 |
| Johnson, MD | 2 |
| Pride, GL | 3 |
| Lynch, JR | 1 |
| Zaidat, OO | 2 |
| Rumboldt, Z | 2 |
| Cloft, HJ | 2 |
| Gouya, G | 1 |
| Arrich, J | 1 |
| Wolzt, M | 1 |
| Huber, K | 1 |
| Verheugt, FW | 1 |
| Gurbel, PA | 2 |
| Pirker-Kees, A | 1 |
| Siller-Matula, JM | 1 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Nomani, F | 1 |
| Kamal, AK | 2 |
| Alvarez-Sabín, J | 2 |
| Quintana, M | 1 |
| Santamarina, E | 1 |
| Maisterra, O | 1 |
| Jabbari, E | 1 |
| Sethuraman, S | 1 |
| Sekaran, L | 1 |
| Tobin, WO | 5 |
| Kinsella, JA | 5 |
| Kavanagh, GF | 2 |
| O'Donnell, JS | 2 |
| McGrath, RT | 1 |
| Feeley, TM | 4 |
| Murphy, RP | 5 |
| McCabe, DJ | 8 |
| Silver, B | 1 |
| Wulf Silver, R | 1 |
| de Vos-Koppelaar, NC | 1 |
| Kerkhoff, H | 1 |
| de Vogel, EM | 1 |
| Zock, E | 1 |
| Dieleman, HG | 1 |
| Liu, G | 1 |
| Zhao, K | 1 |
| Michalczyk, MJ | 1 |
| Opalacz, A | 1 |
| LaMuraglia, GM | 1 |
| Michiels, JJ | 3 |
| Berneman, Z | 1 |
| Gadisseur, A | 1 |
| Lam, KH | 1 |
| De Raeve, H | 1 |
| Schroyens, W | 1 |
| Selim, MH | 1 |
| Falcone, GJ | 1 |
| Rosand, J | 1 |
| Al-Shahi Salman, R | 1 |
| Dennis, MS | 2 |
| He, F | 1 |
| Xia, C | 1 |
| Zhang, JH | 1 |
| Li, XQ | 1 |
| Zhou, ZH | 1 |
| Li, FP | 1 |
| Lv, Y | 1 |
| Chen, HS | 1 |
| Hu, Z | 1 |
| Yang, L | 1 |
| Zhang, Q | 1 |
| Zheng, M | 1 |
| Shang, X | 1 |
| Yan, C | 1 |
| Sandhu, RK | 1 |
| Hohnloser, SH | 2 |
| Pfeffer, MA | 1 |
| Yuan, F | 1 |
| Yusuf, S | 2 |
| McAlister, FA | 1 |
| Jickling, GC | 1 |
| Liu, F | 2 |
| Tantry, US | 1 |
| Alderazi, YJ | 1 |
| Batchelder, A | 1 |
| Hunter, J | 1 |
| Cairns, V | 1 |
| Sandford, R | 1 |
| Munshi, A | 1 |
| Naylor, AR | 1 |
| Fang, J | 1 |
| Wong, LK | 2 |
| Leng, X | 1 |
| Pu, Y | 1 |
| Zou, X | 1 |
| Soo, Y | 1 |
| Cotsonis, GA | 1 |
| Davis, KA | 1 |
| Miyares, MA | 1 |
| Dietrich, E | 1 |
| Xu, C | 1 |
| Wang, P | 1 |
| Xin, H | 1 |
| Yang, F | 1 |
| Jiang, W | 1 |
| Bai, Y | 1 |
| Han, J | 1 |
| Zhang, G | 1 |
| Zhao, G | 1 |
| Gong, Y | 1 |
| McDonough, CW | 1 |
| Royster, AJ | 1 |
| Sheehan, TO | 1 |
| Burkley, B | 1 |
| Langaee, TY | 1 |
| Mocco, J | 1 |
| Zuckerman, SL | 1 |
| Mummareddy, N | 1 |
| Stephens, ML | 1 |
| Ingram, C | 1 |
| Shaffer, CM | 1 |
| Denny, JC | 1 |
| Brilliant, MH | 1 |
| Kitchner, TE | 1 |
| Linneman, JG | 1 |
| Roden, DM | 1 |
| Johnson, JA | 1 |
| Shahidi, S | 1 |
| Owen-Falkenberg, A | 1 |
| Gottschalksen, B | 1 |
| Ellemann, K | 1 |
| Yang, C | 1 |
| Qian, J | 1 |
| Tang, X | 1 |
| Hu, Y | 2 |
| Niu, PP | 1 |
| Guo, ZN | 1 |
| Jin, H | 1 |
| Xing, YQ | 1 |
| Yang, X | 1 |
| Guo, R | 1 |
| Chang, T | 1 |
| Riaz, H | 1 |
| Alansari, SA | 1 |
| Khan, MS | 1 |
| Riaz, T | 1 |
| Raza, S | 1 |
| Luni, FK | 1 |
| Khan, AR | 1 |
| Riaz, IB | 1 |
| Krasuski, RA | 1 |
| Rothwell, PM | 12 |
| Norrving, B | 1 |
| Mehta, Z | 1 |
| Lin, Y | 2 |
| Čulić, V | 1 |
| Landman, GW | 1 |
| Kleefstra, N | 1 |
| Zhou, Y | 1 |
| Russo, NW | 1 |
| Petrucci, G | 1 |
| Rocca, B | 1 |
| Ping, Y | 1 |
| Dai, H | 1 |
| Sun, X | 1 |
| Tong, X | 1 |
| Lo, WT | 1 |
| Mo, D | 1 |
| Gao, F | 2 |
| Ma, N | 1 |
| Miao, Z | 1 |
| Illuminati, G | 1 |
| Schneider, F | 1 |
| Pizzardi, G | 1 |
| Masci, F | 1 |
| Calio', FG | 1 |
| Ricco, JB | 1 |
| Moris, D | 1 |
| Bakoyiannis, C | 1 |
| Avgerinos, E | 1 |
| Wood, H | 1 |
| Ou, L | 1 |
| Biller, J | 3 |
| Halkes, PH | 5 |
| Gray, LJ | 2 |
| Guiraud-Chaumeil, B | 3 |
| Yatsu, FM | 3 |
| Stern, S | 1 |
| Cohen, MJ | 1 |
| Gilon, D | 1 |
| Leshno, M | 1 |
| Brezis, M | 1 |
| Swain, S | 1 |
| Turner, C | 1 |
| Tyrrell, P | 1 |
| Rudd, A | 1 |
| Ross, M | 1 |
| England, T | 1 |
| Willmot, MR | 1 |
| Sare, GM | 1 |
| Dharmasaroja, P | 1 |
| Sander, D | 1 |
| Schwertfeger, M | 1 |
| Köfüncü, E | 1 |
| Diehm, C | 1 |
| Pittrow, D | 1 |
| Lam, SK | 1 |
| Owen, A | 1 |
| Koton, S | 1 |
| Howard, SC | 2 |
| Warlow, CP | 5 |
| Murphy, MF | 1 |
| Vande Griend, JP | 1 |
| Saseen, JJ | 1 |
| Slaughter, MS | 1 |
| Sobieski, MA | 1 |
| Gallagher, C | 1 |
| Dia, M | 1 |
| Silver, MA | 1 |
| Rouhl, RP | 1 |
| Lodder, J | 2 |
| Boncoraglio, GB | 1 |
| Bodini, A | 1 |
| Brambilla, C | 1 |
| Corsini, E | 1 |
| Carriero, MR | 1 |
| Parati, EA | 1 |
| Maidan, L | 1 |
| Cotsonis, G | 1 |
| Romano, JG | 2 |
| Levine, SR | 3 |
| Sabaliauskiene, Z | 1 |
| Grybauskas, P | 1 |
| Gaigalaite, V | 1 |
| Ptasekas, J | 1 |
| Yu, SC | 1 |
| Lam, WW | 1 |
| Chan, AY | 1 |
| Jiang, WJ | 1 |
| Georgiadis, D | 2 |
| Arnold, M | 1 |
| von Buedingen, HC | 1 |
| Valko, P | 1 |
| Sarikaya, H | 1 |
| Rousson, V | 1 |
| Mattle, HP | 4 |
| Bousser, MG | 7 |
| Baumgartner, RW | 4 |
| Chamorro, A | 3 |
| Ford, I | 3 |
| Fox, K | 2 |
| Hennerici, M | 1 |
| Khalil, S | 1 |
| Mohanaruban, K | 1 |
| Haq, S | 1 |
| Lökk, J | 1 |
| Schwab, S | 2 |
| Lemmens, R | 2 |
| Chen, F | 1 |
| Ni, Y | 1 |
| Fieuws, S | 2 |
| Thijs, V | 2 |
| Gomez, CR | 1 |
| Qureshi, AI | 1 |
| Weber, R | 2 |
| Weimar, C | 2 |
| Sebastian, J | 1 |
| Derksen, C | 1 |
| Khan, K | 1 |
| Saqqur, M | 1 |
| Dengler, R | 1 |
| Schwartz, A | 1 |
| Grond, M | 1 |
| Schumacher, H | 1 |
| Machnig, T | 1 |
| Eschenfelder, CC | 1 |
| Leonard, J | 1 |
| Weissenborn, K | 1 |
| Kastrup, A | 1 |
| Haberl, R | 2 |
| Albanese, A | 1 |
| Esposito, G | 1 |
| Puca, A | 1 |
| Tuttolomondo, A | 1 |
| Tirpakova, B | 1 |
| Di Giuda, D | 1 |
| Maira, G | 1 |
| Di Lazzaro, V | 1 |
| Simmons, BB | 1 |
| Yeo, A | 1 |
| Fung, K | 1 |
| Geraghty, OC | 2 |
| Kennedy, J | 2 |
| Chandratheva, A | 2 |
| Marquardt, L | 1 |
| Buchan, AM | 3 |
| Chang, HM | 2 |
| Huang, YN | 1 |
| Chollate, P | 1 |
| Koh, A | 1 |
| Kaste, M | 3 |
| Paul, NL | 1 |
| Taguchi, Y | 1 |
| Takashima, S | 1 |
| Nukui, T | 1 |
| Dougu, N | 1 |
| Toyoda, S | 1 |
| Tanaka, K | 1 |
| Hwang, DY | 1 |
| Pless, ML | 1 |
| Fischer, D | 1 |
| Haentjes, J | 1 |
| Klein, G | 1 |
| Schieffer, B | 1 |
| Drexler, H | 1 |
| Meyer, GP | 1 |
| Schaefer, A | 1 |
| Kral, M | 1 |
| Herzig, R | 1 |
| Sanak, D | 1 |
| Skoloudik, D | 1 |
| Vlachova, I | 1 |
| Bartkova, A | 1 |
| Hlustik, P | 1 |
| Kovacik, M | 1 |
| Kanovsky, P | 1 |
| Brennan, D | 1 |
| Mak, KH | 1 |
| Fox, KA | 1 |
| Topol, EJ | 1 |
| Charles, J | 1 |
| Miller, G | 1 |
| McArthur, KS | 1 |
| Quinn, TJ | 1 |
| Walters, MR | 2 |
| Poisson, S | 1 |
| Borja, J | 1 |
| García-Rafanell, J | 1 |
| Guthrie, R | 1 |
| Holmes, D | 1 |
| Fox, KM | 1 |
| de Cordoüe, A | 1 |
| Fratacci, MD | 1 |
| Vidal-Jordana, A | 1 |
| Barroeta-Espar, I | 1 |
| Sáinz Pelayo, MP | 1 |
| Mateo, J | 1 |
| Delgado-Mederos, R | 1 |
| Chaturvedi, S | 3 |
| Bhattacharya, P | 1 |
| Torbey, MT | 1 |
| Raj, MD | 1 |
| McDonald, C | 1 |
| Brooks, AJ | 1 |
| Drummond, M | 1 |
| Lau, HM | 1 |
| Patel, MI | 1 |
| Bariol, SV | 1 |
| Wang, AC | 1 |
| Woo, HH | 1 |
| Urabe, T | 2 |
| Sackett, DL | 3 |
| Ge, L | 1 |
| Niu, G | 1 |
| Han, X | 1 |
| Wu, Q | 1 |
| Wu, H | 1 |
| Guo, D | 1 |
| Kasahara, Y | 1 |
| Nakagomi, T | 1 |
| Matsuyama, T | 1 |
| Stern, D | 1 |
| Taguchi, A | 1 |
| Bhatt, LK | 1 |
| Addepalli, V | 1 |
| Rosenberg, K | 1 |
| Aw, D | 1 |
| Sharma, JC | 1 |
| Khan, M | 1 |
| Rogers, RK | 1 |
| Sakhuja, R | 1 |
| Margey, R | 1 |
| Stone, JH | 1 |
| Rosenfield, K | 1 |
| Jaff, MR | 1 |
| Acelajado, MC | 1 |
| Oparil, S | 1 |
| Eikelboom, J | 1 |
| Joyner, CD | 1 |
| Lip, GY | 2 |
| Shestakovska, O | 1 |
| Lansberg, MG | 1 |
| Khatri, P | 1 |
| Lang, ES | 1 |
| Nguyen-Huynh, MN | 1 |
| Schwartz, NE | 1 |
| Sonnenberg, FA | 1 |
| Schulman, S | 1 |
| Spencer, FA | 1 |
| Alonso-Coello, P | 1 |
| Guyatt, GH | 1 |
| Akl, EA | 1 |
| Kate, MP | 1 |
| Asil, T | 1 |
| Ir, N | 1 |
| Karaduman, F | 1 |
| Cagli, B | 1 |
| Tuncel, S | 1 |
| Paikin, JS | 1 |
| Eikelboom, JW | 2 |
| Furlan, AJ | 4 |
| Reisman, M | 1 |
| Massaro, J | 1 |
| Mauri, L | 1 |
| Adams, H | 1 |
| Felberg, R | 1 |
| Herrmann, H | 1 |
| Kar, S | 1 |
| Landzberg, M | 1 |
| Raizner, A | 1 |
| Wechsler, L | 1 |
| Obeyesekere, MN | 1 |
| Lockwood, S | 1 |
| Mottram, P | 1 |
| Alison, JF | 1 |
| Fischer-Betz, R | 1 |
| Specker, C | 1 |
| Brinks, R | 1 |
| Schneider, M | 1 |
| Vendrell, M | 1 |
| Valero, R | 1 |
| Mercadal, J | 1 |
| Enseñat, J | 1 |
| Fábregas, N | 1 |
| Burton, TM | 1 |
| Lacey, M | 1 |
| Yu, Y | 1 |
| Monsalvo, ML | 1 |
| Lang, K | 1 |
| Sander, S | 1 |
| Rossen, JD | 1 |
| Chalouhi, N | 1 |
| Wassef, SN | 1 |
| Thomas, J | 1 |
| Abel, TJ | 1 |
| Jabbour, PM | 1 |
| Kung, DK | 1 |
| Hasan, DM | 1 |
| Collins, R | 1 |
| McGrath, RA | 1 |
| Rist, PM | 1 |
| Buring, JE | 1 |
| Kase, CS | 1 |
| Kurth, T | 1 |
| Grundmann, K | 1 |
| Jaschonek, K | 1 |
| Kleine, B | 1 |
| Dichgans, J | 2 |
| Topka, H | 1 |
| De Schryver, EL | 4 |
| van Gijn, J | 16 |
| Kovich, O | 1 |
| Otley, CC | 1 |
| Haberl, RL | 1 |
| Stoddard, MF | 1 |
| Singh, P | 1 |
| Dawn, B | 1 |
| Longaker, RA | 1 |
| Engelborghs, S | 1 |
| Pickut, BA | 1 |
| De Deyn, PP | 1 |
| Ito, E | 1 |
| Takahashi, A | 1 |
| Yamamoto, H | 1 |
| Kuzuhara, S | 1 |
| Nakajima, M | 1 |
| Michel, P | 1 |
| Bogousslavsky, J | 6 |
| Izquierdo, J | 1 |
| Roquer, J | 1 |
| Rodríguez-Campello, A | 1 |
| Soler Singla, LL | 1 |
| Guimaraens, L | 1 |
| Pou, A | 1 |
| Sandercock, PA | 1 |
| Alberts, MJ | 4 |
| Bergman, DL | 1 |
| Molner, E | 1 |
| Jovanovic, BD | 1 |
| Ushiwata, I | 1 |
| Teruya, J | 1 |
| Elkind, MS | 2 |
| Replogle, RE | 1 |
| Rappard, G | 1 |
| Graybeal, CL | 1 |
| White, J | 1 |
| Purdy, P | 1 |
| Brass, LM | 1 |
| Cimminiello, C | 1 |
| Matias-Guiu, J | 2 |
| Rupprecht, HJ | 1 |
| Pearce, LA | 1 |
| Dippel, DW | 2 |
| Van Kooten, F | 1 |
| Leebeek, FW | 1 |
| van Vliet, HH | 1 |
| Mehicevic, A | 1 |
| Li, SS | 1 |
| Nesher, G | 1 |
| Berkun, Y | 1 |
| Mates, M | 1 |
| Baras, M | 1 |
| Nesher, R | 1 |
| Rubinow, A | 1 |
| Sonnenblick, M | 1 |
| Moonis, M | 1 |
| Culebras, A | 1 |
| Rotta-Escalante, R | 1 |
| Vila, J | 5 |
| Domínguez, R | 3 |
| Abiusi, G | 1 |
| Famulari, A | 5 |
| Rey, R | 1 |
| Bauso-Tosselli, L | 1 |
| Gori, H | 1 |
| Ferrari, J | 1 |
| Reich, E | 1 |
| Solenski, NJ | 1 |
| Homma, S | 1 |
| DiTullio, MR | 1 |
| Sciacca, RR | 1 |
| Mohr, JP | 3 |
| Moore, M | 1 |
| Power, M | 1 |
| Harrison, P | 4 |
| Sidhu, PS | 2 |
| Brown, MM | 3 |
| Machin, SJ | 2 |
| Einecke, D | 1 |
| Frey, JL | 1 |
| Tran, H | 1 |
| Anand, SS | 1 |
| Leonardi-Bee, J | 1 |
| Sivenius, J | 12 |
| Yatsu, F | 1 |
| Dewey, ME | 1 |
| Weir, NU | 1 |
| Lanthier, S | 1 |
| Armstrong, D | 1 |
| Domi, T | 1 |
| deVeber, G | 1 |
| Wiersma, TJ | 1 |
| van Binsbergen, JJ | 1 |
| Verhoeven, S | 1 |
| van Bentum, ST | 1 |
| Goudswaard, AN | 1 |
| Howlett-Smith, H | 1 |
| Stern, BJ | 1 |
| Hertzberg, VS | 1 |
| Frankel, MR | 1 |
| Benesch, CG | 1 |
| Sila, CA | 1 |
| Jovin, TG | 1 |
| Koroshetz, WJ | 1 |
| Segal, H | 2 |
| Blasbery, K | 1 |
| Furtado, C | 1 |
| Silver, L | 2 |
| Droste, DW | 1 |
| Kaps, M | 1 |
| Lees, KR | 2 |
| Siebler, M | 2 |
| Ringelstein, EB | 1 |
| Houben, J | 1 |
| Yamamoto, K | 1 |
| Yasunaga, Y | 1 |
| Mackie, IJ | 1 |
| Lawrie, AS | 1 |
| Purdy, G | 1 |
| Costa, J | 1 |
| Ferro, JM | 1 |
| Torres, F | 1 |
| Norris, JW | 2 |
| Biondi, A | 1 |
| Katz, JM | 1 |
| Vallabh, J | 1 |
| Segal, AZ | 1 |
| Gobin, YP | 1 |
| Weir, E | 1 |
| Gebel, JM | 1 |
| Fahey, CD | 1 |
| Brey, RL | 2 |
| Nitschmann, S | 1 |
| Hartung, HP | 1 |
| Boltuch, J | 1 |
| Sabeti, S | 1 |
| Amighi, J | 1 |
| Dick, P | 1 |
| Mlekusch, W | 1 |
| Schlager, O | 1 |
| Ahmadi, A | 1 |
| Minar, E | 1 |
| Schillinger, M | 1 |
| Aguilar, M | 1 |
| Hart, R | 1 |
| Sudlow, C | 3 |
| Ballotta, E | 1 |
| Thiene, G | 1 |
| Baracchini, C | 1 |
| Ermani, M | 1 |
| Militello, C | 1 |
| Da Giau, G | 1 |
| Barbon, B | 1 |
| Angelini, A | 1 |
| Fieschi, C | 3 |
| Volante, F | 1 |
| Bezerra, DC | 1 |
| Cannon, CP | 1 |
| Murphy, S | 1 |
| Feske, SK | 1 |
| Esagunde, RU | 1 |
| Lee, MP | 1 |
| Gan, HY | 1 |
| Wong, MC | 1 |
| Chen, CL | 1 |
| Tulsyan, N | 1 |
| Ouriel, K | 1 |
| Kashyap, VS | 1 |
| Cavallari, LH | 1 |
| Helgason, CM | 1 |
| Brace, LD | 1 |
| Viana, MA | 1 |
| Nutescu, EA | 1 |
| Calvet, D | 1 |
| Touzé, E | 1 |
| van Wijk, I | 2 |
| Chang, YJ | 1 |
| Ryu, SJ | 1 |
| Lee, TH | 1 |
| Wallaschofski, H | 1 |
| Lohmann, T | 1 |
| Hild, E | 1 |
| Kobsar, A | 1 |
| Siegemund, A | 1 |
| Spilcke-Liss, E | 1 |
| Hentschel, B | 1 |
| Stumpf, C | 1 |
| Daniel, WG | 1 |
| Garlichs, CD | 1 |
| Eigenthaler, M | 1 |
| Ahmed, N | 1 |
| Coffey, JB | 1 |
| Oh, R | 1 |
| Kurukulasuriya, LR | 1 |
| Govindarajan, G | 1 |
| Sowers, J | 1 |
| Yamaguchi, K | 1 |
| Hisano, M | 1 |
| Sakata, M | 1 |
| Minatogawa, Y | 1 |
| Suzuki, T | 1 |
| Ozawa, N | 1 |
| Kitagawa, M | 1 |
| Murashima, A | 1 |
| Luijckx, GJ | 1 |
| De Keyser, JH | 2 |
| Albucher, JF | 1 |
| Martel, P | 1 |
| Cordonnier, C | 1 |
| Schrama, E | 1 |
| Eusman, JP | 1 |
| Offerhaus, L | 1 |
| Gorelick, P | 2 |
| Sechenova, O | 1 |
| Hennekens, CH | 1 |
| Gardner, MJ | 1 |
| Flik, KR | 1 |
| Dreese, JC | 1 |
| Athanasian, EA | 1 |
| Lyden, JP | 1 |
| Sylaja, PN | 1 |
| Liao, JK | 1 |
| de Borst, GJ | 1 |
| Hilgevoord, AA | 1 |
| de Vries, JP | 1 |
| van der Mee, M | 1 |
| Moll, FL | 1 |
| van de Pavoordt, HD | 1 |
| Ackerstaff, RG | 1 |
| Macdonald, S | 1 |
| Feng, L | 1 |
| Wei, C | 1 |
| Sun, Y | 1 |
| Fintel, DJ | 1 |
| Kirshner, HS | 1 |
| Ryckborst, KJ | 1 |
| Eliasziw, M | 1 |
| Overgaard, K | 1 |
| Poulsen, TS | 1 |
| Husted, SE | 3 |
| Sztriha, LK | 1 |
| Sas, K | 1 |
| Seres, E | 1 |
| Boda, K | 1 |
| Lenti, L | 1 |
| Csifcsak, G | 1 |
| Kovacs, N | 1 |
| Vecsei, L | 1 |
| Luo, M | 1 |
| Xie, RM | 1 |
| Quan, HB | 1 |
| Cai, YY | 1 |
| Gorter, JW | 2 |
| Weinberger, J | 1 |
| Berger, C | 1 |
| Stauder, A | 1 |
| Xia, F | 1 |
| Sommer, C | 1 |
| Smout, J | 1 |
| Cleanthis, M | 1 |
| Stansby, G | 1 |
| Gengo, FM | 1 |
| Rainka, M | 1 |
| Robson, M | 1 |
| Gengo, MF | 1 |
| Forrest, A | 1 |
| Hourihane, M | 1 |
| Bates, V | 1 |
| Syed, A | 1 |
| Cuthbertson, FC | 1 |
| Chang, YY | 1 |
| Liu, JS | 1 |
| Lai, SL | 1 |
| Wu, HS | 1 |
| Lan, MY | 1 |
| Adams, RJ | 1 |
| Albers, G | 1 |
| Benavente, O | 1 |
| Furie, K | 1 |
| Goldstein, LB | 1 |
| Halperin, J | 1 |
| Harbaugh, R | 1 |
| Katzan, I | 2 |
| Kelly-Hayes, M | 1 |
| Kenton, EJ | 1 |
| Marks, M | 1 |
| Hills, NK | 1 |
| Verro, P | 1 |
| Gorelick, PB | 2 |
| Nguyen, D | 1 |
| Serebruany, VL | 1 |
| Malinin, AI | 1 |
| Pokov, AN | 1 |
| Hanley, DF | 1 |
| Nielsen, AA | 1 |
| Veien, KT | 1 |
| Jørgensen, LG | 1 |
| Buck, TC | 1 |
| Brandslund, I | 1 |
| Christensen, C | 1 |
| Skliut, M | 1 |
| Jamieson, DG | 1 |
| Boysen, G | 2 |
| Born, GV | 1 |
| Görög, P | 1 |
| Begent, NA | 1 |
| Ritter, JM | 1 |
| Genton, E | 2 |
| Herskovits, E | 4 |
| Vazquez, A | 3 |
| Smud, R | 2 |
| Tamaroff, L | 4 |
| Fraiman, H | 4 |
| Gonzalez, AM | 3 |
| Matera, V | 3 |
| Hinton, RC | 1 |
| Stewart, ME | 1 |
| Douglas, JT | 1 |
| Lowe, GD | 1 |
| Prentice, CR | 2 |
| Forbes, CD | 3 |
| Orefice, G | 1 |
| Carrieri, P | 1 |
| Indaco, A | 1 |
| Iorillo, L | 1 |
| Fioretti, A | 1 |
| Aushri, Z | 1 |
| Berginer, V | 1 |
| Nathan, I | 1 |
| Dvilansky, A | 1 |
| Wilkerson, RJ | 1 |
| Liem, PH | 1 |
| Carter, WJ | 1 |
| Bastard, J | 1 |
| Goas, JY | 1 |
| White, RP | 2 |
| Robertson, JT | 3 |
| Fields, WS | 9 |
| Lechner, H | 1 |
| Ott, E | 1 |
| Bertha, G | 1 |
| Girstenbrey, W | 1 |
| Quan, M | 1 |
| Puffer, JC | 1 |
| Johnson, RA | 1 |
| Soelberg Sørensen, P | 1 |
| Agerskov Andersen, L | 1 |
| Gormsen, J | 1 |
| Pedersen, H | 1 |
| Marquardsen, J | 3 |
| Petersson, H | 1 |
| Heltberg, A | 1 |
| Simonsen, N | 1 |
| Munck, O | 1 |
| Ramirez-Lassepas, M | 2 |
| Kistler, JP | 1 |
| Ropper, AH | 1 |
| Heros, RC | 1 |
| Eichner, ER | 1 |
| Tohgi, H | 3 |
| Dyken, ML | 4 |
| Svensson, J | 1 |
| Mettinger, KL | 1 |
| Blombäck, M | 1 |
| Cain, TD | 1 |
| Wood, JS | 1 |
| Beard, OW | 1 |
| Rushton, FW | 1 |
| Kukora, JS | 1 |
| Grotta, JC | 2 |
| Bigelow, RH | 2 |
| Hu, H | 1 |
| Hankins, L | 1 |
| Donaldson, IM | 1 |
| Whisnant, JP | 3 |
| Sherman, DG | 3 |
| Saavedra, JC | 1 |
| Vergara, F | 1 |
| Wiernsperger, N | 1 |
| Fukatsu, A | 1 |
| Itoh, E | 1 |
| Gonzáles, AM | 1 |
| Chapleau, CE | 1 |
| Reuther, R | 1 |
| Dorndorf, W | 2 |
| Loew, D | 1 |
| Green, D | 1 |
| Kucuk, O | 1 |
| Haring, O | 1 |
| Dyer, A | 1 |
| Arimori, S | 1 |
| Rascol, A | 2 |
| David, J | 2 |
| Boneu, B | 3 |
| Clanet, M | 1 |
| Bierme, R | 2 |
| Aursnes, I | 1 |
| Abildgaard, U | 1 |
| Myhre, HO | 1 |
| Bjørnson, J | 1 |
| Monreal, M | 1 |
| Monasterio, I | 1 |
| Peto, R | 1 |
| Yeung Laiwah, AC | 1 |
| Marx, JL | 1 |
| Dunn, JK | 1 |
| Hardy, RJ | 3 |
| Passamani, ER | 1 |
| Friedman, LM | 1 |
| Lemak, NA | 4 |
| Frankowski, RF | 2 |
| Gent, M | 3 |
| Barnett, HJ | 9 |
| Taylor, DW | 2 |
| Soyka, D | 1 |
| Brechter, C | 1 |
| Bäcklund, H | 1 |
| Krook, H | 1 |
| Müller, R | 1 |
| Nitelius, E | 1 |
| Olsson, JE | 3 |
| Olsson, O | 1 |
| Thornberg, A | 1 |
| Eschwege, E | 1 |
| Haguenau, M | 1 |
| Lefauconnier, JM | 1 |
| Touboul, D | 1 |
| Touboul, PJ | 1 |
| Delgado, G | 1 |
| Martínez-Lage, JM | 1 |
| Viteri, C | 1 |
| Harbold, NB | 1 |
| Laiwah, AC | 1 |
| Hansen, PE | 2 |
| Hansen, JH | 1 |
| Stenbjerg, S | 1 |
| Okamoto, S | 1 |
| Marshall, M | 1 |
| Tomlin, P | 1 |
| Newton, R | 1 |
| Sørensen, PS | 1 |
| Kusunoki, M | 1 |
| Kimura, K | 1 |
| Nagatsuka, K | 1 |
| Isaka, Y | 1 |
| Uyama, O | 1 |
| Yoneda, S | 1 |
| Abe, H | 1 |
| Carson, SN | 1 |
| Demling, RH | 1 |
| Esquivel, CO | 1 |
| Jones, FH | 1 |
| De Marinis, M | 1 |
| Prencipe, M | 3 |
| Falchetti, R | 1 |
| Paolucci, S | 1 |
| Toda, N | 2 |
| Shimizu, K | 1 |
| Ohta, T | 1 |
| Ostendorf, P | 2 |
| Schmutzler, R | 1 |
| Maruyama, S | 2 |
| Hirai, S | 1 |
| Ikeda, Y | 2 |
| Shinohara, Y | 1 |
| Matsuda, T | 1 |
| Fujishima, M | 1 |
| Kameyama, M | 2 |
| Robicsek, F | 1 |
| Slattery, J | 1 |
| Shorrock, CJ | 1 |
| Langman, MJ | 1 |
| Steiner, M | 2 |
| Glantz, M | 1 |
| Lekos, A | 1 |
| van Latum, JC | 2 |
| van Swieten, JC | 2 |
| Alguacil García, GF | 1 |
| Martínez Albadelejo, M | 1 |
| Spektor, S | 1 |
| Ashkenazi, E | 1 |
| Israel, Z | 1 |
| Schelp, R | 1 |
| Bickel, A | 1 |
| Kolominsky, P | 1 |
| Schweiger, H | 1 |
| Rohack, JJ | 1 |
| Solomon, DH | 1 |
| Feinberg, WM | 1 |
| Tozer, R | 1 |
| Hastie, IR | 1 |
| Riekkinen, PJ | 7 |
| Laakso, M | 9 |
| Moore, WS | 3 |
| Beebe, HG | 1 |
| Bernstein, EF | 1 |
| Brener, BJ | 1 |
| Brott, T | 1 |
| Caplan, LR | 1 |
| Day, A | 1 |
| Goldstone, J | 3 |
| Hobson, RW | 3 |
| Matchar, DB | 2 |
| McCrory, DC | 2 |
| Feussner, JR | 1 |
| Eriksson, SE | 3 |
| Komiya, T | 1 |
| Kudo, M | 1 |
| Mizuno, Y | 1 |
| Herderscheê, D | 1 |
| Hijdra, A | 1 |
| Pennese, F | 1 |
| Palombo, V | 1 |
| Taormina, F | 1 |
| Fraccalaglio, L | 1 |
| Brillante, C | 1 |
| Abate, G | 1 |
| Chollet, F | 1 |
| Yamazaki, M | 1 |
| Handa, M | 1 |
| Fukuyama, M | 1 |
| Itagaki, I | 1 |
| Satoh, H | 1 |
| Kobayashi, T | 1 |
| Higo, K | 1 |
| Karasawa, A | 1 |
| Dawson, DV | 1 |
| Massey, EW | 1 |
| Oster, G | 1 |
| Huse, DM | 1 |
| Lacey, MJ | 1 |
| Epstein, AM | 1 |
| Ansell, J | 1 |
| Recht, L | 1 |
| McCann, RL | 1 |
| Macko, R | 1 |
| Deecke, L | 1 |
| Zeiler, K | 1 |
| Lowenthal, A | 6 |
| Smets, P | 6 |
| Bischof, G | 1 |
| Pratschner, T | 1 |
| Kail, M | 1 |
| Mittlböck, M | 1 |
| Turkof, E | 1 |
| Puig, S | 1 |
| Polterauer, P | 1 |
| Kretschmer, G | 1 |
| Bellavance, A | 1 |
| Weiss, DG | 2 |
| Towne, JB | 1 |
| Wright, CB | 1 |
| Bower, S | 1 |
| Sandercock, P | 7 |
| Krupski, WC | 1 |
| Cillessen, JP | 1 |
| Slattery, JM | 1 |
| Boiten, J | 1 |
| Hartmann, A | 1 |
| Meairs, S | 1 |
| Harrison, MJ | 4 |
| van 't Veer, WJ | 1 |
| Cole, DJ | 3 |
| Drummond, JC | 3 |
| Patel, PM | 3 |
| Nary, JC | 1 |
| Applegate, RL | 1 |
| Koefoed, BG | 1 |
| Gulløv, AL | 1 |
| Petersen, P | 2 |
| Sternon, J | 1 |
| Ammash, N | 1 |
| Warnes, CA | 1 |
| Diethrich, EB | 1 |
| Ndiaye, M | 1 |
| Reid, DB | 1 |
| van de Lisdonk, EH | 1 |
| Donati, F | 1 |
| Regli, F | 2 |
| Regli, L | 1 |
| van Genderen, PJ | 2 |
| Jansen, PH | 1 |
| Young, B | 1 |
| Toole, JF | 1 |
| Ernst, CB | 1 |
| Cohen, SN | 1 |
| Broderick, JP | 1 |
| Dempsey, RJ | 1 |
| Hosking, JD | 1 |
| Forbes, C | 2 |
| Reynolds, LR | 1 |
| Catella-Lawson, F | 1 |
| FitzGerald, GA | 1 |
| Bruhn, HD | 1 |
| Koudstaal, A | 1 |
| Leenknegt, H | 1 |
| Manning, WJ | 1 |
| Chesney, CM | 1 |
| Hamann, GF | 2 |
| Gibbs, CR | 1 |
| Li-Saw-Hee, FL | 1 |
| Eccles, M | 1 |
| Freemantle, N | 1 |
| Mason, J | 1 |
| Tijssen, JG | 1 |
| Puranen, J | 2 |
| Riekkinen, P | 2 |
| Pizzulli, L | 1 |
| Lüderitz, B | 1 |
| Schipper, JP | 1 |
| McKay, LD | 1 |
| Cross, LM | 1 |
| Grau, AJ | 1 |
| Ruf, A | 1 |
| Vogt, A | 1 |
| Lichy, C | 1 |
| Buggle, F | 1 |
| Patscheke, H | 1 |
| Takada, T | 1 |
| Akiyama, H | 1 |
| Moriyasu, H | 1 |
| Yamaguchi, T | 1 |
| Bystedt, J | 1 |
| Asplund, K | 1 |
| Libetta, C | 1 |
| Goertler, M | 4 |
| Baeumer, M | 2 |
| Kross, R | 2 |
| Blaser, T | 4 |
| Lutze, G | 3 |
| Jost, S | 1 |
| Wallesch, CW | 3 |
| Riggs, PN | 1 |
| DeWeese, JA | 1 |
| Morgan, MK | 1 |
| Sekhon, LH | 1 |
| Finfer, S | 1 |
| Grinnell, V | 1 |
| Chong, ZZ | 1 |
| Feng, YP | 1 |
| Labovitz, AJ | 1 |
| Wakatsuki, A | 1 |
| Izumiya, C | 1 |
| Okatani, Y | 1 |
| Sagara, Y | 1 |
| Gupta, I | 1 |
| Bennett, G | 1 |
| Gompertz, P | 1 |
| Van Damme, H | 1 |
| Sakalihasan, N | 1 |
| Limet, R | 1 |
| Newell, DW | 1 |
| Hemphill, JC | 1 |
| Mosso, M | 1 |
| Rasmussen, PA | 1 |
| Perl, J | 1 |
| Barr, JD | 1 |
| Markarian, GZ | 1 |
| Sila, C | 1 |
| Krieger, D | 1 |
| Masaryk, TJ | 1 |
| Hughes, RL | 1 |
| Tomita, F | 1 |
| Kohya, T | 1 |
| Kitabatake, A | 1 |
| Sudlow, CL | 1 |
| Dunbabin, DW | 1 |
| Sarasin, FP | 1 |
| Gaspoz, JM | 1 |
| Bounameaux, H | 1 |
| Bergmann, SR | 1 |
| MacWalter, RS | 1 |
| Dutta, D | 1 |
| Fraser, HW | 1 |
| Nimmo, MJ | 1 |
| Siegel, AM | 1 |
| Sandor, P | 1 |
| Kollias, SS | 1 |
| Scheen, AJ | 1 |
| Krueger, S | 3 |
| Franke, A | 1 |
| Wieker, K | 1 |
| Darius, H | 2 |
| Bertrand-Hardy, JM | 2 |
| Humphreys, M | 2 |
| Ohyama, H | 1 |
| Hosomi, N | 1 |
| Takahashi, T | 1 |
| Mizushige, K | 1 |
| Kohno, M | 1 |
| Loy, M | 1 |
| Kalashnikova, LA | 1 |
| Nasonov, EL | 1 |
| Aleksandrova, EN | 1 |
| Kosheleva, NM | 1 |
| Reshetniak, TM | 1 |
| Salozhin, KV | 1 |
| O'Connor, CM | 1 |
| Gattis, WA | 1 |
| Hellkamp, AS | 1 |
| Larsen, RL | 1 |
| Harrington, RA | 1 |
| O'Gara, PT | 1 |
| Kopecky, SL | 1 |
| Gheorghiade, M | 1 |
| Daly, R | 1 |
| Califf, RM | 1 |
| Fuster, V | 2 |
| Redman, AR | 1 |
| Ryan, GJ | 1 |
| Lalouschek, W | 1 |
| Müllner, M | 1 |
| Arquizan, C | 1 |
| Lamy, C | 1 |
| Zuber, M | 1 |
| Cabanes, L | 1 |
| Derumeaux, G | 1 |
| Coste, J | 1 |
| Prisco, D | 1 |
| Du, ZD | 1 |
| Cao, QL | 1 |
| Joseph, A | 1 |
| Koenig, P | 1 |
| Heischmidt, M | 1 |
| Waight, DJ | 1 |
| Rhodes, J | 1 |
| Brorson, J | 1 |
| Hijazi, ZM | 1 |
| Hofmann, K | 1 |
| Fabris, F | 2 |
| Pernigotti, L | 1 |
| Dougherty, JH | 1 |
| Levy, DE | 2 |
| Weksler, BB | 1 |
| Packham, MA | 2 |
| Spetzler, RF | 1 |
| Myers, MD | 1 |
| Bell, M | 1 |
| Deykin, D | 1 |
| Gurewich, V | 1 |
| Harker, L | 1 |
| Hirsch, J | 1 |
| Dalessio, DJ | 1 |
| Lunev, DK | 1 |
| Romasenko, MV | 1 |
| Kniazeva, GR | 1 |
| Kutchak, EN | 1 |
| Bragina, LK | 1 |
| Sandok, BA | 1 |
| Sundt, TM | 1 |
| Machleder, HI | 1 |
| Kurtzke, JF | 1 |
| Armitage, P | 1 |
| Grobe, T | 1 |
| Hirsh, J | 2 |
| Fassio, G | 1 |
| Albizzati, MG | 1 |
| Bassi, S | 1 |
| Frattola, L | 1 |
| Mitchell, JR | 1 |
| al-Mefty, O | 1 |
| Marano, G | 1 |
| Raiaraman, S | 1 |
| Nugent, GR | 1 |
| Rodman, N | 1 |
| Oelz, O | 1 |
| Gertz, SD | 1 |
| Kurgan, A | 1 |
| Wajnberg, RS | 1 |
| Nelson, E | 1 |
| Elliott, J | 1 |
| McDowell, FH | 1 |
| Dechavanne, M | 1 |
| Follea, G | 1 |
| Trzeciak, MC | 1 |
| Burén, A | 1 |
| Ygge, J | 1 |
| Watson, RT | 1 |
| ten Cate, JW | 1 |
| Vos, J | 1 |
| Oosterhuis, H | 1 |
| Prenger, D | 1 |
| Jenkins, CS | 1 |
| Ts'ao, CH | 1 |
| Ali, N | 1 |
| Kolb, T | 1 |
| Reynier, M | 1 |
| Monnier, G | 1 |
| Eyraud, H | 1 |
| Dubreuil, J | 1 |
| Journeau, G | 1 |
| Roquet, F | 1 |
| Michaud, PA | 1 |
| Jestico, J | 1 |
| Marshall, J | 3 |
| Helmers, C | 1 |
| Evangelisti, GB | 1 |
| Faggioli, F | 1 |
| Garagnani, A | 1 |
| Lama, G | 1 |
| Tazaki, Y | 1 |
| Sawada, T | 1 |
| Duncan, GW | 1 |
| Pessin, MS | 1 |
| Adams, RD | 1 |
| Mazal, S | 1 |
| Sindermann, F | 1 |
| McDonald, JW | 1 |
| Stuart, RK | 1 |
| Mustard, JF | 1 |
| Kinlough-Rathbone, RL | 1 |
| Wu, KK | 1 |
| Hoak, JC | 1 |
| Cervantes, FD | 1 |
| Schneiderman, LJ | 1 |
| Harker, LA | 2 |
| Kendall, MJ | 1 |
| Chen, DR | 1 |
| Chang, TW | 1 |
| Udaka, F | 1 |
| Fushimi, H | 1 |
| Sawada, H | 1 |
| Pop, GA | 1 |
| Hachinski, V | 1 |
| Oddens, BJ | 1 |
| Kawakami, M | 1 |
| Kodama, N | 1 |
| Vinazzer, H | 2 |
| Bundlie, SR | 1 |
| Mahon, J | 1 |
| Steel, K | 1 |
| Feagan, BG | 1 |
| Laupacis, A | 1 |
| Pederson, LL | 1 |
| Kilpeläinen, H | 1 |
| Penttilä, I | 1 |
| Farrell, B | 1 |
| Godwin, J | 1 |
| Richards, S | 1 |
| Warlow, C | 4 |
| Davis, S | 1 |
| Stachenko, SJ | 1 |
| Bravo, G | 1 |
| Côté, R | 1 |
| Boucher, J | 1 |
| Battista, RN | 1 |
| de Falco, FA | 1 |
| Montariello, A | 1 |
| Mastroroberto, G | 1 |
| Visconti, OS | 1 |
| Penttilä, IM | 1 |
| Adams, HP | 3 |
| Gordon, DL | 1 |
| Kappelle, J | 1 |
| van Latum, A | 1 |
| Donnan, GA | 1 |
| Besson, G | 1 |
| Loherstorfer, E | 1 |
| Seboldt, H | 1 |
| Widder, B | 1 |
| Kleiser, B | 1 |
| Krapf, H | 1 |
| Reuchlin, G | 1 |
| Dürr, A | 1 |
| Inzitari, D | 1 |
| Fratiglioni, L | 1 |
| Baldereschi, M | 1 |
| Candelise, L | 1 |
| Anzalone, N | 1 |
| Bonatti, ML | 1 |
| Gandolfo, C | 1 |
| Mamoli, A | 1 |
| Rasura, M | 1 |
| Thompson, J | 1 |
| McDonald, PJ | 1 |
| Johnson, CD | 1 |
| Landercasper, J | 1 |
| Merz, BJ | 1 |
| Cogbill, TH | 1 |
| Strutt, PJ | 1 |
| Cochrane, RH | 1 |
| Olson, RA | 1 |
| Hutter, RD | 1 |
| Randi, ML | 1 |
| Casonato, A | 1 |
| Dal Bo Zanon, R | 1 |
| Manzoni, S | 1 |
| Tonin, P | 1 |
| De Zanche, L | 1 |
| Girolami, A | 1 |
| Edwards, WH | 2 |
| Mulherin, JL | 1 |
| Jenkins, JM | 1 |
| Calandre, L | 2 |
| Molina, JA | 1 |
| España Alonso, A | 1 |
| Perales Teijo, I | 1 |
| Allegue Rodríguez, F | 1 |
| Ledo Pozueto, A | 1 |
| Wade, J | 1 |
| Lapinski, RH | 1 |
| Vzquez, A | 1 |
| Benjamin, V | 1 |
| Bruno, A | 1 |
| Godersky, JC | 1 |
| Loftus, CM | 1 |
| Mitchell, VL | 1 |
| Banwart, KJ | 1 |
| Jones, MP | 1 |
| Zichner, R | 1 |
| Weihrauch, TR | 1 |
| Nielsen, HK | 1 |
| Krusell, LR | 1 |
| Fasting, H | 1 |
| Faergeman, O | 1 |
| Hass, WK | 1 |
| Pryse-Phillips, W | 1 |
| Molony, BA | 1 |
| Anderson, S | 1 |
| Kamm, B | 1 |
| Violi, F | 1 |
| Alessandri, C | 1 |
| Ghiselli, A | 1 |
| Germani, M | 1 |
| Caliendo, C | 1 |
| Censi, C | 1 |
| Servi, M | 1 |
| Balsano, F | 1 |
| Caneschi, S | 2 |
| Bonaventi, C | 2 |
| Finzi, F | 2 |
| Tito, P | 2 |
| D'Andrea, G | 3 |
| Toldo, M | 2 |
| Cananzi, A | 1 |
| Cortelazzo, S | 1 |
| Ferro-Milone, F | 2 |
| Scheinberg, P | 1 |
| Gilligan, BS | 1 |
| Dobkin, BH | 1 |
| Langer, SL | 1 |
| Albers, JW | 1 |
| Welch, KM | 2 |
| Canazi, A | 1 |
| Joseph, R | 1 |
| Grunfeld, S | 1 |
| Oster, SB | 1 |
| Frericks, H | 1 |
| Sze, PC | 1 |
| Reitman, D | 1 |
| Pincus, MM | 1 |
| Sacks, HS | 1 |
| Chalmers, TC | 1 |
| Hertzer, NR | 1 |
| Mirsen, TR | 1 |
| Hachinski, VC | 1 |
| Goodman, DS | 1 |
| Stalder, M | 1 |
| Bachmann, F | 1 |
| Becker, WL | 1 |
| Burde, RM | 1 |
| Cipolle, RJ | 1 |
| Lee, TK | 1 |
| Chen, YC | 1 |
| Lien, IN | 1 |
| Liu, MC | 1 |
| Huang, ZS | 1 |
| Brick, JF | 1 |
| Brick, JE | 1 |
| Sheng, FC | 1 |
| Busuttil, RW | 1 |
| Gary, HE | 1 |
| De Martiis, M | 1 |
| Parenzi, A | 1 |
| Barlattani, A | 1 |
| De Martiis, A | 1 |
| Carolei, A | 1 |
| Fiorelli, M | 1 |
| Freeman, JW | 1 |
| Tuhrim, S | 1 |
| Reggia, JA | 1 |
| Murakami, M | 1 |
| Rosenthal, D | 1 |
| Lamis, PA | 1 |
| Stanton, PE | 1 |
| Clark, MD | 1 |
| Ellison, RG | 1 |
| Perry, MO | 1 |
| Kasuya, A | 1 |
| Holm, K | 1 |
| Brandon, RA | 1 |
| Eadie, MJ | 1 |
| Gomara, S | 1 |
| Ozaita, G | 1 |
| Bermejo, F | 1 |
| Wohns, RN | 1 |
| Tans, JT | 1 |
| Tulleken, CA | 1 |
| Geeraert, AJ | 1 |
| Al Saigh, AH | 1 |
| Gallus, AS | 1 |
| Gary, H | 1 |
| Vital, D | 1 |
| Sherry, S | 1 |
| Ninet, J | 1 |
| Bachet, P | 1 |
| Pasquier, J | 1 |
| Wolf, PA | 1 |
| Bunt, TJ | 1 |
| Haynes, JL | 1 |
| Rubin, JR | 1 |
| Smith, DB | 1 |
| Hitchcock, M | 1 |
| Philpott, PJ | 1 |
| Fogelholm, R | 1 |
| Géraud, J | 1 |
| Guiraud, B | 2 |
| Fernet, P | 2 |
| Géraud, G | 1 |
| Vroom, FQ | 2 |
| Greenhouse, AH | 1 |
| Currier, RD | 1 |
| Haerer, AF | 1 |
| Lereboullet, J | 1 |
| Rosa, A | 1 |
| Olivier-Martin, R | 1 |
| Millikan, CH | 1 |
| Mundall, J | 1 |
| Quintero, P | 1 |
| Von Kaulla, KN | 1 |
| Harmon, R | 1 |
| Austin, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Tra[NCT03354429] | Phase 3 | 11,016 participants (Actual) | Interventional | 2018-01-22 | Completed | ||
| Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II[NCT04078737] | Phase 3 | 6,412 participants (Actual) | Interventional | 2019-09-23 | Completed | ||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Int[NCT02415400] | Phase 4 | 4,614 participants (Actual) | Interventional | 2015-06-04 | Completed | ||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Predictors of the Unfavourable Outcomes in Acute Ischemic Stroke Patients Treated With Alteplase, a Multi-centre Prospective Study[NCT06058884] | Phase 4 | 592 participants (Actual) | Interventional | 2022-01-03 | Completed | ||
| International Multicenter Registry on Takotsubo Cardiomyopathy[NCT01947621] | 4,000 participants (Anticipated) | Observational | 2011-01-31 | Recruiting | |||
| Comparison of Mirror Therapy and PNF on Lower Extremity Function in Chronic Stroke Patients.[NCT05948384] | 36 participants (Anticipated) | Interventional | 2023-07-24 | Recruiting | |||
| A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.[NCT01994720] | Phase 3 | 13,307 participants (Actual) | Interventional | 2014-01-07 | Completed | ||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081] | 1,067 participants (Anticipated) | Observational [Patient Registry] | 2021-02-03 | Recruiting | |||
| A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER[NCT02303795] | Phase 2 | 1,005 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794] | Phase 4 | 222 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298] | Phase 4 | 178 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Feasibility of Applying Remote Ischemic Conditioning in Secondary Prevention in Patients With Minor Ischemic Stroke or Transient Ischemic Attack -A Single-arm Futility Study[NCT03004820] | 167 participants (Actual) | Interventional | 2016-12-06 | Completed | |||
| Impact of Catheter Ablation of Atrial Tachyarrhythmias on ABC Stroke and ABC Bleeding Risk Scores[NCT05635864] | 150 participants (Anticipated) | Observational | 2021-06-03 | Recruiting | |||
| Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS),[NCT02313909] | Phase 3 | 7,213 participants (Actual) | Interventional | 2014-12-23 | Terminated (stopped due to Study halted early due to no efficacy improvement over aspirin at an interim analysis and very little chance of showing overall benefit if study were completed) | ||
| Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911] | Phase 2 | 424 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| China Registry of Non-disabling Ischemic Cerebrovascular Events: A Prospective Multi-center, National Registry Trail[NCT03079674] | 10,000 participants (Anticipated) | Observational [Patient Registry] | 2017-06-01 | Not yet recruiting | |||
| Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009] | Phase 3 | 3,000 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study[NCT05644314] | 144 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
| Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis[NCT00576693] | Phase 3 | 451 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Stroke Imaging Package Study of Intracranial Atherosclerosis[NCT03719820] | 550 participants (Anticipated) | Observational [Patient Registry] | 2018-11-14 | Recruiting | |||
| Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging[NCT05907629] | 300 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| Evolocumab Added to Statin Therapy in Patients With Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)---a Pilot Study[NCT05741086] | Phase 3 | 80 participants (Anticipated) | Interventional | 2023-04-15 | Recruiting | ||
| China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): a New, Prospective, Multi-center, Randomized Controlled Trial in China[NCT01763320] | Phase 3 | 380 participants (Actual) | Interventional | 2014-03-05 | Completed | ||
| Ticagrelor Versus Clopidogrel in Ischemic Stroke. a Randomized Double-blinded Controlled Trial[NCT05553613] | Phase 3 | 900 participants (Actual) | Interventional | 2022-10-01 | Completed | ||
| Randomized,Double-blind Trial Comparing the Effects of a Rivaroxaban Regimen During the First 30 Days,Versus Aspirin for the Acute Treatment of TIA or Minor Stroke[NCT01923818] | Phase 2/Phase 3 | 3,700 participants (Anticipated) | Interventional | 2013-09-30 | Not yet recruiting | ||
| Carotid Stenosis Management During COVID-19 Era - Best Medical Intervention Alone (CASCOM Pilot Study): A Prospective Observational Study[NCT04947046] | 120 participants (Anticipated) | Observational | 2020-03-11 | Recruiting | |||
| Ticagrelol Versus Aspirin in Ischemic Stroke[NCT03884530] | Phase 3 | 169 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| A Prospective Multicenter Clinical Study of Aspirin for Prophylaxis in Patients With Hereditary or Acquired Thrombotic Thrombocytopenic Purpura[NCT05568147] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| EARLY: Prospective, Randomised, National, Multi-centre, Open-label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox [NCT00562588] | Phase 4 | 551 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445] | Phase 4 | 160 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| Intracranial Stenting in Non-acute Symptomatic Ischemic Stroke: an Open-label, Randomised Controlled Trial[NCT05063630] | 300 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | |||
| Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis:A Prospective Multi-center, Registry Trial[NCT01994161] | 840 participants (Anticipated) | Observational [Patient Registry] | 2012-12-31 | Recruiting | |||
| Wingspan One Year Vascular Imaging Events and Neurologic Outcomes (WOVEN)[NCT04221984] | 129 participants (Actual) | Observational [Patient Registry] | 2019-11-12 | Completed | |||
| Registry of Emergent Large veSsel oCclUsion duE to IntraCranial AtherosclerosiS[NCT05403593] | 600 participants (Anticipated) | Observational [Patient Registry] | 2021-12-15 | Recruiting | |||
| Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306] | Phase 3 | 3,020 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the Maurora® Sirolimus-Eluting Stent Versus the Apollo Stent in Intracranial Atherosclerotic Stenosis(Maurora ICAS Trial)[NCT05719883] | 156 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | |||
| Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)[NCT00004732] | 2,502 participants (Actual) | Interventional | 2000-12-31 | Completed | |||
| Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)[NCT04948749] | 792 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | |||
| The Effect of Early Administration of PCSK9 Inhibitor, Alirocumab to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile, a Single Center Study, Registry Based, Pragmatic, Prospective Trial[NCT06083961] | Phase 4 | 200 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | ||
| Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial[NCT00496769] | Phase 3 | 6,421 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism [NCT00201461] | Phase 2/Phase 3 | 900 participants (Anticipated) | Interventional | 2003-06-30 | Active, not recruiting | ||
| Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke - WATCH AFib A Prospective, Intraindividual-controlled, Multicenter Clinical Study[NCT06005233] | 400 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | |||
| Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497] | Phase 4 | 1,220 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Patent Foramen Ovale in Cryptogenic Stroke Study[NCT00697151] | Phase 4 | 630 participants (Actual) | Interventional | 1993-06-30 | Completed | ||
| Medical Treatment With or Without Transcatheter Patent Foramen Ovale CloSure for Older Patients With CrypTogenic StrOke and Patent Foramen Ovale. The STOP Trial[NCT05907694] | 714 participants (Anticipated) | Interventional | 2023-12-01 | Active, not recruiting | |||
| Focal Cerebral Arteriopathy Steroid Trial[NCT06040255] | Phase 4 | 80 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease[NCT00816166] | Phase 2/Phase 3 | 125 participants (Actual) | Interventional | 2008-10-31 | Terminated | ||
| An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis[NCT00929383] | 82 participants (Actual) | Observational | 2009-02-28 | Completed | |||
| The Role of Additional Antiplatelet Therapy in the Ischemic Stroke With Atrial Fibrillation and Co-morbiD Atherosclerosis During edOxaban treatmeNt. (ADD-ON) Study, Multicenter Registry-based Analysis[NCT04010955] | 1,200 participants (Anticipated) | Observational [Patient Registry] | 2019-10-01 | Recruiting | |||
| PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis[NCT03507374] | Early Phase 1 | 20 participants (Actual) | Interventional | 2018-10-30 | Terminated (stopped due to Funding withdrawn) | ||
| Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups[NCT01645306] | Phase 2 | 158 participants (Actual) | Interventional | 2013-03-08 | Completed | ||
| ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial[NCT00161070] | Phase 4 | 4,500 participants | Interventional | 1997-07-31 | Completed | ||
| Does Pretreatment With Persantin Reduce Periprocedural Troponin-I Release in Patients Undergoing Elective Single Vessel PCI[NCT00767663] | Phase 4 | 30 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)[NCT00109382] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2003-05-31 | Completed | ||
| Body Cooling During Carotid Endarterectomy: No-profit, Open, Mono-centric, Feasibility Study[NCT02629653] | 10 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
| Evaluation of Diagnostic and Predictive Capabilities of Novel Application of Carotid Carotid Stenosis Pressure Gradient Measurement in Patients Undergoing Percutaneous Carotid Angioplasty and Stenting (CAS).[NCT06123767] | 200 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| Risk Factors for Complications After Carotid Endarterectomy: A Multicenter International Observational Study[NCT03788980] | 10 participants (Actual) | Observational | 2018-04-13 | Terminated (stopped due to Lack of funding and resources) | |||
| Radial Versus Femoral Access For Carotid Artery Stenting In Patients With Carotid-Artery Stenosis ：a Prospective, Randomized, Multicenter, Noninferiority Trial[NCT05416853] | 2,688 participants (Anticipated) | Interventional | 2022-07-04 | Recruiting | |||
| Improvements of Hand Function in Chronic Stroke Related to Upper Arm Anesthesia[NCT00006414] | 12 participants | Observational | 2000-10-31 | Completed | |||
| A Sequential Phase I - Phase II Pilot Study to Compare Cardiac Imaging Capabilities of ICE With TEE Followed by a Randomized Comparison of ICE Guided Cardioversion With Conventional Cardioversion Strategy in Patients With Atrial Fibrillation[NCT00281073] | Phase 1/Phase 2 | 95 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits (NIMBUS Trial)[NCT02603406] | Phase 2 | 44 participants (Actual) | Interventional | 2016-07-15 | Completed | ||
| Evaluation of Neurological Outcome in Patients Undergoing Cerebral Angiography and Revascularization Using Angioplasty and Stent-Supported Angioplasty[NCT00597974] | 108 participants (Actual) | Observational | 2003-09-30 | Completed | |||
| MRI Evaluation of Nidus Occlusion After Gamma Knife Radiosurgery of Cerebral Arteriovenous Malformations - A Prospective Preliminary Study[NCT03995823] | 50 participants (Anticipated) | Observational | 2019-07-01 | Recruiting | |||
| Cerebral Aneurysms: a Retrospective Study on the Experience in Our Hospital With a Comparative Analysis Between the Different Techniques Used in Its Treatment[NCT04792944] | 247 participants (Actual) | Observational | 2007-01-01 | Completed | |||
| Induction of Mucosal Tolerance to E-Selectin for the Secondary Prevention of Stroke[NCT00012454] | Phase 2 | 60 participants | Interventional | 2001-03-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Moderate/Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention. GUSTO Moderate bleeding is a bleeding requiring transfusion of whole blood or packed red blood cells without haemodynamic compromise (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 36 |
| PLACEBO | 11 |
Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 28 |
| PLACEBO | 7 |
Participants with subsequent stroke or death (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 303 |
| PLACEBO | 362 |
Participants with ICH or fatal bleeding event (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 22 |
| PLACEBO | 6 |
Number of participants with ischaemic stroke (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 276 |
| PLACEBO | 345 |
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.0 - No symptoms,1 - No significant disability. Able to carry out all usual activities, despite some symptoms. 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. (NCT03354429)
Timeframe: Visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 1282 |
| PLACEBO | 1284 |
Participants with premature permanent discontinuation of IP due to bleeding (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 152 |
| PLACEBO | 32 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
"Time to first occurrence during the time the participants were treated with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 15.28 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 17.73 |
"Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 57.24 |
| Vitamin K Antagonist | 69.19 |
"Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 65.72 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 60.56 |
"Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo.~N is the number of participants with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 40.51 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 21.03 |
"Time to first occurrence during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 15.85 |
| Vitamin K Antagonist | 17.17 |
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: End of treatment visit (Day 90+-7d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.85 |
| ASA 100 mg | 0.84 |
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Premature treatment discontinuation visit(<15 days after last dose)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.72 |
| ASA 100 mg | 0.68 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 1 (Enrolment)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.70 |
| ASA 100 mg | 0.70 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 2 (Day 7+-2d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.80 |
| ASA 100 mg | 0.79 |
Participants with stroke, MI, death or life-threatening bleeding. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 457 |
| ASA 100 mg | 508 |
"Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS.~Modified Rankin Score:~0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead.~Disability defined as mRS > 1.~Odds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 1107 |
| ASA 100 mg | 1194 |
Participants with all-cause death. If no event, censoring at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 68 |
| ASA 100 mg | 58 |
Participants with ischaemic stroke, MI or CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 423 |
| ASA 100 mg | 475 |
Participants with stroke, MI or death. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 442 |
| ASA 100 mg | 497 |
Participants with CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 41 |
| ASA 100 mg | 35 |
Participants with disabling stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 277 |
| ASA 100 mg | 307 |
Participants with fatal stroke. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 18 |
| ASA 100 mg | 17 |
Participants with ischaemic stroke. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 385 |
| ASA 100 mg | 441 |
Participants with MI. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 25 |
| ASA 100 mg | 21 |
"Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).~PLATO Major bleeding is defined as a bleed that is any one of:~Fatal~Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages <10 mm evident only on gradient-echo MRI)~Intrapericardial bleed with cardiac tamponade~Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery~Significantly disabling (eg. intraocular with permanent vision loss)~Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L)~Transfusion of 2 or more units (whole blood or packed red blood cells [PRBCs]) for bleeding." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 31 |
| ASA 100 mg | 38 |
Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: Time from first dose and up to and including 7 days following the date of last dose of the study
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 82 |
| ASA 100 mg | 37 |
Participants with stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 390 |
| ASA 100 mg | 450 |
"Change from baseline to end of treatment visit in NIHSS (National Institutes of Health Stroke Scale):~0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=-5 | -4 | -3 | -2 | -1 | 0 | 1 | 2 | 3 | 4 | 5 | >5 | Missing | |
| ASA 100 mg | 127 | 438 | 810 | 1073 | 1131 | 683 | 79 | 31 | 16 | 11 | 6 | 14 | 450 |
| Ticagrelor 90 mg | 132 | 403 | 779 | 1088 | 1099 | 681 | 67 | 28 | 18 | 13 | 6 | 10 | 474 |
Major bleeding event (as per ISTH), defined as bleeding event that met at least one of following: fatal bleeding; symptomatic bleeding in a critical area or organ (intraarticular, intramuscular with compartment syndrome, intraocular, intraspinal, pericardial, or retroperitoneal); symptomatic intracranial haemorrhage; clinically overt bleeding associated with a recent decrease in the hemoglobin level of greater than or equal to (>=) 2 grams per decilitre (g/dL) (20 grams per liter [g/L]; 1.24 millimoles per liter [mmol/L]) compared to the most recent hemoglobin value available before the event; clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. The results were based on classification of events that have been positively adjudicated as major bleeding events. Incidence rate estimated as number of subjects with incident events divided by cumulative at-risk time, where subject is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.82 |
| Acetylsalicylic Acid 100 mg OD | 0.67 |
All-cause mortality includes all deaths of participants due to any cause. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.88 |
| Acetylsalicylic Acid 100 mg OD | 1.50 |
Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. Cardiovascular death includes death due to hemorrhage and death with undetermined/unknown cause. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms. The diagnosis of myocardial infarction requires the combination of: 1)evidence of myocardial necrosis (either changes in cardiac biomarkers or post-mortem pathological findings); and 2)supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 6.20 |
| Acetylsalicylic Acid 100 mg OD | 5.85 |
Non-major clinically relevant bleeding was defined as non-major overt bleeding but required medical attention (example: hospitalization, medical treatment for bleeding), and/or was associated with the study drug interruption of more than 14 days. The results were based on the outcome events at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 3.52 |
| Acetylsalicylic Acid 100 mg OD | 2.32 |
Intracranial hemorrhage included all bleeding events that occurred in intracerebral, sub arachnoidal as well as subdural or epidural sites. The below table displays results for all randomized participants and the outcomes at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 0.70 |
| Acetylsalicylic Acid 100 mg OD | 0.35 |
Life-threatening bleeding was defined as a subset of major bleeding that met at least one of the following criteria: 1) fatal bleeding; 2) symptomatic intracranial haemorrhage; 3) reduction in hemoglobin of at least 5 g/dl (50 g/l; 3.10 mmol/L); 4) transfusion of at least 4 units of packed red cells or whole blood; 5) associated with hypotension requiring the use of intravenous inotropic agents; 6) necessitated surgical intervention. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.02 |
| Acetylsalicylic Acid 100 mg OD | 0.43 |
Components of composite efficacy outcome (adjudicated) includes stroke (ischemic, hemorrhagic, and undefined stroke, TIA with positive neuroimaging) and systemic embolism. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 5.14 |
| Acetylsalicylic Acid 100 mg OD | 4.78 |
"Disabling stroke is defined as stroke with modified Rankin score (mRS) greater than or equal to (>=) 4 as assessed by investigator. mRS spans 0-6, running from perfect health to death. A score of 0-3 indicates functional status ranging from no symptoms to moderate disability (defined in the mRS as requiring some help, but able to walk without assistance); mRS 4-6 indicates functional status ranging from moderately severe disability (unable to walk or to attend to own bodily needs without assistance)through to death. CV death includes death due to hemorrhage and death with undetermined/unknown cause. Diagnosis of myocardial infarction requires combination of: 1) evidence of myocardial necrosis either changes in cardiac biomarkers or post-mortem pathological findings); 2) supporting information derived from clinical presentation, electrocardiographic changes, or results of myocardial or coronary artery imaging." (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) | ||||
|---|---|---|---|---|---|
| Stroke | Ischemic stroke | Disabling stroke | CV death(includes death due to hemorrhage) | Myocardial infarction | |
| Acetylsalicylic Acid 100 mg OD | 4.71 | 4.56 | 0.84 | 0.66 | 0.67 |
| Rivaroxaban 15 mg OD | 5.11 | 4.71 | 1.20 | 0.99 | 0.49 |
Any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days after enrollment OR any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days of any revascularization procedure of the qualifying symptomatic intracranial artery done during follow-up, OR an ischemic stroke in the territory of the symptomatic intracranial artery from day 31 after study entry to completion of follow-up. (NCT00576693)
Timeframe: Mean length of follow-up was 2.4 years
| Intervention | participants (Number) |
|---|---|
| Intensive Medical Management Plus Stenting | 52 |
| Intensive Medical Management Alone | 34 |
MRI was performed to assess growth in stroke lesion volume by diffusion-weighted imaging (DWI). DWI was to give evidence of the development of the ischaemic lesion corresponding to the evolved stroke. (NCT00562588)
Timeframe: Baseline and day 8
| Intervention | mL (Median) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | -0.0600 |
| Aggrenox | 0.0000 |
MRI was performed to assess growth in stroke lesion volume by diffusion-weighted imaging (DWI). DWI was to give evidence of the development of the ischaemic lesion corresponding to the evolved stroke. (NCT00562588)
Timeframe: Baseline and day 90
| Intervention | mL (Median) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | -0.8400 |
| Aggrenox | -0.7100 |
MRI was performed to assess growth in stroke lesion volume by fluid-attenuated inversion recovery (FLAIR). (NCT00562588)
Timeframe: Baseline and day 8
| Intervention | mL (Median) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | 0.4100 |
| Aggrenox | 0.3300 |
MRI was performed to assess growth in stroke lesion volume by fluid-attenuated inversion recovery (FLAIR). (NCT00562588)
Timeframe: Baseline and day 90
| Intervention | mL (Median) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | 0.1900 |
| Aggrenox | 0.1150 |
The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead) (NCT00562588)
Timeframe: Baseline and 90 days
| Intervention | Units on a scale (Median) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | -2 |
| Aggrenox | -2 |
The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead) (NCT00562588)
Timeframe: Baseline and 8 days
| Intervention | units on a scale (Median) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | -1.0 |
| Aggrenox | -1.0 |
Changes of special biochemical laboratory value (MCP-1) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory (NCT00562588)
Timeframe: 8 days
| Intervention | µg/mL (Geometric Mean) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | 1.06 |
| Aggrenox | 1.08 |
Changes of special biochemical laboratory values (CRP) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory (NCT00562588)
Timeframe: 8 days
| Intervention | mg/L (Geometric Mean) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | 1.27 |
| Aggrenox | 1.17 |
Changes of special biochemical laboratory value (MMP-9) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory (NCT00562588)
Timeframe: 8 days
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | 0.974 |
| Aggrenox | 0.983 |
(NCT00562588)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | 38 |
| Aggrenox | 28 |
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. Best value - 0 (No symptoms), worst value - 6 (Dead) (NCT00562588)
Timeframe: 90 days
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | |
| Aggrenox | 70 | 84 | 62 | 16 | 32 | 4 | 5 |
| Aspirin for 7 Days, Followed by Aggrenox | 58 | 75 | 50 | 30 | 31 | 6 | 4 |
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. Best value - 0 (No symptoms), worst value - 6 (Dead) (NCT00562588)
Timeframe: 8 days
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | Missing | |
| Aggrenox | 47 | 74 | 52 | 38 | 44 | 8 | 2 | 8 |
| Aspirin for 7 Days, Followed by Aggrenox | 46 | 59 | 42 | 39 | 51 | 12 | 0 | 5 |
The primary aim of CREST is to assess if the efficacy of CAS differs from that of CEA in preventing stroke, myocardial infarction and death during a 30-day peri-procedural period, or ipsilateral stroke over the follow-up period in patients with symptomatic (>=50%) or asymptomatic (>=60%) extracranial carotid stenosis. Four-year follow-up, proportions reflecting the absolute efficacy of carotid-artery stenting (CAS) over that of carotid endarterectomy (CEA) were based on Kaplan-Meier survival estimates at the end of the 4 years. (NCT00004732)
Timeframe: 30 days and 4 years
| Intervention | Percentage (Mean) |
|---|---|
| Carotid-Artery Stenting | 7.2 |
| Carotid Endarterectomy | 6.8 |
4-year follow-up, proportions reflecting the absolute efficacy of carotid-artery stenting (CAS) over that of carotid endarterectomy (CEA) were based on Kaplan-Meier survival estimates at the end of the 4 years. (NCT00004732)
Timeframe: 4 years
| Intervention | Percentage (Mean) | |
|---|---|---|
| Men | Women | |
| Carotid Endarterectomy | 6.8 | 6.7 |
| Carotid-Artery Stenting | 6.2 | 8.9 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events per year (Number) |
|---|---|
| Apixaban, 2.5 or 5 mg Twice Daily | 4.21 |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 6.35 |
Event rate=percent of participants with an event divided by the total participants in the arm. Intended-treatment period=date of randomization to the efficacy cutoff date, which was to be the date on which at least 226 unrefuted original primary efficacy events occurred (date revised to May 28, 2010 following cessation of study for superior efficacy.) (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events (Number) |
|---|---|
| Apixaban, 2.5 or 5 mg Twice Daily | 1.62 |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 3.63 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Day 1 to first bleeding event up to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events per year (Number) |
|---|---|
| Apixaban, 2.5 or 5 mg Twice Daily | 10.85 |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 8.32 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events per year (Number) | ||
|---|---|---|---|
| All-cause death (n=111, 140) | Net clinical benefit (n=163, 220) | Vascular death (n=84, 96) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 4.42 | 7.13 | 3.03 |
| Apixaban, 2.5 or 5 mg Twice Daily | 3.51 | 5.23 | 2.65 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to the earlier of a patient's discontinuation of double-blind study drug or the attainment of at least 226 primary efficacy events up to May 28, 2010
| Intervention | Percentage of events per year (Number) | ||
|---|---|---|---|
| Major bleeding | Major or CRNM bleeding | All bleeding | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 0.92 | 3.24 | 8.32 |
| Apixaban, 2.5 or 5 mg Twice Daily | 1.41 | 4.46 | 10.85 |
BL=baseline, LLN=lower limit of normal, ULN=upper limit of normal. Hemoglobin (g/dL), low: BL>2 or value ≤8; hematocrit(%), low: <0.75*BL; erythrocytes (*10^6 cells/μL), low: <0.75*BL; platelet count (*10^9 cells/L),low: <100*10^9 cells/L; leukocytes (*10^3 cells/μL), low if <0.8*BL and BL
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin, low (n=1956, 1893) | Hemoglobin, high (n=1956, 1893) | Hematocrit, low (n=1728, 1687) | Hematocrit, high (n=1728, 1687) | Erythrocytes, low (n=1728, 1687) | Erythrocytes, high (n=1728, 1687) | Platelet count, low (n=2148, 2098) | Platelet count, high (n=2148, 2098) | Leukocytes, low (n=1738, 1698) | Leukocytes, high (n=1738, 1698) | Neutrophils (absolute), low (n=2170, 2138) | Neutrophils (absolute), high (n=2170, 2138) | Eosinophils (absolute), low (n=2170, 2138) | Eosinophils (absolute), high (n=2170, 2138) | Basophils (absolute), low (n=2170, 2138) | Basophils (absolute), high (n=2170, 2138) | Monocytes (absolute), low (n=2170, 2138) | Monocytes (absolute), high (n=2170, 2138) | Lymphocytes (absolute), low (n=2170, 2138) | Lymphocytes (absolute), high (n=2170, 2138) | Alkaline phosphatase (ALP), low (n=2781, 2758) | ALP, high (n=2781, 2758) | Aspartate phosphatase (AST), low (n=2779, 2753) | AST, high (n=2779, 2753) | Alanine aminotransferase (ALT), low (n=2779, 2753) | ALT, high (n=2779, 2753) | Bilirubin (total), low (n=2781, 2758) | Bilirubin (total), high (n=2781, 2758) | Bilirubin (direct), low (n=2773, 2750) | Bilirubin (direct), high (n=2773, 2750) | Blood urea nitrogen (BUN), low (n=2201, 2172) | BUN, high (n=2201, 2172) | Creatinine, low (n=2209, 2178) | Creatinine, high (n=2209, 2178) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 120 | 0 | 9 | 0 | 12 | 0 | 10 | 0 | 14 | 18 | 1 | 0 | 0 | 68 | 0 | 0 | 0 | 2 | 62 | 5 | 0 | 27 | 0 | 33 | 0 | 31 | 0 | 43 | 0 | 248 | 0 | 50 | 0 | 71 |
| Apixaban, 2.5 or 5 mg Twice Daily | 131 | 0 | 13 | 0 | 12 | 0 | 7 | 0 | 12 | 14 | 2 | 0 | 0 | 48 | 0 | 0 | 0 | 0 | 52 | 4 | 0 | 34 | 0 | 28 | 0 | 23 | 0 | 30 | 0 | 241 | 0 | 42 | 0 | 67 |
LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Sodium, serum (mEq/L):low if <0.95*BL and BL
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sodium (serum), low (n=1768, 1740) | Sodium (serum), high (n=1768, 1740) | Potassium (serum), low (n=1763, 1737) | Potassium (serum), high (n=1763, 1737) | Chloride (serum), low (n=1768, 1740) | Chloride (serum), high (n=1768, 1740) | Calcium (total), low (n=106, 109) | Calcium (total), high (n=106, 109) | Bicarbonate, low (n=1664, 1619) | Bicarbonate, high (n=1664, 1619) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 6 | 2 | 8 | 28 | 3 | 1 | 0 | 0 | 0 | 0 |
| Apixaban, 2.5 or 5 mg Twice Daily | 2 | 1 | 6 | 20 | 0 | 0 | 0 | 0 | 0 | 0 |
ULN=upper limit of normal; LLN=lower limit of normal; BL=baseline. Creatine kinase (U/L), high:>5*ULN; protein, total(g/L):low if <0.90*BL when BL
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Creatine kinase, low (n=2780, 2758) | Creatine kinase, high (n=2780, 2758) | Protein (total), low (n=103, 109) | Protein (total), high (n=103, 109) | Uric acid, low (n=386, 390) | Uric acid, high (n=386, 390) | Glucose (urine), low (n=2, 3) | Glucose (urine), high (n=2, 3) | Protein (urine), low (n=3, 5) | Protein (urine), high (n=3, 5) | Blood (urine), low (n=3, 5) | Blood (urine), high (n=3, 5) | Leukocyte esterase (urine), low (n=3,5) | Leukocyte esterase (urine), high (n=3,5) | Red blood cells (RBC) (urine), low (n=2,2) | RBC (urine), high (n=2,2) | White blood cells (urine), low (n=2,2) | WBC (urine), high (n=2,2) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 0 | 25 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Apixaban, 2.5 or 5 mg Twice Daily | 0 | 13 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| AEs | SAEs | Bleeding AEs | Discontinuations due to AE | Deaths | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 1925 | 804 | 259 | 362 | 115 |
| Apixaban, 2.5 or 5 mg Twice Daily | 1833 | 657 | 281 | 266 | 91 |
"The primary effectiveness endpoint was a composite of the two following outcomes:~Stroke in the same territory (distal to the target lesion) as the presenting event within 12 months of randomization~Hard Transient Ischemic Attack (TIA) in the same territory (distal to the target lesion) as the presenting event from day 2 through month 12 post-randomization~A subject was deemed to be a primary endpoint success if neither of these outcomes occurred.~The Kaplan-Meier success rate at 12-months post-operatively was calculated with Kaplan-Meier time-to-event methodology, where the time variable for patients who were successful (no stroke within 12 months or hard TIA between 2 days and 12 months) was censored at the time of last follow-up, and the time variable for patients who were not successful (had a stroke within 12 months or hard TIA between 2 days and 12 months) was censored at the time of the first event (stroke with 12 months or hard TIA between 2 days and 12 months)." (NCT00816166)
Timeframe: One Year
| Intervention | percent probability (Number) |
|---|---|
| Stent Group | 62.24 |
| Medical Therapy Group | 83.68 |
"Any stroke or neurological death at NCT00929383)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 12 |
The cumulative stroke rate at 12 months (any stroke or neurological death /= 31 days is 15.9% or 13 events per 82 patients (NCT00929383)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 13 |
The rate of recurrent ischemic stroke from 31 days to 12 months post procedure was 1.3% or 1 event per 77 patients analyzed. (NCT00929383)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 1 |
"The rate of restenosis at 12 months was defined as the degree of residual stenosis greater than 50% as determined by the study sites using the WASID method. There was a 10.4% rate of restenosis >50% or 8 patients out of 77 analyzed. The differences in this analysis population N=77 vs. ITT N= 82 populations results from exclusion of N=4 patients with no stent implanted and N=1 patient who died prior to any follow up measures of restenosis.~The WASID method is a standardized protocol for measuring intracranial arterial stenosis.~[1-(Dstenosis/Dnormal)] x100=% stenosis (where D=vessel diameter)" (NCT00929383)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 8 |
The number of Wingspan Stents successfully deployed across the target lesion. (NCT00929383)
Timeframe: Peri-procedural
| Intervention | patients w stent implanted (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 78 |
"Anti-drug antibodies were measured at baseline and 3 month after IMP application.~Number of patients with positive anti-drug antibodies compared to baseline are counted." (NCT01645306)
Timeframe: 3 month (+/- 1 month) after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| 40 mg Revacept | 0 |
| 120 mg Revacept | 0 |
patients with any stroke & TIA, myocardial infarction & percutaneous coronary intervention (PCI), death or bleeding within one year (365 days) after IMP application. (NCT01645306)
Timeframe: 365 days after IMP application
| Intervention | Number of Events (Number) |
|---|---|
| Placebo | 19 |
| 40 mg Revacept | 15 |
| 120 mg Revacept | 10 |
patients with major bleedings occuring within 90 days after IMP application (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 5 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
The number of new diffusion weighted imaging (DWI) lesion(s) reported. (1 day after intervention compared to baseline). (NCT01645306)
Timeframe: 1 day post intervention
| Intervention | Number of new lesions (Mean) |
|---|---|
| Placebo | 1.2 |
| 40 mg Revacept | 1.0 |
| 120 mg Revacept | 0.6 |
patients with any stroke or TIA occuring within 90 days after IMP application. (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 6 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
All adverse events were assessed during complete study period (~ 1 year after IMP application). (NCT01645306)
Timeframe: ~ 365 days after IMP application (whole study period)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| patients with adverse events | patients with drug related AEs | patients with serious AEs | patients with drug related serious AEs | patients with AE with fatal outcome events | |
| 120 mg Revacept | 32 | 2 | 15 | 0 | 1 |
| 40 mg Revacept | 41 | 10 | 17 | 4 | 0 |
| Placebo | 35 | 4 | 17 | 1 | 0 |
203 reviews available for aspirin and Ischemic Attack, Transient
| Article | Year |
|---|---|
Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Humans; Ischemic Attack | 2022 |
Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis.
Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2021 |
Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Endarterectomy, Carotid; Hematoma; Hemorrhage; Hemorrhagi | 2022 |
P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: A systematic review and meta-analysis.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Ag | 2022 |
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; | 2022 |
Does prior use of antiplatelet therapy modify the effect of dual antiplatelet therapy in transient ischaemic attack/minor ischaemic stroke: A systematic review and meta-analysis.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Str | 2022 |
Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials.
Topics: Aspirin; Cilostazol; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic S | 2022 |
Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Factor XI; Fibrinolyt | 2022 |
The use of dual antiplatelet therapy for ischemic cerebrovascular events.
Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic St | 2023 |
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2022 |
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2022 |
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2022 |
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2022 |
Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack | 2023 |
Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; Ische | 2023 |
Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Isc | 2023 |
Clinical Updates on Antiplatelet Therapy for Secondary Prevention in Acute Ischemic Stroke.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Humans; Ischemic Attack, Transient; Ischemic Stroke; Plat | 2023 |
A Meta-Analysis of Randomized and Observational Studies: Aspirin Protects from Cardiac Surgery-Associated Acute Kidney Injury.
Topics: Acute Kidney Injury; Aspirin; Cause of Death; Coma; Coronary Artery Bypass; Heart Arrest; Heart Bloc | 2019 |
Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and
Topics: Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Humans; Ischemic Attack, Transient; Ischemic Strok | 2019 |
[Dual antiplatelet therapy for secondary stroke prevention in patients with acute ischemic stroke. CIERTO group recommendation].
Topics: Aspirin; Benzodiazepines; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient | 2019 |
Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale: Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Foramen Ovale, Patent; Humans; Ischemic Attack, Transi | 2019 |
Transient Ischemic Attack.
Topics: Aspirin; Brain; Clopidogrel; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Drug The | 2020 |
Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; | 2020 |
Antiplatelet therapy for transient ischaemic attack and minor ischaemic stroke.
Topics: Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Early Medical Intervention; Humans; Ischemic Attac | 2020 |
Antiplatelet Therapy for Transient Ischemic Attack and Minor Stroke.
Topics: Aspirin; Clopidogrel; Drug Resistance; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Atta | 2020 |
The 2020 breakthroughs in early secondary prevention: dual antiplatelet therapy versus single antiplatelet therapy.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Early Medical Intervention; Hemorrh | 2021 |
Meta-Analysis Comparing the Safety and Efficacy of Single vs Dual Antiplatelet Therapy in Post Transcatheter Aortic Valve Implantation Patients.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemi | 2021 |
Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials.
Topics: Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2021 |
Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis.
Topics: Aspirin; Bayes Theorem; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet T | 2021 |
P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack.
Topics: Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Purinergic P2Y | 2021 |
Meta-Analysis of Usefulness of Antiplatelet Therapy in Ischemic Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Early Medical Intervention; Hemorrhage; Humans; Is | 2021 |
Clinical Effects of Dual Antiplatelet Therapy or Aspirin Monotherapy after Acute Minor Ischemic Stroke or Transient Ischemic Attack, a Meta-Analysis.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Ag | 2021 |
P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis.
Topics: Aspirin; Cerebral Infarction; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhage | 2022 |
Aspirin's Benefits Were Previously Underestimated and Are Primarily Accrued in the Acute Setting.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke | 2017 |
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Plat | 2017 |
Recurrent Ischemic Stroke: Strategies for Prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; P | 2017 |
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; | 2018 |
Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemor | 2019 |
Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack | 2018 |
Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Human | 2019 |
Early Secondary Prevention in Transient Ischemic Attack (TIA) and Minor Stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pla | 2019 |
[Secondary prevention with clopidogrel after TIA or stroke].
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; N | 2013 |
The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review.
Topics: Aspirin; Bleeding Time; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2013 |
The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials.
Topics: Aged; Aspirin; Dipyridamole; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; | 2013 |
Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hemorrhage; Humans; Ischemi | 2013 |
Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Human | 2013 |
Antithrombotic therapy in transient ischemic attack patients.
Topics: Aspirin; Fibrinolytic Agents; Humans; Ischemic Attack, Transient | 2014 |
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studie | 2014 |
Stroke: transient ischemic attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Clopidogrel; Diffusion Magnetic Resonance I | 2014 |
Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pla | 2015 |
P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggre | 2015 |
Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Gastrointestinal Hemorrhag | 2015 |
Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic | 2015 |
Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study.
Topics: Algorithms; Anticoagulants; Aspirin; Brain Ischemia; Calibration; Cerebral Hemorrhage; Dipyridamole; | 2016 |
[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack].
Topics: Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic At | 2015 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2016 |
Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc | 2016 |
Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses: A Meta-Analysis.
Topics: Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Drug Administration Schedule; Heart Valve Dise | 2016 |
Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Random | 2016 |
Aspirin, stroke and drug-drug interactions.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Drug In | 2016 |
Aspirin nonresponse in patients with arterial causes of ischemic stroke: considerations in detection and management.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Secondary Prevention; | 2008 |
Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; I | 2008 |
Transient ischemic attack: risk stratification and treatment.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Endarterectomy, Carotid; Humans; Ischemic Attack | 2008 |
Combination antiplatelet agents for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combinat | 2008 |
ESPRIT: is aspirin plus dipyridamole superior to aspirin alone in TIA or minor stroke patients?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; H | 2008 |
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic; | 2009 |
Is there a decline in the vascular event rate after transient ischemic attack or stroke in antiplatelet trials?
Topics: Aged; Aspirin; Double-Blind Method; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; P | 2009 |
Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
Topics: American Heart Association; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; I | 2010 |
Oral antiplatelet therapy in stroke prevention. Minireview.
Topics: Administration, Oral; Aspirin; Clopidogrel; Dipyridamole; Drug Combinations; Humans; Ischemic Attack | 2010 |
Diagnosis and management of transient ischaemic attack and ischaemic stroke in the acute phase.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Diagnosis, Differential; Diagnostic Imaging; | 2011 |
Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs--is antiplatelet monotherapy still reasonable?
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Aspirin; Chronic Disease; Clopidogrel; Delayed-Act | 2011 |
Prevention of stroke following transient ischemic attack.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Brain; Carotid Stenosis; Clin | 2011 |
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemi | 2011 |
New insights in antiplatelet therapy for patients with ischemic stroke.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; I | 2011 |
[New clinical concept and therapeutic strategy for TIA].
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Diffusion Magnetic Resonance Imaging; Humans; Ischemic Attac | 2010 |
Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Ischemic Attack, Transient; Platelet Aggregati | 2012 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2003 |
[Treatment of acute stroke -- an overview].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Brain Edema; Case-Control Studies; Cereb | 2003 |
The role of warfarin and aspirin in secondary prevention of stroke.
Topics: Anticoagulants; Aspirin; Clopidogrel; Heart Septal Defects, Atrial; Humans; Ischemic Attack, Transie | 2004 |
Risk factors for cranial ischemic complications in giant cell arteritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Female; G | 2004 |
Antiplatelet treatment for secondary prevention of acute ischemic stroke and transient ischemic attacks: mechanisms, choices and possible emerging patterns of use.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Human | 2003 |
Transient ischemic attacks: Part II. Treatment.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Aspirin; Female; | 2004 |
A review of published TIA treatment recommendations.
Topics: Anticoagulants; Aspirin; Disease Management; Dose-Response Relationship, Drug; Fibrinolytic Agents; | 2004 |
The results of MATCH: light or heat?
Topics: Aspirin; Clopidogrel; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Humans; Ischem | 2004 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.
Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Humans; Is | 2005 |
Stroke prevention. MATCHing therapy to the patient with TIA.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc | 2005 |
Post-varicella arteriopathy of childhood: natural history of vascular stenosis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiog | 2005 |
Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Humans; Ischemic At | 2005 |
Triflusal for preventing serious vascular events in people at high risk.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2005 |
Antiplatelet agents in secondary prevention of stroke: a perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Brain Ischemia; Clinical Trials | 2005 |
Antiphospholipid antibodies in young adults with stroke.
Topics: Adolescent; Adult; Age Factors; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagu | 2005 |
Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
Topics: Aspirin; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; R | 2005 |
What is the role of dipyridamole in long-term secondary prevention after an ischemic stroke or transient ischemic attack?
Topics: Aspirin; Dipyridamole; Evidence-Based Medicine; Humans; Ischemic Attack, Transient; Platelet Aggrega | 2005 |
Emerging drugs in peripheral arterial disease.
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Arteries; Aspirin; Clopidogrel; D | 2006 |
[Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: no significant benefits. Results of the Match study].
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; | 2006 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2006 |
MATCH results: implications for the internist.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Controlled Clinical Trials as Topic; Double-Blind Method; Dru | 2006 |
Clinical inquiries. What is the best management for patients who have a TIA while on aspirin therapy?
Topics: Aspirin; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Ischemic Attack, Transient; Pla | 2006 |
Stroke prevention in diabetes and obesity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Blood Glucose; Cardiovascular | 2006 |
[Options in the management of persistent foramen ovale after an ischemic stroke].
Topics: Aspirin; Brain Ischemia; Heart Septal Defects, Atrial; Humans; Ischemic Attack, Transient; Platelet | 2006 |
Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2006 |
Current management of transient ischemic attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Endarterectomy, Carotid; Humans; Ischemic Attack, T | 2007 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Dipyridamole with aspirin is better than aspirin alone in preventing vascular events after ischaemic stroke or TIA.
Topics: Aspirin; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient | 2007 |
Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Guidelines as Topic; Humans; Ischemic | 2007 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2007 |
Independent predictors of stroke in patients with atrial fibrillation: a systematic review.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Case-Control Studies; Cohort Stu | 2007 |
[What should be done after the first TIA?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopi | 2007 |
Chances and battles in stroke research.
Topics: Aspirin; Biomedical Research; Endarterectomy, Carotid; Europe; Fibrinolytic Agents; History, 20th Ce | 2007 |
Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' resu
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Embolism, C | 2007 |
Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Family P | 2007 |
Antiplatelet agents and randomized trials.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; P | 2007 |
Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggre | 2008 |
Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggre | 2008 |
Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dipyridamole; Female; Humans; Ischemi | 2008 |
Current therapy of cerebrovascular disease.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Female; Humans; Ische | 1984 |
[Management of transient ischemic cerebral attacks (author's transl)].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Cerebral Revascularization; Enda | 1982 |
Aspirin for prevention of stroke: a review.
Topics: Aspirin; Cell Adhesion; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Platelet Aggr | 1983 |
Therapeutical aspects of cerebrovascular disease.
Topics: Aspirin; Blood Coagulation; Cerebrovascular Disorders; Clofibrate; Dipyridamole; Erythrocyte Aggrega | 1983 |
Transient ischemic attacks.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Cerebral Angiography; Cerebral Revascularization; Ce | 1983 |
Platelet inhibitors for TIAs. A review of prospective drug trial results.
Topics: Aged; Aspirin; Clofibrate; Dipyridamole; Drug Therapy, Combination; Female; Humans; Ischemic Attack, | 1984 |
Therapy of ischemic cerebral vascular disease due to atherothrombosis. (2).
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Auscultation; Basilar Artery; Blood Platelets; | 1984 |
Platelets, carotids, and coronaries. Critique on antithrombotic role of antiplatelet agents, exercise, and certain diets.
Topics: Angina Pectoris; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Carotid Artery Thrombosi | 1984 |
Medical Grand Rounds: extracranial carotid artery disease.
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Auscultation; Carotid Art | 1980 |
[Action mechanism of platelet suppressants and platelet suppressant therapy].
Topics: Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Heparin; Humans; Ischemic Attack, Tra | 1981 |
[Specific measures in drug therapy in stroke. Anticoagulants, inhibitors of thrombocyte aggregation, initial barbiturate therapy].
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Barbiturates; Carotid Arteries; Cerebral Infar | 1980 |
Recent advances in the treatment of cerebrovascular diseases.
Topics: Anticoagulants; Aspirin; Carotid Arteries; Cerebral Revascularization; Cerebrovascular Disorders; En | 1980 |
[Medical or chirurgical treatment in transient cerebral ischemia? (author's transl)].
Topics: Aged; Anticoagulants; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Endarterectomy; Female; | 1981 |
Cerebrovascular disease.
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Blood Platelets; Cerebrovascular Disorders; Fibrin | 1981 |
[Transitory cerebral ischemic attacks].
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Blood Platelets; Endarterectomy; Hemodynamics; Huma | 1981 |
Current status of platelet inhibitor therapy in coronary artery disease.
Topics: Aspirin; Coronary Disease; Female; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; | 1982 |
[Spontaneous and heparin-induced recanalization of the completely occluded internal carotid artery--a neglected phenomenon? 2 case reports and review of the literature].
Topics: Aspirin; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiography; Combined Modality Therapy | 1995 |
Stroke prevention.
Topics: Alcohol Drinking; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Di | 1995 |
What's new in stroke?
Topics: Acute Disease; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebrova | 1995 |
Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the ad hoc Committee, American Heart Association.
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Combined Modality Th | 1995 |
Medical treatment for stroke prevention.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
[From heart to brain and from brain to heart: impact of an anticoagulant treatment with aspirin in secondary prevention].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dementia, Vascular; Humans; Ischemic Attack, Transient | 1994 |
Surgical management of carotid artery atherosclerotic disease.
Topics: Aged; Angiography; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Cause of Death; Cerebrovascul | 1993 |
[Low dose acetylsalicylic acid in secondary prevention of stroke].
Topics: Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Humans; Ischemic Attack, Trans | 1993 |
[Carotid endarterectomy--results of current studies and their consequences].
Topics: Aspirin; Carotid Stenosis; Cerebral Infarction; Clinical Trials as Topic; Endarterectomy, Carotid; H | 1993 |
Antiplatelet and anticoagulant therapy.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Transient; | 1993 |
Incidence, natural history, and risk factors in lacunar infarction.
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cerebral Infarction; Diabetic Angiopathies; Fem | 1993 |
[High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia].
Topics: Aspirin; Cerebral Infarction; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ischemi | 1995 |
[Aspirin dosage for prevention of cerebral infarct: arguments for low dosage].
Topics: Aspirin; Cerebral Infarction; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administra | 1995 |
Stroke prevention: the emerging strategies.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Decision Trees; Humans; Isc | 1996 |
Aspirin wars: the optimal dose of aspirin prevent stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Humans; Ischemic Attack, | 1996 |
[Response to 6 questions apropos transient cerebral ischemia].
Topics: Anticoagulants; Aspirin; Endarterectomy, Carotid; Humans; Ischemic Attack, Transient; Platelet Aggre | 1996 |
Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders.
Topics: Adult; Aged; Aspirin; Capillaries; Cerebral Arteries; Diagnosis, Differential; Erythromelalgia; Fema | 1996 |
Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Fi | 1997 |
Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Diagnosis, Differential; Erythromelalgia; Headache; Humans; | 1997 |
Role of transesophageal echocardiography in the management of thromboembolic stroke.
Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Aspirin; Cerebrovascular Disorde | 1997 |
[Acute cerebral infarct: physiopathology and modern therapeutic concepts].
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Infarction; Cerebrovascular Circula | 1997 |
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.
Topics: Angina Pectoris; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Consumer Product Safet | 1998 |
[Consensus antithrombotic prophylaxis of vascular incidents in patients with manifest atherosclerotic vascular diseases. Central Guidance Organization for Peer Review].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Coronary | 1998 |
Antiplatelet drugs in secondary prevention of stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Huma | 1998 |
The crucial, controversial carotid artery. Part II: Treatment.
Topics: Arteriosclerosis; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Humans; Ischemic Attack, Trans | 1998 |
Carotid endarterectomy.
Topics: Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Pressure; Car | 1998 |
Antithrombotic and thrombolytic therapy for ischemic stroke.
Topics: Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Platelet Aggregati | 1999 |
Fibromuscular dysplasia of the internal carotid artery. Personal experience with 13 cases and literature review.
Topics: Aged; Aneurysm; Angioplasty, Balloon; Aspirin; Blindness; Brain Ischemia; Carotid Artery Diseases; C | 1999 |
Ischemic stroke. Clinical strategies based on mechanisms and risk factors.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Brai | 2000 |
[Transient ischemic attacks and prolonged reversible ischemic neurologic deficit. Diagnosis, differential diagnosis and treatment].
Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Diagnosis, Differential; Dipyridamole; Endarterectomy, | 2000 |
Update on antiplatelet therapy for stroke prevention.
Topics: Aspirin; Clinical Trials as Topic; Delayed-Action Preparations; Dipyridamole; Dose-Response Relation | 2000 |
[Antithrombotic therapy for stroke prevention in patients with atrial fibrillation].
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Diabetes Compli | 2000 |
Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib | 2000 |
Prevention of ischaemic stroke--antiplatelets.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; Pl | 2000 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
[Pharma-clinics. The drug of the month. Dipyridamole-acetylsalicylic acid combination (Aggrenox)].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Ischemic A | 2000 |
Analysis of trials evaluating combinations of acetylsalicylic acid and dipyridamole in the secondary prevention of stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Female; Humans; I | 2001 |
Management of stroke and TIA.
Topics: Aged; Aspirin; Blood Pressure; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; | 2001 |
From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Heparin; Humans; Intracranial Art | 2002 |
[Role of arterio-arterial embolisms in the pathogenesis of cerebral circulatory disorders].
Topics: Adult; Aged; Aspirin; Basilar Artery; Blood Coagulation; Carotid Arteries; Carotid Artery Diseases; | 1978 |
Strokes, transient ischemic attacks and asymptomatic bruits.
Topics: Aged; Anticoagulants; Aspirin; Auscultation; Blood Platelets; Blood Pressure; Carotid Arteries; Cere | 1979 |
The pathophysiology of transient cerebral ischemic attacks.
Topics: Arteriosclerosis; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Cholesterol; Embolism; Endoc | 1979 |
[Transient ischemia attacks in general practice].
Topics: Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Carotid Arteries; Diagnosis, | 1979 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
[Transient cerebral ischemia--etiology and management].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Female; Humans; Hypotension; Intracranial Embolism and Th | 1976 |
Transient cerebral ischemic attacks.
Topics: Anticoagulants; Arrhythmias, Cardiac; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blindn | 1976 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (first of three parts).
Topics: Animals; Antidepressive Agents, Tricyclic; Aspirin; Blindness; Blood Platelets; Cerebrovascular Diso | 1975 |
[Epidemiological study of cerebral infarction and transient cerebral ischemic attack in Japan].
Topics: Adult; Aged; Aspirin; Cerebral Infarction; Diagnosis, Differential; Female; Humans; Ischemic Attack, | 1992 |
Aspirin: dose and indications in modern stroke prevention.
Topics: Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Humans; Ischemic Attack, Trans | 1992 |
Management of transient ischaemic attacks.
Topics: Aspirin; Diagnosis, Differential; Endarterectomy, Carotid; Humans; Ischemic Attack, Transient; Warfa | 1991 |
Aspirin in transient ischemic attacks and minor stroke: a meta-analysis.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Female; Humans; | 1991 |
Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly.
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Fem | 1991 |
Therapy in cerebrovascular disease: current status and future directions.
Topics: Age Factors; Anticoagulants; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Forecasting; H | 1991 |
[Study Group: "Evaluation of the efficacy of therapeutic treatments in cerebrovascular diseases"].
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Female; | 1990 |
Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocardial Infarction; Rando | 1990 |
Surgery offers no more than medical treatment in the management of transient ischaemic attack.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Risk Factors | 1990 |
[Optimal dosage of acetylsalicyclic acid (ASS). II: Use in preventing thrombosis of the cerebrovascular circulation--prevention of strokes and preliminary stages].
Topics: Aspirin; Dose-Response Relationship, Drug; Humans; Intracranial Embolism and Thrombosis; Ischemic At | 1989 |
[Prognosis and management of transient cerebral ischemia].
Topics: Anticoagulants; Aspirin; Humans; Ischemic Attack, Transient; Prognosis | 1989 |
[Acetylsalicylic acid in the treatment of arterial thromboembolytic diseases. 2. Clinical documentation].
Topics: Aspirin; Cardiac Surgical Procedures; Diabetic Angiopathies; Female; Glomerulonephritis, Membranopro | 1989 |
Controversies in the management of cerebral vascular disease.
Topics: Aspirin; Atrial Fibrillation; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders; | 1988 |
Transient ischaemic attacks: controversies in treatment. A review.
Topics: Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Endarterectomy; Humans; Ischemic Atta | 1988 |
Medical prevention of ischemic stroke.
Topics: Adult; Age Factors; Aged; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Foll | 1985 |
Transient ischemic attacks and stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Risk Factors; Ticlopidine | 1988 |
The role of arachidonic acid metabolites in cardiovascular homeostasis. Biochemical, histological and clinical cardiovascular effects of non-steroidal anti-inflammatory drugs and their interactions with cardiovascular drugs.
Topics: Arteriosclerosis; Aspirin; Coronary Disease; Eicosanoic Acids; Heart Valve Prosthesis; Homeostasis; | 1987 |
[Aspirin as a platelet antiaggregant: indications and controversies].
Topics: Arteriovenous Shunt, Surgical; Aspirin; Coronary Artery Bypass; Female; Heart Valve Prosthesis; Huma | 1987 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
Cerebral embolism.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Calcinosis; Cardiomyopathy, Hypertrophic; Clinical Tri | 1986 |
Carotid surgery in stroke prevention.
Topics: Aged; Arteriosclerosis; Aspirin; Blindness; Carotid Arteries; Carotid Artery Diseases; Cerebrovascul | 1986 |
The management of TIAs in 1986.
Topics: Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Dipyridamo | 1986 |
Aspirin and other platelet-aggregation inhibiting drugs.
Topics: Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Female; Heart Valv | 1985 |
Does platelet antiaggregant therapy lessen the severity of stroke?
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Humans; Ischemic | 1985 |
Clinical aspects of antiplatelet therapy.
Topics: Angina Pectoris; Aspirin; Blood Coagulation Disorders; Clinical Trials as Topic; Dipyridamole; Femal | 1985 |
Transient ischaemic attacks. Current treatment concepts.
Topics: Anticoagulants; Aspirin; Blood Platelets; Carotid Arteries; Humans; Ischemic Attack, Transient | 1985 |
[The fate of patients with carotid stenosis. Comparative study, based on the literature, of their natural history and evolution under medical treatment or following endarterectomy].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Brain Ischemia; Carotid Artery Diseases; Combined Modalit | 1985 |
227 trials available for aspirin and Ischemic Attack, Transient
| Article | Year |
|---|---|
Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
Topics: Adult; Aged; Aspirin; Cerebral Hemorrhage; Double-Blind Method; Drug Therapy, Combination; Female; H | 2021 |
Ticagrelor versus Clopidogrel in
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Combination | 2021 |
Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Ge | 2022 |
Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial.
Topics: Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Headache; Humans; Ischemic At | 2022 |
Infarct on Brain Imaging, Subsequent Ischemic Stroke, and Clopidogrel-Aspirin Efficacy: A Post Hoc Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic | 2022 |
Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrha | 2022 |
Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Hypertension; Ischemic Attack, Transient; P | 2022 |
Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial.
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; He | 2022 |
Aspirin platelet reactivity on platelet function and clinical outcome in minor stroke or transient ischemic attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2022 |
Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Factor XIa; Fibrinolytic Agent | 2022 |
A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Pilot Proje | 2023 |
A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Pilot Proje | 2023 |
A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Pilot Proje | 2023 |
A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Pilot Proje | 2023 |
Aminotransferase Level and the Effects of Dual Antiplatelet in Minor Stroke or Transient Ischemic Attack: A post hoc Analysis of a Randomized Control Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fema | 2023 |
Aminotransferase Level and the Effects of Dual Antiplatelet in Minor Stroke or Transient Ischemic Attack: A post hoc Analysis of a Randomized Control Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fema | 2023 |
Aminotransferase Level and the Effects of Dual Antiplatelet in Minor Stroke or Transient Ischemic Attack: A post hoc Analysis of a Randomized Control Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fema | 2023 |
Aminotransferase Level and the Effects of Dual Antiplatelet in Minor Stroke or Transient Ischemic Attack: A post hoc Analysis of a Randomized Control Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fema | 2023 |
Genotype-Guided Dual Antiplatelet Use for Transient Ischemic Attack and Minor Stroke by Imaging Status: Subgroup Analysis of the CHANCE-2 Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Genotype; Hemorrhage; Humans; | 2023 |
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclero
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Atorvastatin; Brain Ischemia; Clopidogrel; | 2023 |
Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Infarction; Ischemic Attack, Tr | 2023 |
Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Neoplasm Recu | 2023 |
Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; East Asian People; Female; Hemorrhage; Humans; | 2023 |
Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack.
Topics: Aspirin; Body Mass Index; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attac | 2023 |
Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.
Topics: Acute Disease; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female | 2023 |
Vulnerable and Stabilized States After Cerebral Ischemic Events: Implications of Kinetic Modeling in the SOCRATES, POINT, and THALES Trials.
Topics: Aspirin; Cerebral Infarction; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platele | 2023 |
Ticagrelor Versus Clopidogrel in Minor Stroke or Transient Ischemic Attack With Intracranial Artery Stenosis: A Post Hoc Analysis of CHANCE-2.
Topics: Arteries; Aspirin; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; Female; Humans; | 2023 |
Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial.
Topics: Aged; Aspirin; Biomarkers; China; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Femal | 2020 |
Association of Black Race With Early Recurrence After Minor Ischemic Stroke or Transient Ischemic Attack: Secondary Analysis of the POINT Randomized Clinical Trial.
Topics: Aged; Aspirin; Black or African American; Clopidogrel; Female; Humans; Ischemic Attack, Transient; I | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Platelet function in stroke/transient ischemic attack patients treated with tocotrienol.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind | 2020 |
A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
Topics: Administration, Oral; Aspirin; Atrial Fibrillation; Atrial Flutter; Bioprosthesis; Brazil; Cause of | 2021 |
Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial.
Topics: Aged; Aspirin; Carotid Artery Diseases; Clopidogrel; Comorbidity; Double-Blind Method; Dual Anti-Pla | 2020 |
Personalized antiplatelet therapy based on clopidogrel/aspirin resistance tests in acute ischemic stroke and transient ischemic attack: Study protocol of a multi-center, single-blinded and randomized controlled trial.
Topics: Aftercare; Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Ischemic Stroke | 2021 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intrac | 2017 |
Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial.
Topics: Aged; Aspirin; China; Clopidogrel; Double-Blind Method; Dual Anti-Platelet Therapy; Hemorrhage; Huma | 2016 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
Rationale and Study Design for a Single-Arm Phase IIa Study Investigating Feasibility of Preventing Ischemic Cerebrovascular Events in High-Risk Patients with Acute Non-disabling Ischemic Cerebrovascular Events Using Remote Ischemic Conditioning.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Ther | 2018 |
The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, D | 2018 |
Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial.
Topics: Aged; Aspirin; China; Clopidogrel; Double-Blind Method; Dual Anti-Platelet Therapy; Female; Humans; | 2017 |
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Comorbidity; Double-Blind Method; Factor Xa Inhibitor | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA.
Topics: Aged; Aspirin; Blood Pressure; Body Mass Index; Clopidogrel; Double-Blind Method; Female; Follow-Up | 2018 |
The Acute S
Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Is | 2019 |
Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Endpoint Determination; Female; Hemorrhage; Humans; Ischemic Attac | 2019 |
The influence of mean arterial pressure on the efficacy and safety of dual antiplatelet therapy in minor stroke or transient ischemic attack patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arterial Pressure; Aspirin; Blood Pressure; Case-Cont | 2019 |
Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2019 |
Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial.
Topics: Aspirin; Hemorrhage; Humans; Ischemic Attack, Transient; Mortality; Myocardial Infarction; Observer | 2019 |
Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2019 |
Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile.
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Co | 2019 |
Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke.
Topics: Acute Disease; Aspirin; Clinical Protocols; Clopidogrel; Drug Therapy, Combination; Drug-Related Sid | 2019 |
Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study.
Topics: Adult; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Humans; I | 2014 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
RApid Primary care Initiation of Drug treatment for Transient Ischaemic Attack (RAPID-TIA): study protocol for a pilot randomised controlled trial.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Clinical Protocols; Dipyridamole; Drug Admi | 2013 |
Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Double-Blind Method; Drug The | 2013 |
[Treatment of aspirin resistance patients at transient ischemic attack by buyang huanwu decoction combination with aspirin: a randomized control observation].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Resistance; Drugs, Chinese Herbal; Female; Humans; Isc | 2013 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
Topics: Aged; Aspirin; Brain Ischemia; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; | 2014 |
The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE).
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Headache; Humans; Ischemic Attack, Transie | 2014 |
Clopidogrel plus aspirin versus aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; M | 2015 |
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopid | 2015 |
Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Glyc | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ischemic | 2015 |
Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design.
Topics: Adenosine; Aspirin; Double-Blind Method; Fibrinolytic Agents; Follow-Up Studies; Humans; Internation | 2015 |
Dual antiplatelet therapy in stroke and ICAS: Subgroup analysis of CHANCE.
Topics: Aged; Aspirin; Clopidogrel; Constriction, Pathologic; Double-Blind Method; Drug Therapy, Combination | 2015 |
Does the Stenting Versus Aggressive Medical Therapy Trial Support Stenting for Subgroups With Intracranial Stenosis?
Topics: Angioplasty; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Constriction, Patholo | 2015 |
Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds.
Topics: Aged; Aspirin; Cerebral Cortex; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Female; | 2015 |
Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial.
Topics: Adult; Aspirin; Clinical Protocols; Factor Xa Inhibitors; Female; Humans; Ischemic Attack, Transient | 2015 |
Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Chi-Square Distribution; China; Clopidogrel; Disease Progression; Double-Blind Method | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transien | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transien | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transien | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transien | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events).
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Comorbidity; Drug Therapy, Combi | 2016 |
Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).
Topics: Adenosine; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Aspirin; Cohort Studies; Dou | 2017 |
Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA.
Topics: Aged; Aspirin; Brain; Brain Infarction; Brain Ischemia; Clopidogrel; Female; Humans; Image Processin | 2017 |
Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.
Topics: Adenosine; Adult; Aged; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug; Double-Blind Met | 2017 |
Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Glycated Serum Al | 2017 |
A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
Topics: Aged; Aspirin; Blood Pressure; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Drug Tolerance; | 2008 |
Serum urate predicts long-term risk of acute coronary events in women after a transient ischaemic attack and stroke.
Topics: Acute Disease; Aged; Aspirin; Biomarkers; Coronary Disease; Female; Humans; Ischemic Attack, Transie | 2008 |
Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis.
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Constriction, Pathologic; Double-Blind Met | 2009 |
Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double- | 2009 |
The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population.
Topics: Activities of Daily Living; Aged; Aspirin; Cognition; Diabetes Complications; Dose-Response Relation | 2009 |
Dipyridamole-associated headache in stroke patients--interindividual differences?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Dipyridamole; Drug Therapy, Combination; Femal | 2009 |
Reproducibility of measures of visit-to-visit variability in blood pressure after transient ischaemic attack or minor stroke.
Topics: Aged; Aspirin; Blood Pressure; Blood Pressure Determination; Endarterectomy, Carotid; Female; Follow | 2009 |
Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Aspirin; Aspirin, Dipyridamole Drug Combinatio | 2010 |
Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial.
Topics: Adult; Aged; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Drug Therapy, Combina | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Hu | 2011 |
Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study.
Topics: Adult; Aged; Aspirin; Blood Platelets; Blood Specimen Collection; Dipyridamole; Drug Therapy, Combin | 2011 |
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; N | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Ischemic | 2012 |
Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Co | 2012 |
High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cross-Over Studies; Female; Humans; Ischemic Attack, Tr | 2013 |
Effect of low-dose aspirin on functional outcome from cerebral vascular events in women.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Female; Follow-Up Studies; Humans; Ischemic Attack, Transi | 2013 |
Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke.
Topics: Adult; Aged; Aspirin; Cerebral Infarction; Drug Therapy, Combination; Female; Humans; Ischemic Attac | 2003 |
Antiplatelet effect of aspirin in patients with cerebrovascular disease.
Topics: Age Factors; Aspirin; Blood Platelets; Cerebrovascular Disorders; Cohort Studies; Dose-Response Rela | 2004 |
Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inh | 2004 |
Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; | 2004 |
What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke?
Topics: Adult; Aged; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ischemi | 2004 |
Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study.
Topics: Aged; Aspirin; Cerebral Infarction; Double-Blind Method; Female; Follow-Up Studies; Humans; Ischemic | 2004 |
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M | 2004 |
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M | 2004 |
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M | 2004 |
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M | 2004 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Surgical vs medical treatment for isolated internal carotid artery elongation with coiling or kinking in symptomatic patients: a prospective randomized clinical study.
Topics: Aged; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Female; Fibrinolytic Agents; Follo | 2005 |
Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives.
Topics: Age Factors; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Femal | 2005 |
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Follow-U | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug Therapy, Combination; Fem | 2006 |
Dose titration to reduce dipyridamole-related headache.
Topics: Aged; Aspirin; Dipyridamole; Drug Administration Schedule; Drug Therapy, Combination; Female; Headac | 2006 |
Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Confidence Intervals; Dose-Response Relationship, Drug; Drug Therapy, | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Clinical observation on 30 cases of transient cerebral ischemia attack treated with acupuncture and medication.
Topics: Acupuncture Points; Acupuncture Therapy; Adult; Aged; Aspirin; Combined Modality Therapy; Drug Admin | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Long-term occurrence of death and cardiovascular events in patients with transient ischaemic attack or minor ischaemic stroke: comparison between arterial and cardiac source of the index event.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cause of Death; Cerebral Hemorrhage; Cerebral In | 2008 |
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel | 2008 |
Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-b
Topics: Adult; Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Biomarkers; Clopidogrel; Diabetes Mell | 2008 |
A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
Topics: Adrenergic beta-Antagonists; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascula | 1980 |
Randomised trial of pentoxifylline versus acetylsalicylic acid plus dipyridamole in preventing transient ischaemic attacks.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up Studie | 1981 |
[Role of antiplatelet agents in the prevention of cerebral ischemic accidents].
Topics: Adult; Aged; Anticoagulants; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials as Topic; C | 1983 |
Prognostic value of in vitro measurements of platelet aggregability and fibrinolytic activity in patients with reversible cerebral ischemic attacks.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Double-Blind Method; Female; Fibrinolysis; Humans; I | 1983 |
The effect of ticlopidine on TIA compared with aspirin: a double-blind, twelve-month follow-up study.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; Humans; I | 1984 |
Anticoagulant and platelet-antiaggregating therapy in stroke and threatened stroke.
Topics: Anticoagulants; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Clinical Trials as Topic; C | 1983 |
Variation in the use of angiography and carotid endarterectomy by neurologists in the UK-TIA aspirin trial.
Topics: Aged; Angiography; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Clinical Trials as Topic; E | 1983 |
Medical Grand Rounds: extracranial carotid artery disease.
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Auscultation; Carotid Art | 1980 |
A randomized clinical trial of pentoxifylline and antiaggregants in recent transient ischemic attacks (TIA). A one year follow-up.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Follow-Up Studies; Humans; Isc | 1981 |
[The treatment of transitory ischemic attacks with acetylsalicylic acid: results of a double-blind-study (author's transl)].
Topics: Aspirin; Cerebral Infarction; Humans; Ischemic Attack, Transient; Placebos; Recurrence; Vertebrobasi | 1980 |
The factor VIII complex in atherosclerosis: effects of aspirin.
Topics: Adult; Aged; Antigens; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Factor VIII; Female; Hum | 1981 |
[Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial].
Topics: Aspirin; Clinical Trials as Topic; Dihydroergotoxine; Dipyridamole; Humans; Ischemic Attack, Transie | 1982 |
The Canadian trial of aspirin and sulfinpyrazone in threatened stroke.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Canada; Cerebrovascular Disorders; Clinical Trials a | 1980 |
AMIS negative on aspirin and heart attacks.
Topics: Aspirin; Blood Coagulation; Clinical Trials as Topic; Female; Humans; Ischemic Attack, Transient; Ma | 1980 |
A stochastic model for the occurrence of transient ischemic attacks.
Topics: Aspirin; Clinical Trials as Topic; Humans; Ischemic Attack, Transient; Models, Cardiovascular; Place | 1980 |
Aspirin for transient ischemic attacks.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Ischemic Attack, Trans | 1980 |
Summary of ongoing clinical trials of platelet-active drugs in cardiovascular disease.
Topics: Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials a | 1980 |
Summary of design features: clinical trials of platelet-active drugs in cerebrovascular disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; | 1980 |
Controlled trial of aspirin in cerebral ischemia.
Topics: Actuarial Analysis; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Is | 1980 |
A randomized trial of aspirin and sulfinpyrazone in patients with threatened stroke. Results and methodologic issues.
Topics: Actuarial Analysis; Aspirin; Canada; Cerebrovascular Disorders; Clinical Trials as Topic; Death, Sud | 1980 |
[anti-platelet therapy or anti-coagulants as prevention in transient ischemic attacks and reversible ischemic stroke].
Topics: Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Drug The | 1980 |
["A.I.C.L.A." controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Part I: Protocol (author's transl)].
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; | 1981 |
A randomized trial of E5510 versus aspirin in patients with transient ischemic attacks. The Japanese E5510 TIA study-1 (JETS-1) Group.
Topics: Aged; Aspirin; Double-Blind Method; Fatty Acids, Monounsaturated; Female; Humans; Incidence; Ischemi | 1995 |
Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial.
Topics: Aspirin; Dose-Response Relationship, Drug; Gastrointestinal Hemorrhage; Humans; Ischemic Attack, Tra | 1995 |
Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Hum | 1995 |
Recurrent stroke after transient ischaemic attack or minor ischaemic stroke: does the distinction between small and large vessel disease remain true to type? Dutch TIA Trial Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebral Arteries; Cerebrovascular Disorders; Double-Blind Method; Female; | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Antiplatelet treatment in elderly people with transient ischaemic attacks or ischaemic strokes.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Dipyridamole; Double-Blind | 1995 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing.
Topics: Adenosine Diphosphate; Aged; Aspirin; Cerebral Infarction; Collagen; Drug Monitoring; Female; Follow | 1994 |
Silent infarction on a second CT scan in 91 patients without manifest stroke in the Dutch TIA trial.
Topics: Adult; Aged; Aspirin; Atenolol; Cerebral Infarction; Female; Humans; Ischemic Attack, Transient; Mal | 1994 |
[Comparative study of ASA and heparan sulfate in the secondary prevention of cerebrovascular disorders].
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Female; Fibrinolytic Agents; Follow-Up | 1993 |
Shear-induced platelet aggregation in cerebral ischemia.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta-Thromboglobulin; Brain Ischemia; Cerebral Infarction; | 1994 |
[SPIRIT: new life spirit for anticoagulant treatment in the secondary prevention of brain infarcts? A new study. Stroke Prevention in Reversible Ischaemia Trial].
Topics: Aspirin; Cerebral Infarction; Coumarins; Humans; Ischemic Attack, Transient | 1994 |
Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event.
Topics: Aged; Aspirin; Cerebral Infarction; Dipyridamole; Drug Therapy, Combination; Female; Humans; Ischemi | 1993 |
Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Female; Fol | 1993 |
Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The Veterans Affairs Cooperative Study Group.
Topics: Adult; Aspirin; Blindness; Carotid Arteries; Carotid Stenosis; Cerebrovascular Disorders; Endarterec | 1993 |
Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis.
Topics: Aspirin; Carotid Artery, External; Carotid Stenosis; Cerebrovascular Disorders; Chi-Square Distribut | 1993 |
European Stroke Prevention Study (ESPS): antithrombotic therapy is also effective in the elderly.
Topics: Actuarial Analysis; Aged; Aspirin; Cause of Death; Cerebral Infarction; Cerebrovascular Disorders; D | 1993 |
Does cerebral infarction after a previous warning occur in the same vascular territory?
Topics: Aspirin; Atenolol; Basilar Artery; Carotid Arteries; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Aspirin wars: the optimal dose of aspirin prevent stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Humans; Ischemic Attack, | 1996 |
An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study.
Topics: Anesthesia; Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebral Infarction; Combined Modality Ther | 1996 |
European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Topics: Adult; Aged; Aspirin; Cerebrovascular Disorders; Demography; Dipyridamole; Double-Blind Method; Fema | 1996 |
We need stronger predictors of major vascular events in patients with a recent transient ischemic attack or nondisabling stroke. Dutch TIA Trial Study Group.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Dose-Response Relationship, Drug; | 1997 |
Up to date review of the secondary preventive measures for recurrent ischaemic stroke and transient ischaemic episodes.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Hu | 1998 |
Risk factors and antiplatelet therapy in TIA and stroke patients.
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Eu | 1998 |
Efficacy of antiplatelet treatment in hypertensive patients with TIA or stroke.
Topics: Aspirin; Blood Pressure; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Drug Therapy, | 1998 |
Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Delayed-Action Preparations; Dipyridamole; Disease-Free Su | 1998 |
Rapid decline of cerebral microemboli of arterial origin after intravenous acetylsalicylic acid.
Topics: Adult; Aged; Aspirin; Carotid Stenosis; Cerebral Arteries; Cerebrovascular Disorders; Female; Fibrin | 1999 |
Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; | 1999 |
Transesophageal echocardiography and unexplained cerebral ischemia: a multicenter follow-up study. The STEPS Investigators. Significance of Transesophageal Echocardiography in the Prevention of Recurrent Stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebrovascular Disorders; Echocardiography | 1999 |
[Prevention of vascular complications after cerebral ischemia of arterial origin. European Stroke and Australian Stroke Prevention in Reversible Ischemia Trial (ESPRIT): moderated coagulation, aspirin-dipyridamole combination or aspirin alone?].
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Humans; | 1999 |
Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind Method; H | 1999 |
Cardiac safety in the European Stroke Prevention Study 2 (ESPS2).
Topics: Angina Pectoris; Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; Longitudinal Studies; My | 2001 |
Acetylsalicylic acid and microembolic events detected by transcranial Doppler in symptomatic arterial stenoses.
Topics: Aged; Aspirin; Carotid Stenosis; Cerebrovascular Circulation; Female; Humans; Intracranial Embolism | 2001 |
[Does early high dosage dipyridamole in prevention of secondary stroke induce cardiac events?].
Topics: Administration, Oral; Angina Pectoris; Aspirin; Cause of Death; Cerebral Infarction; Delayed-Action | 2001 |
Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS).
Topics: Aged; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroc | 2001 |
Cessation of embolic signals after antithrombotic prevention is related to reduced risk of recurrent arterioembolic transient ischaemic attack and stroke.
Topics: Aged; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Intracranial Emb | 2002 |
Stroke therapy: status of anti-platelet aggregation drugs.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Evaluation; Humans; Ischemic Atta | 1977 |
Of platelets, their antagonists, and transient cerebral ischemia.
Topics: Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Humans; In Vitro Techniques; Ischemic Atta | 1978 |
A randomized trial of aspirin and sulfinpyrazone in threatened stroke.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; | 1978 |
Guidelines for the management of transient ischemic attacks.
Topics: Anticoagulants; Aspirin; Blood Platelets; Carotid Arteries; Clinical Trials as Topic; Dipyridamole; | 1978 |
Aspirin to prevent a stroke?
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Ischemic Attack, Trans | 1978 |
Controversy in neurology: the Canadian study on TIA and aspirin. A critique of the Canadian TIA study.
Topics: Aspirin; Canada; Clinical Trials as Topic; Double-Blind Method; Humans; Ischemic Attack, Transient; | 1979 |
Controversy in neurology: the Canadian study on TIA and aspirin. A critique of the Canadian TIA study. Reply.
Topics: Aspirin; Canada; Clinical Trials as Topic; Double-Blind Method; Humans; Ischemic Attack, Transient; | 1979 |
Controversy in the interpretation of clinical trials.
Topics: Aspirin; Canada; Clinical Trials as Topic; Double-Blind Method; Humans; Ischemic Attack, Transient; | 1979 |
Controlled trial of aspirin in cerebral ischemia (AITIA study).
Topics: Actuarial Analysis; Aspirin; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; Hemor | 1979 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
An investigation of the effect on platelet function of acetylsalicylic acid, dipyridamole and the two drugs in combination in patients with transient attacks of ischaemia.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Female; Hum | 1979 |
Does aspirin prevent stroke?
Topics: Anticoagulants; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyr | 1979 |
The role of platelets in transient ischemic attacks and cerebral vascular accidents.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Transient; Mal | 1978 |
Anticoagulants in cerebrovascular disease. A critical review of studies.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coumarins; Evaluation | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (first of three parts).
Topics: Animals; Antidepressive Agents, Tricyclic; Aspirin; Blindness; Blood Platelets; Cerebrovascular Diso | 1975 |
[Clinical and experimental study of Ligusticum wallichii and aspirin in the treatment of transient ischemic attack].
Topics: Administration, Oral; Aged; Animals; Aspirin; Drugs, Chinese Herbal; Female; Follow-Up Studies; Huma | 1992 |
Aspirin for cerebral transient ischemic attacks or minor ischemic strokes.
Topics: Aspirin; Brain Ischemia; Double-Blind Method; Humans; Ischemic Attack, Transient; Myocardial Infarct | 1992 |
Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebrovascular Disorders; Death, Sudden, Cardiac; Diagnosis, Differential; | 1992 |
[How much information is retained by participants in clinical trials?].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 1992 |
Aspirin for cerebral transient ischemic attacks or minor ischemic strokes.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient | 1992 |
Differences in the outcome of patients with TIA versus minor stroke.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Cause of Death; Cerebral Infarction; Dose-Response | 1992 |
Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group.
Topics: Aspirin; Cerebrovascular Disorders; Chi-Square Distribution; Female; Follow-Up Studies; Humans; Isch | 1991 |
Effect of pentosan polysulfate on fibrinolysis: basic tests and clinical application.
Topics: Aspirin; Blood Coagulation Tests; Drug Evaluation; Fibrinolysis; Humans; Ischemic Attack, Transient; | 1991 |
Antiplatelet therapy is effective in the prevention of stroke or death in women: subgroup analysis of the European Stroke Prevention Study (ESPS).
Topics: Aspirin; Cause of Death; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Female; | 1991 |
The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.
Topics: Aged; Aspirin; Brain Ischemia; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; | 1991 |
[Clinical efficacy of picotamide].
Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Tr | 1991 |
The European Stroke Prevention Study: results according to sex.
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male; | 1991 |
Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly.
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Fem | 1991 |
The European Stroke Prevention Study (ESPS): results by arterial distribution.
Topics: Aspirin; Carotid Arteries; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Drug Therap | 1991 |
A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Female; Follow-Up Studies; Humans; Is | 1991 |
[European atrial fibrillation trial (EAFT). Secondary prevention with anticoagulants and aspirin in patients with non-valvular atrial fibrillation having suffered a transient ischemic attack or a regressive vascular accident].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Tr | 1991 |
[Study Group: "Evaluation of the efficacy of therapeutic treatments in cerebrovascular diseases"].
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Female; | 1990 |
Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocardial Infarction; Rando | 1990 |
European Stroke Prevention Study. ESPS Group.
Topics: Age Factors; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical T | 1990 |
Role of platelets and antiplatelet agents in cerebrovascular disease. Clues from trials.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Humans; Ischemic Attack, Transient; Platelet Agg | 1990 |
[Prevention of recurrence of cerebrovascular thromboses. A randomized comparative study of acetylsalicylic acid and sodium pentosan polysulfate].
Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Intracranial Embolism and Thrombosis; Ische | 1987 |
Comparative study of pentoxifylline vs antiaggregants in patients with transient ischaemic attacks.
Topics: Aged; Aspirin; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pentoxif | 1989 |
A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cerebral Infarction; Clinical Trials as Topic; | 1989 |
Aspirin for prevention of myocardial infarction and stroke.
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Ischemic Att | 1989 |
A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.
Topics: Aspirin; Cerebrovascular Disorders; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; M | 1989 |
United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Dose-Re | 1988 |
The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. The Dutch TIA Study Group.
Topics: Aspirin; Atenolol; Cerebrovascular Disorders; Disability Evaluation; Follow-Up Studies; Humans; Isch | 1988 |
Medical prevention of ischemic stroke.
Topics: Adult; Age Factors; Aged; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Foll | 1985 |
[The Dutch TIA study of the preventive action of very low doses of acetylsalicylic acid and atenolol].
Topics: Aspirin; Atenolol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; | 1988 |
Antiplatelet agents in the secondary prevention of stroke: meta-analysis of the randomized control trials.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; Drug Combinations; Human | 1988 |
Carotid endarterectomy--a crisis in confidence.
Topics: Aspirin; Carotid Arteries; Cerebrovascular Disorders; Clinical Trials as Topic; Endarterectomy; Huma | 1988 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
Cerebral embolism.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Calcinosis; Cardiomyopathy, Hypertrophic; Clinical Tri | 1986 |
Controlled trial of aspirin in cerebral ischemia: an addendum.
Topics: Aspirin; Blindness; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Di | 1986 |
[Randomized clinical study of the efficacy of buflomedil in the prevention of recurrence of cerebral ischemia in comparison with anti-platelet aggregation agents].
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Ischemic Attack, Transient; Pyrrolidines; R | 1986 |
Severity of stroke and aspirin.
Topics: Aspirin; Clinical Trials as Topic; Humans; Ischemic Attack, Transient; Prospective Studies | 1986 |
[Acetylsalicylic acid in the treatment of ischemic cerebrovascular disorders].
Topics: Adult; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Follow-Up Studies; Huma | 1986 |
Aspirin and the prevention of stroke after transient ischaemic attack.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind | 1986 |
[Pathophysiology and treatment of thrombosis. (2) The effect of ticlopidine on TIA compared with aspirin. A double-blind, 12-month and open 24-month follow-up study].
Topics: Aspirin; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; Humans; Ischemic Attack, | 1987 |
[The extra-intracranial bypass operation: results of an international randomized study].
Topics: Aspirin; Brain Ischemia; Cerebral Angiography; Cerebral Revascularization; Humans; Ischemic Attack, | 1986 |
Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants.
Topics: Aged; Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Combinations; Female; Humans; Ischemic A | 1985 |
Does platelet antiaggregant therapy lessen the severity of stroke?
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Humans; Ischemic | 1985 |
Clinical aspects of antiplatelet therapy.
Topics: Angina Pectoris; Aspirin; Blood Coagulation Disorders; Clinical Trials as Topic; Dipyridamole; Femal | 1985 |
404 other studies available for aspirin and Ischemic Attack, Transient
| Article | Year |
|---|---|
Biochemical aspirin resistance in acute stroke patients and its association with clinical factors: a prospective pilot study.
Topics: Aged; Aspirin; Humans; Ischemic Attack, Transient; Peptide Fragments; Pilot Projects; Prospective St | 2021 |
Under Treatment of High-Risk TIA Patients with Clopidogrel-Aspirin in the Emergency Setting.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Eligibility Determination; | 2021 |
Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial.
Topics: Age Factors; Aged; Aspirin; Body Mass Index; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-45 | 2022 |
Dual Antiplatelet Therapy Is Superior to Aspirin in Preventing Short-Term Recurrent Stroke at the Cost of More Major Bleeding.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggrega | 2021 |
Hyperglycemia, Risk of Subsequent Stroke, and Efficacy of Dual Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial.
Topics: Aspirin; Blood Glucose; Clopidogrel; Humans; Hyperglycemia; Ischemic Attack, Transient; Ischemic Str | 2022 |
Evaluation of Evidence-Based Dual Antiplatelet Therapy for Secondary Prevention in US Patients With Acute Ischemic Stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke | 2022 |
Cinnamon and Aspirin for Mild Ischemic Stroke or Transient Ischemic Attack: A Pilot Trial.
Topics: Aspirin; Cinnamomum zeylanicum; Clopidogrel; Constriction, Pathologic; Double-Blind Method; Drug The | 2022 |
Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Ischemic Attack, Tra | 2022 |
Antiplatelets and Anticoagulants in Ischemic Stroke,Transient Ischaemic Attack: A Practice Survey Among Singapore Neurologists.
Topics: Adult; Anticoagulants; Aspirin; Cerebrovascular Disorders; Female; Heparin; Humans; Ischemic Attack, | 2022 |
Dual Antiplatelet Therapy With Aspirin Plus Clopidogrel for 30 Days Is the Best Option After Minor Stroke or TIA.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2022 |
No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Humans; Ischemic Attack, | 2022 |
Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective.
Topics: Aspirin; Canada; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Humans; Ischemic Atta | 2023 |
Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients.
Topics: Aspirin; Body Weight; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, T | 2022 |
Association between body mass index and bleeding events associated with the use of aspirin in ischemic stroke or transient ischemic attack patients.
Topics: Aspirin; Body Mass Index; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; | 2022 |
Long term survival after a first transient ischaemic attack in England: A retrospective matched cohort study.
Topics: Aspirin; Cohort Studies; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Retros | 2022 |
Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Humans; Ischemic Atta | 2022 |
Ticagrelor Aspirin vs Clopidogrel Aspirin in
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Huma | 2023 |
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attac | 2023 |
Review: After stroke or TIA, adding clopidogrel to aspirin for ≤ 1 month reduces recurrence and MACE.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib | 2019 |
Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; | 2019 |
Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry.
Topics: Aspirin; Heart Failure; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregat | 2020 |
Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial.
Topics: Aged; Aspirin; Clopidogrel; Disability Evaluation; Double-Blind Method; Female; Humans; Intracranial | 2020 |
r-tPA with loading dose of clopidogrel and aspirin therapies for capsular warning syndrome attributed to middle cerebral artery atherosclerotic stenosis: A CARE-compliant case report.
Topics: Aspirin; Clopidogrel; Computed Tomography Angiography; Diagnosis, Differential; Fibrinolytic Agents; | 2020 |
Failure of platelet function analyser 200 to demonstrate clinical clopidogrel resistance in a patient undergoing intracranial vascular stenting.
Topics: Aged; Aspirin; Clopidogrel; Diagnosis, Differential; Drug Resistance; Humans; Intracranial Aneurysm; | 2020 |
Focal Cerebral Arteriopathy in Young Adult Patients With Stroke.
Topics: Acyclovir; Adult; Antibodies, Viral; Antiviral Agents; Aspirin; Carotid Artery, Internal; Carotid St | 2020 |
Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial.
Topics: Adult; Aspirin; Humans; Ischemic Attack, Transient; Odds Ratio; Platelet Aggregation Inhibitors; Pra | 2020 |
Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions.
Topics: Aspirin; Brain Ischemia; Cohort Studies; Drug Therapy, Combination; Glucosephosphate Dehydrogenase; | 2021 |
Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2021 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Stroke; Ticagrelor | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. Reply.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Stroke; Ticagrelor | 2020 |
Dual antiplatelet therapy reduced stroke risk in transient ischemic attack with positive diffusion weighted imaging.
Topics: Adult; Aged; Aspirin; Brain; Clopidogrel; Diffusion Magnetic Resonance Imaging; Drug Therapy, Combin | 2020 |
In acute ischemic stroke or TIA, adding ticagrelor to aspirin reduced stroke or death and increased severe bleeding.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Ischemic Stroke; Stroke; Ticagrelor | 2020 |
The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients.
Topics: Aged; Aptamers, Peptide; Aspirin; Blood Platelets; Collagen; Female; Humans; Intracranial Arterioscl | 2021 |
Two cases of rt-PA with dual antiplatelet therapies with capsular warning syndrome.
Topics: Aspirin; Clopidogrel; Diffusion Magnetic Resonance Imaging; Dual Anti-Platelet Therapy; Fibrinolytic | 2021 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabete | 2021 |
Risk of Early Bleeding with Dual Antiplatelet Therapy in Acute Stroke and Transient Ischemic Attack Regardless of NIHSS Admission.
Topics: Aged; Aspirin; Brazil; Clopidogrel; Databases, Factual; Disability Evaluation; Drug Administration S | 2021 |
Comparison of VerifyNow, thromboelastography, and PL-12 in patients with minor ischemic stroke or transient ischemic attack.
Topics: Adult; Aged; Aspirin; Blood Coagulation Tests; Female; Humans; Ischemic Attack, Transient; Ischemic | 2021 |
Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial.
Topics: Aged; Aspirin; Blood Pressure; Clopidogrel; Cohort Studies; Dual Anti-Platelet Therapy; Female; Huma | 2021 |
Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events.
Topics: Acute Coronary Syndrome; Aspirin; Cerebrovascular Disorders; Coronary Artery Disease; Humans; Intrac | 2021 |
Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Intracranial Hemorrhages; Isc | 2021 |
Effect of aspirin in takotsubo syndrome: protocol of a systematic review and meta-analysis.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Meta-Analysis as Topic; Research Design; Retrospective | 2021 |
The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Ischem | 2017 |
Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports.
Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Heparin; Humans; Ischemic Atta | 2017 |
Different levels of blood pressure, different benefit from dual antiplatelet therapy in minor stroke or TIA patients.
Topics: Adult; Aged; Aspirin; Blood Pressure; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Kapla | 2017 |
Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome
Topics: Adenosine; Aged; Aspirin; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Purinergic P | 2017 |
Stroke: Secondary prevention of ischemic events.
Topics: Aspirin; Family Practice; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Secon | 2017 |
High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resi | 2017 |
Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
Topics: Alleles; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; F | 2017 |
Isolated tricuspid valve Libman-Sacks endocarditis in a patient with antiphospholipid antibody syndrome.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Echocardiography; Endocarditis; Female; H | 2017 |
Letter re: Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Risk Assessment; Stroke | 2017 |
Author response: Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Risk Assessment; Stroke | 2017 |
Charting the Course: Risk Scores for Major Bleeding in Transient Ischemic Attack and Ischemic Stroke.
Topics: Aspirin; Brain Ischemia; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibi | 2018 |
Positive trials in ischaemic stroke reported at ESOC 2018.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Stroke | 2018 |
Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Genotype; Humans; Ischemi | 2018 |
Antiplatelet Agents in Acute Stroke and TIA.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke | 2018 |
Dual Antiplatelet Therapy for Minor Stroke and High-Risk Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2018 |
Antiplatelet Agents in Acute Stroke and TIA.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke | 2018 |
Antiplatelet Agents in Acute Stroke and TIA.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke | 2018 |
Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib | 2018 |
Oral anticoagulation and left atrial appendage closure: a new strategy for recurrent cardioembolic stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Cardiac Surgical Procedures; Ech | 2019 |
New opportunities to optimize antithrombotic therapy for secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Ischemic Attack, Trans | 2019 |
Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrome P-450 CYP2C19; | 2019 |
Guideline: Starting dual antiplatelet therapy ≤ 24 h after high-risk TIA or minor ischemic stroke is recommended.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2019 |
Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brazil; Clopidogrel; Cross-Sectional Studies; Fe | 2019 |
Using Leo Plus stent as flow diverter and endoluminal remodeling in endovascular treatment of intracranial fusiform aneurysms.
Topics: Adult; Aged; Anesthesia, General; Aneurysm; Angiography, Digital Subtraction; Aspirin; Blepharoptosi | 2013 |
Catheter ablation of atrial fibrillation in patients at low thrombo-embolic risk: efficacy and safety of a simplified periprocedural anticoagulation strategy.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Echocardiography, Transesophageal; | 2013 |
Mild encephalitis/encephalopathy with a reversible splenial lesion in children.
Topics: Adolescent; Anti-Inflammatory Agents; Antipyretics; Aspirin; Brain; Brain Edema; Child; Corpus Callo | 2013 |
Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Electrocardiography; F | 2013 |
Triple antiplatelet therapy with addition of cilostazol to aspirin and clopidogrel for Y-stent-assisted coil embolization of cerebral aneurysms.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Embolization, Therapeutic; | 2013 |
Progression of asymptomatic carotid stenosis despite optimal medical therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Asymptomatic Diseases; Biomarkers; Cardiovascular Agents; Carotid | 2013 |
Early dual therapy for Chinese adults with TIA.
Topics: Aspirin; China; Clopidogrel; Drug Therapy, Combination; Female; Humans; Intracranial Hemorrhages; Is | 2013 |
TXA2 synthesis and COX1-independent platelet reactivity in aspirin-treated patients soon after acute cerebral stroke or transient ischaemic attack.
Topics: Acute Disease; Aged; Aspirin; Case-Control Studies; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Fem | 2013 |
Neuroprotective effect of a new synthetic aspirin-decursinol adduct in experimental animal models of ischemic stroke.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzopyrans; Butyrates; Disease Models, A | 2013 |
Implications of aspirin biochemistry in the pathobiology of ischemic cerebrovascular disease.
Topics: Aspirin; Dipyridamole; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; Random | 2014 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
Emergency Rx for major TIA.
Topics: Aspirin; Emergency Treatment; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors | 2013 |
LOAD: a pilot study of the safety of loading of aspirin & clopidogrel in acute ischaemic stroke and transient ischaemic attack. Is the loading dose of aspirin and clopidogrel a good alternative for patients with acute ischaemic stroke and TIA? How this wi
Topics: Aspirin; Brain Ischemia; Female; Humans; Ischemic Attack, Transient; Male; Ticlopidine | 2013 |
The clinical dilemma of treating transient ischaemic attack-like symptoms in patients with coexisting arteriovenous malformation.
Topics: Aged; Aspirin; Female; Humans; Intracranial Arteriovenous Malformations; Intracranial Hemorrhages; I | 2014 |
Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dipyridamole; Enzyme-Linked Immunosorbent Assay; Female; Humans; | 2014 |
Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke.
Topics: Aspirin; China; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; H | 2014 |
The natural history of asymptomatic severe carotid artery stenosis.
Topics: Aged; Aspirin; Asymptomatic Diseases; Blood Flow Velocity; Cardiovascular Agents; Carotid Stenosis; | 2014 |
Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
Topics: Adult; Aged; Aspirin; Cerebral Cortex; Erythromelalgia; Eye; Female; Follow-Up Studies; Humans; Isch | 2015 |
Elderly and forgetful: is aspirin safe for you?
Topics: Aged, 80 and over; Aspirin; Cerebral Amyloid Angiopathy; Cerebral Hemorrhage; Cognition Disorders; C | 2014 |
Aspirin should be discontinued after lobar intracerebral hemorrhage.
Topics: Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cognition Disorders; Comorbidity; Female; Humans; I | 2014 |
Antiplatelet therapy may be continued after intracerebral hemorrhage.
Topics: Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cognition Disorders; Comorbidity; Female; Humans; I | 2014 |
Does clopidogrel with aspirin after acute minor stroke or transient ischemic attack increase the risk of cerebral hemorrhage?
Topics: Aspirin; Cerebral Hemorrhage; Clopidogrel; Humans; Ischemic Attack, Transient; Male; Middle Aged; Ti | 2014 |
Comment: TIA response to antiplatelets stratified by glycated albumin.
Topics: Aspirin; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Stroke; Ticlopidine | 2015 |
Dual antiplatelet therapy for TIA reduces subsequent disability: A CHANCE to improve outcomes?
Topics: Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Outcome Assessment, Health Care; Platelet | 2015 |
Dual Antiplatelet Therapy Prior to Expedited Carotid Surgery Reduces Recurrent Events Prior to Surgery without Significantly Increasing Peri-operative Bleeding Complications.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carotid Stenosis; Clopidogrel; Drug A | 2015 |
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Topics: Aged; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Freq | 2016 |
Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Endarterectomy, C | 2016 |
[Dual platelet inhibition - for how long?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Evidence-Based Medici | 2016 |
The benefits of aspirin in early secondary stroke prevention.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke | 2016 |
High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial.
Topics: Aged; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; Female; Humans; Incidence | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibit | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibit | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibit | 2016 |
Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Female; Foll | 2017 |
[Aspirin use in patients with atherosclerotic cardiovascular disease: the 2016 Chinese expert consensus statement].
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Case-Control Studies; China; Consensus; Coronary | 2017 |
Risk Factors of Subacute Thrombosis After Intracranial Stenting for Symptomatic Intracranial Arterial Stenosis.
Topics: Adult; Aged; Aspirin; Clopidogrel; Constriction, Pathologic; Female; Humans; Ischemic Attack, Transi | 2017 |
Dual Antiplatelet Therapy Does Not Increase the Risk of Bleeding After Carotid Endarterectomy: Results of a Prospective Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogr | 2017 |
Letter by Moris et al Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)".
Topics: Adenosine; Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Tic | 2017 |
Response by Wang and Johnston to Letter Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcom
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregat | 2017 |
In the news: ISC 2017 - getting the heads-up on stroke.
Topics: Aspirin; Double-Blind Method; Humans; Ischemic Attack, Transient; Stroke; Ticagrelor | 2017 |
Cryptogenic stroke in a patient with a PFO: a decision analysis.
Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Decision Trees; Foramen Ovale, Patent; Humans; Int | 2008 |
Diagnosis and initial management of acute stroke and transient ischaemic attack: summary of NICE guidance.
Topics: Anticoagulants; Aspirin; Deglutition Disorders; Dietary Supplements; Endarterectomy, Carotid; Humans | 2008 |
Aspirin non-responders in Thai ischemic stroke/TIA patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Female; Humans; Ischemic At | 2008 |
Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combi | 2006 |
[Secondary prevention with clopidogrel or acetylsalicylic acid after acute cerebrovascular event. Health services research study of private primary care specialists].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Comorbidity; Cross-Sectional Studies; Female; | 2008 |
Is the finding of the PROFESS study consistent with predictions of network meta-analysis?
Topics: Aspirin; Bayes Theorem; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2008 |
Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device.
Topics: Adult; Aged; Aspirin; Brain Diseases, Metabolic; Cardiomyopathy, Dilated; Cause of Death; Cognition | 2008 |
Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Cognition Disorders; Drug Resistance; Female; Follow-Up Studies; Hematologic Tests; H | 2009 |
[The impact of acute cerebral blood flow disturbances on platelet aggregation].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Data Interpretation, Statistical; Female; Hu | 2008 |
Would self-expanding stent occlude middle cerebral artery perforators?
Topics: Adult; Aged; Angioplasty; Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Infarction, Middl | 2009 |
Transient ischemic attack associated with stenosis of accessory middle cerebral artery: a case report.
Topics: Aphasia; Aspirin; Cerebral Angiography; Clopidogrel; Constriction, Pathologic; Humans; Hypertension; | 2009 |
Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Female; Follow-Up Stu | 2009 |
The use of aspirin and dipyridamole in the treatment of acute ischaemic stroke/transient ischaemic attack: an audit-based discussion.
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Medical Audit; | 2009 |
[Guidelines recommend aspirin/dipyridamole retard in high recurrence risk. Well protected from the second stroke].
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebral Infarction; Clinical Trials as Topic | 2009 |
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb | 2009 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Antiplatelet agents in stroke prevention: acute and long-term treatment strategies.
Topics: Aged; Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Pr | 2009 |
[Warning signs of transient ischemic attacks. A stroke threatens every 10th person].
Topics: Aspirin; Cross-Sectional Studies; Family Practice; Fibrinolytic Agents; Germany; Humans; Ischemic At | 2009 |
The role of transcranial Doppler embolic monitoring in the management of intracranial arterial stenosis.
Topics: Angiography, Digital Subtraction; Aspirin; Atorvastatin; Blood Flow Velocity; Cerebral Angiography; | 2011 |
Positional brain ischemia with MCA occlusion successfully treated with extra-intracranial bypass.
Topics: Aspirin; Cerebral Revascularization; Clopidogrel; Humans; Infarction, Middle Cerebral Artery; Ischem | 2010 |
Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fol | 2010 |
Time matters for reducing risk of stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Risk; Stroke; T | 2010 |
Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic A | 2010 |
[Case of branch atheromatous disease presenting capsular warning syndrome].
Topics: Anticoagulants; Aspirin; Atherosclerosis; Atorvastatin; Dextrans; Diffusion Magnetic Resonance Imagi | 2010 |
How can stretching maneuvers involving the neck cause vertebral artery dissection and transient ischemic attack?
Topics: Adult; Aged; Aspirin; Confusion; Headache; Heparin; Humans; Ischemic Attack, Transient; Muscle Stret | 2010 |
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Echocardiography, Transesophageal; Embolism, Paradoxi | 2011 |
TIAs - management in general practice.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Dipyridamole; Dopamine | 2010 |
Letter by Borja and Garcia-Rafanell regarding article, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association"
Topics: Aspirin; Carotid Arteries; Clinical Trials as Topic; Endarterectomy, Carotid; Guidelines as Topic; H | 2011 |
Peter Rothwell: a dedicated flouter of fashion.
Topics: Aspirin; Blood Pressure; Cardiovascular Agents; Endarterectomy, Carotid; Fibrinolytic Agents; Histor | 2011 |
[Intracerebral hemorrhage in anticoagulated patients: what do we do afterwards?].
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Clopidogrel; Female; Follow-Up Studies; Humans; | 2012 |
Stopping anticoagulation before TURP does not appear to increase perioperative cardiovascular complications.
Topics: Aged; Angina Pectoris; Anticoagulants; Arrhythmias, Cardiac; Aspirin; Blood Transfusion; Humans; Isc | 2011 |
Clinician-trialist rounds: 6. Testing for blindness at the end of your trial is a mug's game.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Randomized Controlled | 2011 |
Aspirin treatment increases the risk of cerebral microbleeds.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; | 2011 |
Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model.
Topics: Animals; Aspirin; Brain; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Immunohistochemistry; | 2012 |
Potentiation of aspirin-induced cerebroprotection by minocycline: a therapeutic approach to attenuate exacerbation of transient focal cerebral ischaemia.
Topics: Animals; Aspirin; Blood Glucose; Blood-Brain Barrier; Body Weight; Brain; Brain Edema; Capillary Per | 2012 |
Medical management trumps stenting for intracranial arterial stenosis.
Topics: Angioplasty; Aspirin; Cerebral Arteries; Clopidogrel; Combined Modality Therapy; Constriction, Patho | 2011 |
My patient just had a transient ischaemic attack. Can I predict his risk for stroke? Is stroke inevitable or preventable?
Topics: Aspirin; Clopidogrel; Evidence-Based Medicine; Humans; Ischemic Attack, Transient; Middle Aged; Plat | 2011 |
Transient ischemic attacks in a 22-year-old.
Topics: Anticoagulants; Aspirin; Carotid Stenosis; Diagnosis, Differential; Female; Glucocorticoids; Heparin | 2012 |
Antiplatelet therapy for transient ischemic attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Clopidogrel; Cognition Disorders; | 2012 |
Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Evi | 2012 |
Prevention of stroke in atrial fibrillation: cautious optimism.
Topics: Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; | 2012 |
Combined antithrombotic treatment with aspirin and clopidogrel for patients with capsular warning syndrome: a case report.
Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Internal Capsule; Intracranial Thrombosis; Ischemic Atta | 2012 |
Cardiology patient page: Aspirin.
Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Coronary Artery Disease; Drug Therapy, Combinat | 2012 |
Role for the left atrial appendage occlusion device in managing thromboembolic risk in atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Femal | 2012 |
Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Brain Ische | 2012 |
[Cerebrovascular accident with haemorrhagic transformation in a patient on antiplatelet treatment subjected to surgery of a hypophyseal macroadenoma].
Topics: Adenoma; Aphasia, Broca; Aspirin; Cerebellum; Cerebral Hemorrhage; Craniotomy; Disease Progression; | 2012 |
One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel.
Topics: Adolescent; Adult; Age Factors; Aged; Aspirin; Clopidogrel; Delayed-Action Preparations; Drug Therap | 2012 |
Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Drug Therapy, Combina | 2012 |
Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Br | 2013 |
Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Longitu | 2013 |
[Secondary prevention after stroke. 2 platelet inhibitors are better than one].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebral Infarction; Clinical Trials as Topic; Dipy | 2002 |
Aspirin therapy should be first-line treatment in secondary prevention of stroke--against.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug | 2002 |
Aspirin non-responder status in patients with recurrent cerebral ischemic attacks.
Topics: Aged; Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation; | 2003 |
Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Humans; Ischemic Attack, Transient; Male; | 2003 |
[Transient cerebral ischemia--precursors of stroke. Can warning signs be recognized?].
Topics: Aspirin; Brain; Carotid Stenosis; Cerebral Infarction; Diagnostic Imaging; Exercise; Humans; Ischemi | 2003 |
Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Echocardiography, Tran | 2003 |
Recurrent transient ischemic attacks in a 15-year-old boy with beta-thalassemia minor and thrombophilia. Contribution of perfusion SPECT to clinical diagnosis.
Topics: Adolescent; Anticoagulants; Aspirin; beta-Thalassemia; Brain; Factor V; Female; Heterozygote; Humans | 2003 |
[PRoFESS study presented. Change in secondary prevention].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimida | 2003 |
[Secondary prevention of ischemic insult and transient cerebral ischemia. Is ASS alone enough?].
Topics: Aspirin; Controlled Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ische | 2003 |
[Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2003 |
[Angioplasty and stenting in severe stenosis of basilar artery refractory to pharmacotherapy].
Topics: Aged; Angioplasty, Balloon; Aspirin; Basilar Artery; Constriction, Pathologic; Female; Humans; Ische | 2003 |
Should I start all my ischaemic stroke and TIA patients on a statin, an ACE inhibitor, a diuretic, and aspirin today?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Brain Ischemia; Humans; Hydroxymethylglutaryl-CoA | 2003 |
[Secondary prevention after stroke. Doubled performs better].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Controlled Clinical Trials as Topic; Dipyridamole; | 2003 |
[After stroke or TIA. Double protection by second platelet inhibitor].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Delayed-Action Preparatio | 2003 |
Stent-coil treatment of a distal internal carotid artery dissecting pseudoaneurysm on a redundant loop by use of a flexible, dedicated nitinol intracranial stent.
Topics: Adult; Alloys; Aneurysm, False; Aspirin; Carotid Artery, Internal, Dissection; Carotid Stenosis; Com | 2004 |
Perioperative hemorrhage and combined clopidogrel and aspirin therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Combinations; Endarterectomy, Carotid; Female; G | 2004 |
Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack.
Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Cell Size; Dose-Response Relationship, Drug; Female; | 2004 |
[Secondary prevention of TIA and stroke. How much must thrombocytes not be inhibited?].
Topics: Aspirin; Cerebral Infarction; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemo | 2004 |
[For which patient ASS, clopidogrel or dipyridamole? (interview by Dr. Med. Dirk Einecke)].
Topics: Aspirin; Cerebral Infarction; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Com | 2004 |
[Clopidogrel protection is not increased further by ASS!].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2004 |
[Secondary prevention of stroke with antiplatelet drugs].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, | 2004 |
[Summary of the practice guideline 'TIA' (first revision) from the Dutch College of General Practitioners].
Topics: Aspirin; Dipyridamole; Family Practice; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transi | 2005 |
Warfarin, aspirin, and intracranial vascular disease.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hemorrhage; Humans; | 2005 |
Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry.
Topics: Adult; Aged; Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggreg | 2005 |
[Summary of the practice guideline 'TIA' (first revision) from the Dutch College of General Practitioners].
Topics: Aspirin; Dipyridamole; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Ischemic Attack, Transi | 2005 |
Antiplatelet therapy and spontaneous perirenal hematoma.
Topics: Abdominal Pain; Aged; Aspirin; Diagnosis, Differential; Follow-Up Studies; Hematoma; Humans; Ischemi | 2005 |
Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Case-Control Studies; Cyclo | 2005 |
Progressive symptomatic carotid dissection treated with multiple stents.
Topics: Angiography; Angioplasty; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Art | 2005 |
Use of dipyridamole in patients with recent stroke or TIA.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, | 2005 |
Stroke prevention.
Topics: Aspirin; Canada; Ischemic Attack, Transient; Patient Education as Topic; Platelet Aggregation Inhibi | 2005 |
Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Ther | 2005 |
Oral clopidogrel load in aspirin-resistant capsular warning syndrome.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female | 2005 |
[Cerebral secondary prevention--clopidogrel alone or in combination with ASS].
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Huma | 2005 |
Procedure-related complications and early neurological adverse events of unprotected and protected carotid stenting: temporal trends in a consecutive patient series.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Internal; Carotid Stenosis; Clo | 2005 |
Platelet emboli and ischemia in rabbit's brain caused by ADP or arachidonic acid and the protective effect of ASA and dipyridamole.
Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Aspirin; Dipyridamole; Intracranial Embolism; Isch | 1977 |
Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases.
Topics: Aged; Aspirin; Cerebrovascular Disorders; China; Clopidogrel; Drug Therapy, Combination; Embolism; F | 2006 |
[New DGN-/DSG guidelines].
Topics: Adult; Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebral Infarction; Clinical Trials as Topi | 2005 |
Sex difference in the antiplatelet effect of aspirin in patients with stroke.
Topics: Adult; Aged; Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggreg | 2006 |
Large subcortical infarcts: clinical features, risk factors, and long-term prognosis compared with cortical and small deep infarcts.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain; Cerebral Cortex; Cerebral Infarction; Cohort Studies | 2006 |
Enhanced platelet activation by prolactin in patients with ischemic stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Ischemic Attack, Tran | 2006 |
Periodic plateletpheresis during pregnancy in a high-risk patient with essential thrombocythemia.
Topics: Abortion, Spontaneous; Adult; Anticoagulants; Aspirin; Blood Flow Velocity; Cesarean Section; Female | 2006 |
[The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed].
Topics: Anticoagulants; Aspirin; Cerebral Infarction; Dipyridamole; Drug Therapy, Combination; Humans; Ische | 2006 |
[Treating ischemic stroke as an emergency to prevent cerebral infarction or limit its spread].
Topics: Aspirin; Cerebral Infarction; Emergencies; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; | 2006 |
[Transient ischemic stroke].
Topics: Administration, Oral; Anticoagulants; Aspirin; Diagnosis, Differential; Female; Fibrinolytic Agents; | 2006 |
[Prevention of vascular events after transient ischemic attack or cerebral infarct].
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Cerebral Infarction; Clopidogrel; Dipyridamole; Drug | 2006 |
[The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed].
Topics: Aspirin; Cerebral Infarction; Dipyridamole; Headache; Humans; Ischemic Attack, Transient; Platelet A | 2006 |
[The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed].
Topics: Aspirin; Cerebral Infarction; Dipyridamole; Evidence-Based Medicine; Financial Support; Humans; Isch | 2006 |
Atraumatic compartment syndrome of the dorsal compartment of the upper arm.
Topics: Acute Disease; Aged; Arm; Aspirin; Compartment Syndromes; Diagnosis, Differential; Enoxaparin; Femal | 2006 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; | 2007 |
Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Electronic Data Processing; Female; Humans; Ischemic | 2008 |
[A study on the recurrence of ischemic stroke in nonvalvular atrial fibrillation].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cohort Studies; Female; Follow-Up Stud | 2007 |
Antiplatelet agents for stroke prevention following transient ischemic attack.
Topics: Angioplasty, Balloon; Aspirin; Carotid Artery Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Com | 2008 |
Prediction and prevention of stroke in patients with symptomatic carotid stenosis: the high-risk period and the high-risk patient.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Humans; Ischemic Attack, Transient; | 2008 |
Neuroprotection and glutamate attenuation by acetylsalicylic acid in temporary but not in permanent cerebral ischemia.
Topics: Analysis of Variance; Animals; Aspirin; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; | 2008 |
Comment on "hyperresponsiveness of platelets in ischemic stroke" by Fateh-Moghadam et al.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Epine | 2008 |
Interpretation of ESPRIT in the FASTER trial.
Topics: Aspirin; Clinical Trials as Topic; Data Interpretation, Statistical; Humans; Ischemic Attack, Transi | 2008 |
Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests.
Topics: Aspirin; Drug Resistance; Humans; Ischemic Attack, Transient; Platelet Aggregation; Platelet Aggrega | 2008 |
Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds.
Topics: Aspirin; Diffusion Magnetic Resonance Imaging; Female; Fibrinolytic Agents; Herb-Drug Interactions; | 2008 |
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Combinations; Dru | 2008 |
Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Prescrip | 2008 |
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin; | 2008 |
[Emergency treatment of transient cerebral ischemia].
Topics: Aspirin; Clopidogrel; Emergency Treatment; Humans; Ischemic Attack, Transient; Platelet Aggregation | 2008 |
Experimental basis of platelet aggregation inhibition by acetylsalicylic acid.
Topics: Adenosine Diphosphate; Aspirin; Carotid Artery Thrombosis; Cerebral Infarction; Coronary Circulation | 1984 |
Placebo-controlled, double-blind clinical trials can impede medical progress.
Topics: Adrenergic beta-Antagonists; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Bl | 1980 |
Treatment of cerebral ischemia.
Topics: Aspirin; Brain Ischemia; Carotid Arteries; Dicumarol; Dipyridamole; Endarterectomy; Heart Murmurs; H | 1981 |
Prognostic value of beta-thromboglobulin in patients with transient cerebral ischaemia.
Topics: Adult; Age Factors; Aged; Aspirin; Beta-Globulins; beta-Thromboglobulin; Blood Platelets; Cerebrovas | 1983 |
A comparative study between indobufen and acetylsalicylic acid on beta-thromboglobulin, platelet factor 4 and platelet aggregation in patients with transient ischemic attacks.
Topics: Aspirin; Beta-Globulins; beta-Thromboglobulin; Humans; Ischemic Attack, Transient; Isoindoles; Male; | 1984 |
Plasma thromboglobulin and platelet aggregation index in transient ischaemic attack: effect of aspirin and dipyridamole therapy.
Topics: Adult; Aged; Aspirin; Beta-Globulins; beta-Thromboglobulin; Dipyridamole; Humans; Ischemic Attack, T | 1983 |
Comparison of piroxicam, meclofenamate, ibuprofen, aspirin, and prostacyclin efficacy in a chronic model of cerebral vasospasm.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Behavior, Animal; Cerebral Angiography; Disease Models, | 1983 |
[Debit and credit of a pharmaceutic "evergreen"].
Topics: Aspirin; Drug Industry; Drug Utilization; Germany; History, 19th Century; History, 20th Century; Hum | 1983 |
Enteric-coated aspirin and cyclooxygenase inhibition.
Topics: Adult; Aged; Aspirin; Blood Platelets; Humans; Ischemic Attack, Transient; Middle Aged; Prostaglandi | 1983 |
Surgical management of the occluded carotid artery.
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebr | 1984 |
The significance of carotid stenosis or ulceration.
Topics: Angiography; Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Cerebral Infarction; Fem | 1984 |
The lame brain at the crossroads: which therapeutic road?
Topics: Aged; Aspirin; Carotid Artery Diseases; Cerebral Infarction; Cerebrovascular Disorders; Dipyridamole | 1984 |
The role of the neurologist in the decline of stroke.
Topics: Anticoagulants; Aspirin; Carotid Artery Diseases; Cerebral Infarction; Cerebrovascular Disorders; En | 1983 |
Diagnosis and management of ischemic stroke. Part I.--Threatened stroke and its management.
Topics: Anticoagulants; Arrhythmias, Cardiac; Aspirin; Brain Ischemia; Carotid Artery Thrombosis; Cerebral A | 1983 |
[Present status of the therapy of acute cerebral transient ischemic attacks].
Topics: Acute Disease; Aspirin; Carotid Arteries; Cerebral Infarction; Drug Therapy, Combination; Endarterec | 1983 |
Transient ischemic attacks. Strategies for minimizing stroke risk.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Ischemic Attack, Transient; Middle A | 1984 |
Focal epicerebral ischemia: post-ischemic tissue oxygenation with and without recirculation.
Topics: Animals; Aspirin; Cats; Cerebrovascular Circulation; Injections, Intravenous; Ischemic Attack, Trans | 1984 |
[Fibrinolytic agents, anticoagulants and anti-platelet agents in the management of ischemic cerebrovascular disorders].
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Endopeptidases; Humans; Ischemic Attack, Transie | 1982 |
Cerebral vasospasm: effects of prostaglandin synthetase inhibitors in vitro.
Topics: Animals; Arachidonic Acids; Aspirin; Basilar Artery; Cyclooxygenase Inhibitors; Dogs; Female; In Vit | 1980 |
[Survey and treatment of patients with transient ischemic attacks].
Topics: Aged; Anticoagulants; Aspirin; Cerebral Angiography; Humans; Ischemic Attack, Transient | 1983 |
[Treatment of transient cerebrovascular accidents].
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Endarterectomy; Fibrinolytic Agents; Humans; Isc | 1983 |
What treatments for rheumatoid arthritis can best be assessed by large, simple, long-term trials?
Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Humans; Ischemic Attack, Transient; Outcom | 1983 |
Management of transient cerebral ischaemic attacks by hospital doctors in Scotland.
Topics: Anticoagulants; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Dipyridamole; Female; Humans; | 1983 |
Transient cerebral ischaemic attacks.
Topics: Anticoagulants; Aspirin; Carotid Arteries; Carotid Artery Diseases; Diagnosis, Differential; Humans; | 1982 |
Platelet aggregation in focal cerebral ischemia -a clinical study.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male | 1982 |
[Experimental study of cerebral vasospasm -biochemical analysis of vasoconstrictor in the red blood cell hemolysate and the mechanism of action (author's transl)].
Topics: Animals; Aspirin; Basilar Artery; Cats; Dogs; Erythrocytes; Hemolysis; Ischemic Attack, Transient; V | 1982 |
[Platelet function inhibition and anticoagulation in coronary, cerebral and peripheral arterial occlusive disease. 2. Secondary prevention].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; M | 1982 |
Blood platelets and neurological dysfunction.
Topics: Aspirin; Blood Platelets; Child; Dipyridamole; Humans; Ischemic Attack, Transient; Migraine Disorder | 1982 |
[Preventive drug therapy of transient cerebral ischemic attacks].
Topics: Anticoagulants; Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; Platelet Aggregation; Sul | 1982 |
Platelet hyperaggregability in ischemic cerebrovascular disease and effects of aspirin.
Topics: Arteries; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Humans; Ischemic Attack, Transi | 1982 |
Aspirin and buffered aspirin for TIA's.
Topics: Aspirin; Humans; Ischemic Attack, Transient | 1981 |
Aspirin failure in symptomatic atherosclerotic carotid artery disease.
Topics: Aged; Aspirin; Carotid Artery Diseases; Emergencies; Endarterectomy; Humans; Intracranial Arterioscl | 1981 |
Transient ischemic attacks.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cerebral Angiography; Cerebral Arteries; Endarterectomy; Femal | 1981 |
Circulating platelet aggregates: a chronic platelet activation in patients with transient ischaemic attacks.
Topics: Aspirin; Cerebral Angiography; Dipyridamole; Humans; Intracranial Arteriosclerosis; Ischemic Attack, | 1980 |
For your stroke-prone patients: a guide to drug treatment.
Topics: Aged; Antihypertensive Agents; Aspirin; Brain Diseases; Cerebral Angiography; Cerebrovascular Disord | 1980 |
Aspirin for transient ischemic attacks.
Topics: Aspirin; Humans; Ischemic Attack, Transient | 1980 |
Antiplatelet drugs after myocardial infarction.
Topics: Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregati | 1980 |
Mechanism of cerebral arterial contraction induced by blood constituents.
Topics: Animals; Aspirin; Cerebrovascular Circulation; Cinanserin; Dogs; Female; Hemoglobins; Ischemic Attac | 1980 |
[Should platelet aggregation inhibitors be given in cerebral ischemic insults?].
Topics: Aspirin; Cerebral Infarction; Double-Blind Method; Humans; Ischemic Attack, Transient; Platelet Aggr | 1980 |
Operative indication in asymptomatic carotid arterial disease.
Topics: Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Gui | 1995 |
[Aspirin yes, but how much?].
Topics: Aspirin; Humans; Ischemic Attack, Transient | 1995 |
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis: a case report.
Topics: Aged; Aspirin; Craniotomy; Female; Hematoma, Subdural; Humans; Ischemic Attack, Transient; Meningeal | 1995 |
Can overall results of clinical trials be applied to all patients?
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Endarterectomy, Caro | 1995 |
Stroke prevention.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Dementia, Vascular; Humans; Hypertens | 1995 |
Anticoagulant treatment or antiplatelet therapy after a single carotid TIA?
Topics: Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Follow-Up Studies; Heparin; Humans; Isc | 1995 |
Protective effects of KW-3635, a thromboxane A2 antagonist, on arachidonic acid-induced transient cerebral ischemia in dogs.
Topics: Animals; Arachidonic Acid; Aspirin; Benzimidazoles; Benzoxepins; Blood Pressure; Carotid Arteries; C | 1994 |
Does ticlopidine prevent reversible cerebrovascular ischemic events in women?
Topics: Aspirin; Female; Humans; Ischemic Attack, Transient; Ticlopidine | 1994 |
A follow-up survey of clinical practices for the use of heparin, warfarin, and aspirin.
Topics: Anticoagulants; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Data Collection; Follow | 1994 |
Primary and secondary prevention of stroke in patients with nonrheumatic atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Intracranial | 1994 |
Guidelines for medical treatment for stroke prevention. American College of Physicians.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Cohort Studies; Cost-Benefit Analysis; Decision Support Te | 1994 |
Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Coagulation Disorders; Brain Ischemia; Cerebral Infar | 1994 |
Ticlopidine hydrochloride and prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Ischemic Attack, Trans | 1993 |
Anticoagulants, antiaggregants or nothing following carotid endarterectomy?
Topics: Aged; Aspirin; Carotid Stenosis; Cause of Death; Endarterectomy, Carotid; Female; Follow-Up Studies; | 1993 |
Why is the outcome of transient ischaemic attacks different in different groups of patients?
Topics: Aged; Aspirin; Cohort Studies; Female; Health Services Research; Humans; Ischemic Attack, Transient; | 1993 |
How should clinicians choose treatment for preventing stroke when therapeutic trials are not available to guide the situation?
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Combined Modality Ther | 1995 |
[TIA... An aspirin?].
Topics: Aspirin; Humans; Ischemic Attack, Transient; Neurology; Referral and Consultation | 1996 |
Effect of oncotic pressure of diaspirin cross-linked hemoglobin (DCLHb) on brain injury after temporary focal cerebral ischemia in rats.
Topics: Animals; Aspirin; Blood Volume; Brain; Cerebral Infarction; Coloring Agents; Dose-Response Relations | 1996 |
[Atrial fibrillation and apoplexy--risks and prevention].
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Controlled Clinical T | 1996 |
Cerebrovascular events in adult patients with cyanotic congenital heart disease.
Topics: Adult; Aged; Anemia, Iron-Deficiency; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular | 1996 |
Stenting in the carotid artery: initial experience in 110 patients.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Carotid Artery | 1996 |
[TIA... an aspirin?].
Topics: Aspirin; Family Practice; Humans; Ischemic Attack, Transient | 1996 |
Considerations in the prophylactic treatment of transient ischemic attack or ischemic stroke in the carotid artery territory.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Stenosis; Cerebrovascular Disorders | 1995 |
Hypervolemic-hemodilution during cerebral ischemia in rats: effect of diaspirin cross-linked hemoglobin (DCLHb) on neurologic outcome and infarct volume.
Topics: Animals; Aspirin; Blood Substitutes; Blood Volume; Carotid Artery, External; Cerebral Arteries; Cere | 1997 |
[Anticoagulation in transitory ischemic attack after bypass surgery].
Topics: Adult; Anticoagulants; Aspirin; Coronary Artery Bypass; Coumarins; Heparin; Humans; Ischemic Attack, | 1997 |
Antiplatelet therapy with aspirin in acute ischaemic stroke.
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Routes; Humans; Ischemic Attack, Tran | 1997 |
The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?
Topics: Aged; Alkylating Agents; Aspirin; Erythromelalgia; Female; Fibrinolytic Agents; Hemorrhage; Hemorrha | 1997 |
The role of antiplatelet therapy in stroke prevention.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Ischemic Attack, Transient; Pl | 1997 |
Secondary prevention of stroke--new trials.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Dr | 1998 |
[Secondary prevention of recurrent transient ischemic attacks].
Topics: Anticoagulants; Aspirin; Cerebral Infarction; Drug Therapy, Combination; Female; Humans; Ischemic At | 1998 |
[Consensus on antithrombotic prophylaxis of vascular events in patients with manifested atherosclerotic vascular disease].
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Cou | 1998 |
Subarachnoid molecular hemoglobin after subarachnoid hemorrhage in rats: effect on the area of hypoperfusion.
Topics: Analysis of Variance; Anesthetics, Inhalation; Animals; Antipyrine; Aspirin; Blood; Blood Substitute | 1998 |
Transient ischaemic attacks: new treatments, new questions.
Topics: Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cerebral Hemorrhage; | 1998 |
Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia.
Topics: Aged; Anticoagulants; Aspirin; Case-Control Studies; Cerebrovascular Disorders; Female; Humans; Isch | 1998 |
[Disappearance of embolic signals on transcranial Doppler sonography following antiplatelet therapy in a patient with transient ischemic attacks].
Topics: Aspirin; Female; Humans; Intracranial Embolism and Thrombosis; Ischemic Attack, Transient; Middle Ag | 1998 |
[When salicylates do not help. Practice in recurrent TIA (Transient Ischemic Attack) varies at Swedish hospitals].
Topics: Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient | 1998 |
Diagnosis and management of transient ischaemic attacks in accident and emergency.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diagnosis, Differential; Emergency Treatment; Huma | 1998 |
Transient ischaemic attacks.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Randomized Controlled | 1998 |
Delayed neurological deterioration following resection of arteriovenous malformations of the brain.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Aneurysm; Anticoagulants; Antihypertensive Agents; Asp | 1999 |
Effects of dl-3-n-butylphthalide on production of TXB2 and 6-keto-PGF1 alpha in rat brain during focal cerebral ischemia and reperfusion.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Benzofurans; Brain; Ischemic Attack, Transient; Neur | 1997 |
Oxidative damage in fetal rat brain induced by ischemia and subsequent reperfusion. Relation to arachidonic acid peroxidation.
Topics: Animals; Arachidonic Acid; Aspirin; Brain; Cyclooxygenase Inhibitors; Disease Models, Animal; Female | 1999 |
Anticoagulation in atrial fibrillation in older people.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Contraindications; Hu | 1999 |
AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association.
Topics: Angioplasty; Anticoagulants; Aspirin; Carotid Artery Diseases; Humans; Ischemic Attack, Transient; P | 1999 |
Stent-assisted angioplasty of intracranial vertebrobasilar atherosclerosis: an initial experience.
Topics: Abciximab; Adult; Aged; Angiography; Angioplasty; Antibodies, Monoclonal; Anticoagulants; Aspirin; B | 2000 |
Supplement to the AHA guidelines for the management of transient ischemic attacks.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, | 2000 |
Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Dipyridamole; Drug Therapy, Combi | 2000 |
Alert to physicians: possible interaction of aggrenox and adenosine.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action Preparati | 2000 |
The importance of identifying intracranial haemorrhage as a cause of transient focal neurological symptoms.
Topics: Adult; Aspirin; Diagnosis, Differential; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, | 2000 |
Transient ischemic attacks after dipyridamole-aspirin therapy.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug The | 2000 |
Acetylsalicylic acid induced cessation of transient ischaemic attacks and microembolic signals detected by transcranial Doppler in a patient with essential thrombocythaemia.
Topics: Administration, Oral; Aged; Aspirin; Fibrinolytic Agents; Humans; Infusions, Intravenous; Intracrani | 2001 |
Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia.
Topics: Animals; Antithrombins; Arginine; Aspirin; Blood Pressure; Brain Edema; Cerebrovascular Circulation; | 2001 |
[Emergencies in general practice, 16: Transitory ischemic attacks. When suspected ASS and heparin are contraindicated!].
Topics: Aspirin; Contraindications; Diagnosis, Differential; Emergencies; Family Practice; Heparin; Humans; | 2001 |
Transient ischaemic attacks: a GP guide.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Carotid Arteries; Diagnosis, Differentia | 2001 |
[Antibodies to phospholipids and ischemic disorders of cerebral circulation in young age].
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Antibodies, Antiphospholipid; Anticoagulants; Anti | 1997 |
Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2001 |
Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.
Topics: Adolescent; Adult; Aspirin; Brain Ischemia; Echocardiography, Transesophageal; Female; Follow-Up Stu | 2001 |
[Guidelines for antithrombotic therapy in atrial fibrillation: what the Italian Hemostasis and Thrombosis Society thinks].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Diabetes | 2001 |
Transcatheter closure of patent foramen ovale in patients with paradoxical embolism: intermediate-term risk of recurrent neurological events.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Catheters, Indwelling; Embolism, Paradoxical; Fema | 2002 |
[Antiaggregant therapy in cerebrovascular insufficiency in the aged].
Topics: Aged; Aspirin; Blood Platelet Disorders; Dipyridamole; Drug Evaluation; Female; Humans; Ischemic Att | 1979 |
Platelet activation in acute cerebral ischaemia. Serial measurements of platelet function in cerebrovascular disease.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Aspirin; Blood Cell Count; Blood Platelets; Cerebrovascu | 1977 |
Aspirin and stroke prevention.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Transient; Male; Risk; S | 1978 |
Aspirin dose in prevention of transient ischaemic attacks.
Topics: Aged; Anticoagulants; Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Tra | 1979 |
Methods for detection of hypersensitive platelets. Philadelphia, June 1977.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Blood Coagulation Tests; Blood Platelets; Cardiovascular | 1978 |
Microsurgery in stroke management.
Topics: Aspirin; Cerebral Arteries; Cerebral Revascularization; Cerebrovascular Disorders; Female; Humans; I | 1979 |
Treating thromboembolic disease.
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Fibrinolytic Agents; Heart Valve Pros | 1977 |
[Therapy with anticoagulants and platelet aggregation inhibitors in extracranial vascular stenoses and occlusions].
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Cerebrovascular Disorders | 1979 |
Transient ischemic attacks due to increased platelet aggregation and adhesiveness. Ultrastructural and functional correlation.
Topics: Adolescent; Adult; Aspirin; Blood Coagulation Tests; Blood Platelet Disorders; Blood Platelets; Dipy | 1979 |
[Action mechanism and clinical indications for thrombocyte aggregation inhibitors].
Topics: Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Humans; Ischemic Attack, Transient; Myocard | 1979 |
Endothelial cell damage and thrombus formation following temporary arterial occlusion. Effects of pretreatment with aspirin or heparin.
Topics: Animals; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Circulation; Endotheliu | 1979 |
Moves beginning to approve new indications for aspirin use.
Topics: Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Recurrence; Sex Factors | 1979 |
[Acetylsalicylic acid treatment of transient cerebral ischemia].
Topics: Aspirin; Humans; Ischemic Attack, Transient | 1979 |
Prevention of subsequent infarctions and transient ischemic attacks.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Infarction; Humans; Ischemic Attack, Transient; Middle Aged; | 1979 |
[Antiplatelet drugs (author's transl)].
Topics: Aspirin; Blood Platelets; Clofibrate; Dipyridamole; Female; Humans; Hydroxychloroquine; Ischemic Att | 1979 |
[Transient cerebral ischemic attacks. Treatment program and comparison between anticoagulants and thrombocyte aggregation repressors].
Topics: Aged; Anticoagulants; Aspirin; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male; Time | 1979 |
TIA, stroke, and mitral valve prolapse.
Topics: Adult; Aged; Aspirin; Carotid Artery Thrombosis; Cerebrovascular Disorders; Dipyridamole; Echocardio | 1979 |
Spontaneous platelet aggregation in cerebrovascular disease.
Topics: Adenosine; Adenosine Diphosphate; Adult; Aged; Aspirin; Blindness; Brain Diseases; Female; Humans; I | 1978 |
'Spontaneous' platelet aggregation: its characteristics and relation to aggregation by other agents.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cell Count; Cerebrovascular Disorders; Female; Humans; Ischem | 1978 |
[Acetylsalicylic acid in coronary disease and cerebral ischemia (proceedings)].
Topics: Aspirin; Coronary Disease; Humans; Intracranial Embolism and Thrombosis; Ischemic Attack, Transient; | 1977 |
[Inhibition of platelet adhesiveness and aggregation and protection against cerebral ischemic anoxia by aspirin and 1520 RB. Animal studies].
Topics: Animals; Aspirin; Dogs; Hypoxia, Brain; In Vitro Techniques; Indoles; Ischemic Attack, Transient; Mo | 1977 |
[Treatment of transient ischemic attacks (author's transl)].
Topics: Angiography; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Endarterectomy; Humans; Ischemic | 1978 |
Trial of aspirin during weaning patients with transient ischaemic attacks from anticoagulants.
Topics: Aspirin; Humans; Ischemic Attack, Transient; Substance Withdrawal Syndrome; Warfarin | 1978 |
[Acetylsalicylic acid and transient ischemic attacks].
Topics: Aspirin; Drug Evaluation; Humans; Ischemic Attack, Transient | 1978 |
Transient ischemic attacks and the prevention of strokes.
Topics: Anticoagulants; Aspirin; Carotid Artery Thrombosis; Cerebrovascular Disorders; Endarterectomy; Femal | 1978 |
[Platelet aggregation in atherosclerotic disease after administration of lysine acetylsalicylate].
Topics: Adult; Aged; Angina Pectoris; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Coronary Disea | 1978 |
Transient ischaemic attacks and increased platelet aggregability associated with oral contraceptives. Treatment with dipyridamole and aspirin.
Topics: Adult; Aspirin; Contraceptives, Oral; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Plat | 1977 |
[Transient ischemic attack].
Topics: Aspirin; Coumarins; Humans; Ischemic Attack, Transient | 1977 |
Microembolisation as a cause of clinical disorders.
Topics: Aspirin; Humans; Intracranial Embolism and Thrombosis; Ischemic Attack, Transient; Vision Disorders; | 1977 |
Effects of aspirin and sulfinpyrazone on platelet prostaglandin synthesis.
Topics: Aspirin; Blood Platelets; Collagen; Ischemic Attack, Transient; Kinetics; Prostaglandins; Serotonin; | 1977 |
Effect of drugs of platelets and complications of vascular disease.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clofibrate; Coronary Disease; | 1977 |
Surgical grand rounds carotid artery surgery.
Topics: Anticoagulants; Arteriovenous Shunt, Surgical; Aspirin; Carotid Arteries; Carotid Artery Diseases; C | 1976 |
Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications.
Topics: Adenosine; Adult; Aged; Angina Pectoris; Apyrase; Arterial Occlusive Diseases; Aspirin; Coronary Dis | 1976 |
Letter: Medical management of transient ischaemic attacks.
Topics: Anti-Inflammatory Agents; Anticoagulants; Aspirin; Dipyridamole; Humans; Ischemic Attack, Transient; | 1975 |
Low-dose aspirin and stroke. "It ain't necessarily so".
Topics: Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Humans; Ischemic Attack, Trans | 1992 |
Suppression of the cerebral vasospastic actions of oxyhemoglobin by ascorbic acid.
Topics: Animals; Ascorbic Acid; Aspirin; Basilar Artery; Cattle; Cerebral Arteries; Dogs; Female; Ischemic A | 1991 |
Ischemic stroke. How to keep the first one from happening.
Topics: Aspirin; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypertension; I | 1991 |
Use of acetylsalicylic acid by physicians and in the community.
Topics: Adolescent; Adult; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Community Medicine; Dru | 1991 |
[Carotid endarterectomy for prevention of stroke: comparison of surgical and conservative therapy].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebral | 1991 |
[Rapidly progressing carotid artery stenoses: possibilities of ultrasound prediction and effect of thrombocyte aggregation inhibitors].
Topics: Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Follow-Up Studies; Humans; Intracranial | 1990 |
Controlled clinical trials in cerebrovascular disease. A misused tool.
Topics: Aspirin; Cerebral Revascularization; Cerebrovascular Circulation; Cerebrovascular Disorders; Clinica | 1990 |
Perioperative stroke risk in 173 consecutive patients with a past history of stroke.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anesthesia, General; Aspirin; Cerebrovascular Disorders | 1990 |
Influence of antiplatelet drugs on beta tg and PF4 levels in patients with transient ischemic attacks.
Topics: Adult; Aspirin; Beta-Globulins; beta-Thromboglobulin; Dipyridamole; Female; Humans; Ischemic Attack, | 1985 |
The role of antiplatelet drugs in carotid reconstructive surgery.
Topics: Adult; Aged; Aspirin; Carotid Artery Thrombosis; Carotid Artery, Internal; Dextrans; Dipyridamole; D | 1985 |
Short-term outcome of medically treated patients with transient ischemic attacks, reversible ischemic neurologic deficits and strokes with minimum residuum.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dicumarol; Dipyridamole; Drug Therapy, Combination; Female; | 1985 |
Aspirin for strokes and transient ischaemic attacks.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Statistics as Topic | 1989 |
Aspirin for strokes and transient ischaemic attacks.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient | 1989 |
[Oral lichen planus caused by acetylsalicylic acid].
Topics: Aged; Aspirin; Drug Eruptions; Female; Humans; Ischemic Attack, Transient; Lichen Planus; Mouth Dise | 1989 |
Transient ischaemic attacks.
Topics: Anticoagulants; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Constriction, Pathologic | 1989 |
Risk associated with heparin withdrawal in ischaemic cerebrovascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Heparin; | 1989 |
[Acetylsalicylic acid in acute ischemic coronary and cerebral diseases].
Topics: Aspirin; Humans; Ischemic Attack, Transient; Myocardial Infarction | 1989 |
Blood lipid peroxides in TIA: relation to platelet function and metabolic profile.
Topics: Administration, Oral; Aged; Arteriosclerosis; Aspirin; Blood Glucose; Blood Platelets; Coronary Dise | 1989 |
[Ditazol in the therapy of ischemic cerebrovascular diseases. Clinical results and laboratory experiments (22-to-34-month clinical follow-up)].
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Brain Ischemia; Collagen; Epinephrine; Female; Humans; | 1985 |
Platelet behavior in patients with TIA: responsiveness to small doses of aspirin.
Topics: Adult; Aged; Aspirin; Benzilates; beta-Thromboglobulin; Blood Platelets; Female; Humans; Ischemic At | 1985 |
Management of transient ischemic attacks.
Topics: Aged; Aging; Anticoagulants; Aspirin; Cerebrovascular Disorders; Diagnosis, Differential; Humans; Is | 1987 |
Sneddon's syndrome: an antiphospholipid antibody syndrome?
Topics: Antibodies; Aspirin; Blood Coagulation Factors; Cardiolipins; Cerebral Infarction; Dipyridamole; Fem | 1988 |
Aspirin for strokes and transient ischaemic attacks.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient | 1988 |
Aspirin for strokes and transient ischaemic attacks.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient | 1988 |
Aspirin for strokes and transient ischaemic attacks.
Topics: Aspirin; Carotid Arteries; Cerebrovascular Disorders; Endarterectomy; Humans; Ischemic Attack, Trans | 1988 |
Drugs and platelet activation in migraine and transient ischemic attacks.
Topics: Adult; Aged; Aspirin; beta-Thromboglobulin; Cinnarizine; Female; Flunarizine; Humans; Ischemic Attac | 1985 |
Baseline and activated platelet cytoplasmic ionized calcium in acute ischemic stroke. Effect of aspirin.
Topics: Acute Disease; Adult; Aged; Aspirin; Blood Platelets; Calcium; Cytoplasm; Female; Humans; Ions; Isch | 1988 |
Carotid artery disease. A therapeutic enigma.
Topics: Aspirin; Blindness; Carotid Artery Diseases; Cerebrovascular Disorders; Endarterectomy; Eye Diseases | 1988 |
Medical treatment of transient ischemic attacks: does it influence mortality?
Topics: Anticoagulants; Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Statis | 1988 |
Inhibitory effect of acetylsalicylic acid on platelet function in patients with completed stroke or reversible ischemic neurologic deficit.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cerebrovascular Disorders; | 1988 |
TIAs and carotid endarterectomy: a word of caution.
Topics: Aspirin; Carotid Arteries; Cerebrovascular Disorders; Endarterectomy; Female; Humans; Ischemic Attac | 1988 |
Aspirin, anticoagulants, and hemorrhagic conversion of ischemic infarction: hypothesis and implications.
Topics: Anticoagulants; Aspirin; Carotid Artery Diseases; Cerebral Hemorrhage; Cerebral Infarction; Heparin; | 1986 |
Management of transient ischemic attacks.
Topics: Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Embolism; | 1986 |
Prevention of postoperative neurologic deficits after carotid endarterectomy. Is platelet inhibition beneficial?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Dipyrid | 1987 |
One aspirin can't prevent a stroke but can prevent a major vascular event.
Topics: Aspirin; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Transient; Male; Sex Factors | 1987 |
Pharmacologic approach to ischemic stroke management.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Dipyridamole; Drug Interactions; Heparin; Human | 1986 |
The basis for aspirin dosage in stroke prevention.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Endothelium, | 1987 |
[Remote development of transient ischemic attack, reversible ischemic neurologic deficit and infarct with minimum residual damage. Prospective study of 149 patients treated medically].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Infarction; Female | 1987 |
Transient ischemic attacks at high altitude.
Topics: Adult; Altitude Sickness; Aspirin; Fluid Therapy; Humans; Hypoxia; Ischemic Attack, Transient; Male; | 1986 |
Spontaneous dissection of the carotid artery: an unusual cause of stroke in younger patients.
Topics: Adult; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebral Angiography; Cerebrovasc | 1987 |
Transient ischemic attacks. Locating the source.
Topics: Aged; Aspirin; Blood Coagulation; Carotid Artery Diseases; Cerebrovascular Circulation; Diagnosis, D | 1985 |
Carotid endarterectomy. One solution to the stroke problem.
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebr | 1985 |
Peripheral vascular disease: treatment and referral of the elderly. Part II.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular | 1985 |
Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks.
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; F | 1985 |
Cerebral amyloid angiopathy presenting as transient ischemic attacks. Case report.
Topics: Aged; Amyloidosis; Anticoagulants; Aspirin; Brain; Brain Diseases; Humans; Ischemic Attack, Transien | 1985 |
[Medical treatment of ischemic cerebrovascular disease].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Infarction; Humans; Ischemic Attack, Transient; Pl | 1985 |
[Platelet function disorders and ischemic cerebral accidents. Therapeutic prospects].
Topics: Adult; Aspirin; Blood Coagulation Tests; Blood Platelet Disorders; Cerebrovascular Disorders; Dipyri | 1972 |
Stroke: malignant and benign syndromes.
Topics: Anticoagulants; Aspirin; Carotid Artery Diseases; Cerebral Hemorrhage; Cerebrovascular Disorders; De | 1973 |
Transient ischemic attack: an early warning system for stroke?
Topics: Aged; Angiography; Anticoagulants; Aspirin; Blood Pressure; Brain Edema; Cerebrovascular Disorders; | 1973 |
Acute cerebral infarction. Evaluation and treatment.
Topics: Angiography; Anticoagulants; Aspirin; Blood Pressure Determination; Cerebrospinal Fluid; Cerebrovasc | 1973 |
[Neuropsychiatry in 1973].
Topics: Aspirin; Bipolar Disorder; Dipyridamole; Heart Diseases; Humans; Hydrocephalus; Hypoxia, Brain; Isch | 1973 |
Address of the president-elect: the indication for various methods of treatment of occlusive cerebrovascular disease.
Topics: Anticoagulants; Aspirin; Blood Pressure; Cardiac Output; Carotid Arteries; Cerebral Angiography; Cer | 1973 |
Treatment of stroke: medical or surgical?
Topics: Angiography; Antihypertensive Agents; Aspirin; Blood Pressure; Carotid Arteries; Carotid Artery Thro | 1974 |
[Platelet aggregation inhibiting treatment with aspirin. Biological bases. Application to cerebral vascular accidents].
Topics: Adenosine Diphosphate; Adult; Aspirin; Blood Coagulation Disorders; Blood Coagulation Tests; Blood P | 1972 |
Transient monocular blindness and increased platelet aggregability treated with aspirin. A case report.
Topics: Aspirin; Blindness; Blood Platelet Disorders; Cerebral Angiography; Electroencephalography; Embolism | 1972 |